
<html lang="en"     class="pb-page"  data-request-id="075bde11-9dac-4ad0-8ec8-d88930cf884d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2017.60.issue-18;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.7b00515;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor" /></meta><meta name="dc.Creator" content="Julian  Engel" /></meta><meta name="dc.Creator" content="Steven  Smith" /></meta><meta name="dc.Creator" content="Jonas  Lategahn" /></meta><meta name="dc.Creator" content="Hannah L.  Tumbrink" /></meta><meta name="dc.Creator" content="Lisa  Goebel" /></meta><meta name="dc.Creator" content="Christian  Becker" /></meta><meta name="dc.Creator" content="Elisabeth  Hennes" /></meta><meta name="dc.Creator" content="Marina  Keul" /></meta><meta name="dc.Creator" content="Anke  Unger" /></meta><meta name="dc.Creator" content="Heiko  Müller" /></meta><meta name="dc.Creator" content="Matthias  Baumann" /></meta><meta name="dc.Creator" content="Carsten  Schultz-Fademrecht" /></meta><meta name="dc.Creator" content="Georgia  Günther" /></meta><meta name="dc.Creator" content="Jan G.  Hengstler" /></meta><meta name="dc.Creator" content="Daniel  Rauh" /></meta><meta name="dc.Description" content="Reversible epidermal growth factor receptor (EGFR) inhibitors prompt a beneficial clinical response in non-small cell lung cancer patients who harbor activating mutations in EGFR. However, resistan..." /></meta><meta name="Description" content="Reversible epidermal growth factor receptor (EGFR) inhibitors prompt a beneficial clinical response in non-small cell lung cancer patients who harbor activating mutations in EGFR. However, resistan..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 18, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00515" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00515" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00515" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00515" /></link>
        
    
    

<title>Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00515" /></meta><meta property="og:title" content="Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0010.jpeg" /></meta><meta property="og:description" content="Reversible epidermal growth factor receptor (EGFR) inhibitors prompt a beneficial clinical response in non-small cell lung cancer patients who harbor activating mutations in EGFR. However, resistance mutations, particularly the gatekeeper mutation T790M, limit this efficacy. Here, we describe a structure-guided development of a series of covalent and mutant-selective EGFR inhibitors that effectively target the T790M mutant. The pyrazolopyrimidine-based core differs structurally from that of aminopyrimidine-based third-generation EGFR inhibitors and therefore constitutes a new set of inhibitors that target this mechanism of drug resistance. These inhibitors exhibited strong inhibitory effects toward EGFR kinase activity and excellent inhibition of cell growth in the drug-resistant cell line H1975, without significantly affecting EGFR wild-type cell lines. Additionally, we present the in vitro ADME/DMPK parameters for a subset of the inhibitors as well as in vivo pharmacokinetics in mice for a candidate with promising activity profile." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00515"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00515">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00515&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00515&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00515&amp;href=/doi/10.1021/acs.jmedchem.7b00515" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 7725-7744</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00398" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00593" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julian++Engel">Julian Engel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∥</sup></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Smith">Steven Smith</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jonas++Lategahn">Jonas Lategahn</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hannah+L.++Tumbrink">Hannah L. Tumbrink</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>¶</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Goebel">Lisa Goebel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Becker">Christian Becker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elisabeth++Hennes">Elisabeth Hennes</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>■</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marina++Keul">Marina Keul</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anke++Unger">Anke Unger</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Heiko++M%C3%BCller">Heiko Müller</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthias++Baumann">Matthias Baumann</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carsten++Schultz-Fademrecht">Carsten Schultz-Fademrecht</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Georgia++G%C3%BCnther">Georgia Günther</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jan+G.++Hengstler">Jan G. Hengstler</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Rauh">Daniel Rauh</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-1970-7642" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Lead Discovery Center GmbH, Otto-Hahn-Straße 15, D-44227 Dortmund, Germany</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Leibniz Research Centre for Working Environment and Human Factors (IfADo), TU Dortmund University, D-44139 Dortmund, Germany</span></div><div class="corresp-info"><strong>*</strong>Phone: +49(0)231-755-7080. Fax: +49(0)231-755-7082. E-mail: <a href="/cdn-cgi/l/email-protection#2541444b4c40490b5744504d65515008414a575148504b410b4140"><span class="__cf_email__" data-cfemail="3357525d5a565f1d4152465b7347461e575c41475e465d571d5756">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00515&amp;href=/doi/10.1021%2Facs.jmedchem.7b00515" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 7725–7744</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 30, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 April 2017</li><li><span class="item_label"><b>Published</b> online</span>18 September 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 September 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00515" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00515</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7725%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJulian%2BEngel%252C%2BSteven%2BSmith%252C%2BJonas%2BLategahn%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D18%26contentID%3Dacs.jmedchem.7b00515%26title%3DStructure-Guided%2BDevelopment%2Bof%2BCovalent%2Band%2BMutant-Selective%2BPyrazolopyrimidines%2Bto%2BTarget%2BT790M%2BDrug%2BResistance%2Bin%2BEpidermal%2BGrowth%2BFactor%2BReceptor%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7744%26publicationDate%3DSeptember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00515"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2781</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00515" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Julian&quot;,&quot;last_name&quot;:&quot;Engel&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Smith&quot;},{&quot;first_name&quot;:&quot;Jonas&quot;,&quot;last_name&quot;:&quot;Lategahn&quot;},{&quot;first_name&quot;:&quot;Hannah&quot;,&quot;last_name&quot;:&quot;L. Tumbrink&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Goebel&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Becker&quot;},{&quot;first_name&quot;:&quot;Elisabeth&quot;,&quot;last_name&quot;:&quot;Hennes&quot;},{&quot;first_name&quot;:&quot;Marina&quot;,&quot;last_name&quot;:&quot;Keul&quot;},{&quot;first_name&quot;:&quot;Anke&quot;,&quot;last_name&quot;:&quot;Unger&quot;},{&quot;first_name&quot;:&quot;Heiko&quot;,&quot;last_name&quot;:&quot;Müller&quot;},{&quot;first_name&quot;:&quot;Matthias&quot;,&quot;last_name&quot;:&quot;Baumann&quot;},{&quot;first_name&quot;:&quot;Carsten&quot;,&quot;last_name&quot;:&quot;Schultz-Fademrecht&quot;},{&quot;first_name&quot;:&quot;Georgia&quot;,&quot;last_name&quot;:&quot;Günther&quot;},{&quot;first_name&quot;:&quot;Jan&quot;,&quot;last_name&quot;:&quot;G. Hengstler&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Rauh&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;7725-7744&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00515&quot;},&quot;abstract&quot;:&quot;Reversible epidermal growth factor receptor (EGFR) inhibitors prompt a beneficial clinical response in non-small cell lung cancer patients who harbor activating mutations in EGFR. However, resistance mutations, particularly the gatekeeper mutation T790M, limit this efficacy. Here, we describe a structure-guided development of a series of covalent and mutant-selective EGFR inhibitors that effectively target the T790M mutant. The pyrazolopyrimidine-based core differs structurally from that of aminopyrimidine-based third-generation EGFR inhibitors and therefore constitutes a new set of inhibitors that target this mechanism of drug resistance. These inhibitors exhibited strong inhibitory effects toward EGFR kinase activity and excellent inhibition of cell growth in the drug-resistant cell line H1975, without significantly affecting EGFR wild-type cell lines. Additionally, we present the in vitro ADME/DMPK parameters for a subset of the inhibitors as well as in vivo pharmacokinetics in mice for a candidate with pr&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00515&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00515" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00515&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00515" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00515&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00515" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00515&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00515&amp;href=/doi/10.1021/acs.jmedchem.7b00515" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00515" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00515" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00515%26sid%3Dliteratum%253Aachs%26pmid%3D28853575%26genre%3Darticle%26aulast%3DEngel%26date%3D2017%26atitle%3DStructure-Guided%2BDevelopment%2Bof%2BCovalent%2Band%2BMutant-Selective%2BPyrazolopyrimidines%2Bto%2BTarget%2BT790M%2BDrug%2BResistance%2Bin%2BEpidermal%2BGrowth%2BFactor%2BReceptor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D18%26spage%3D7725%26epage%3D7744%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291235" title="Column chromatography">Column chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291251" title="Sodium">Sodium</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/jmcmar.2017.60.issue-18/20170928/jmcmar.2017.60.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00515&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Reversible epidermal growth factor receptor (EGFR) inhibitors prompt a beneficial clinical response in non-small cell lung cancer patients who harbor activating mutations in EGFR. However, resistance mutations, particularly the gatekeeper mutation T790M, limit this efficacy. Here, we describe a structure-guided development of a series of covalent and mutant-selective EGFR inhibitors that effectively target the T790M mutant. The pyrazolopyrimidine-based core differs structurally from that of aminopyrimidine-based third-generation EGFR inhibitors and therefore constitutes a new set of inhibitors that target this mechanism of drug resistance. These inhibitors exhibited strong inhibitory effects toward EGFR kinase activity and excellent inhibition of cell growth in the drug-resistant cell line H1975, without significantly affecting EGFR wild-type cell lines. Additionally, we present the in vitro ADME/DMPK parameters for a subset of the inhibitors as well as in vivo pharmacokinetics in mice for a candidate with promising activity profile.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74750" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74750" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">First-generation epidermal growth factor receptor (EGFR) inhibitors gefitinib<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and erlotinib<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> provided clinical benefit in patients harboring somatic activating mutations in the gene encoding EGFR such as the L858R point mutation and exon 19 deletions that drive oncogenesis in non-small cell lung cancer (NSCLC) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Treatment with tyrosine kinase inhibitors (TKIs) achieved impressive objective response rates of 50–80% and a doubled median progression-free survival, therefore representing a prime example of targeted cancer therapy that opened up a new era in cancer treatment.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7">(2-7)</a> However, patients acquired resistances and suffered a relapse within 18 months of treatment. Biopsies of resistant tumors revealed a single point mutation of the gatekeeper residue (T790M) as the major resistance mechanism.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8-10)</a> Replacement of the threonine with methionine leads to steric repulsion of the 4-aminoquinazoline-based first-generation EGFR inhibitors and results in a slightly different binding mode that accounts for a dramatic loss of inhibitory activity.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11-13)</a> In addition to the steric repulsion, the change in ATP affinity is well documented.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17">(14-17)</a> While the L858R point mutation leads to a distinct loss of ATP affinity to EGFR, the T790M mutation restores the ATP affinity to almost the same level as in wild-type EGFR, rendering ATP-competitive inhibitors less effective in the presence of cellular ATP concentrations.<a onclick="showRef(event, 'ref14 ref17'); return false;" href="javascript:void(0);" class="ref ref14 ref17">(14, 17)</a> Second-generation EGFR inhibitors that also contain a 4-aminoquinazoline core (afatinib<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and dacomitinib<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a>) were developed and thought to overcome T790M drug resistance as they incorporate a Michael acceptor that covalently modified a unique cysteine (Cys797) at the lip of the EGFR ATP-binding site (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20-22)</a> These covalent inhibitors, characterized by marginal off-rates as well as maximal drug–target residence time, were expected to inhibit T790M drug-resistant EGFR efficiently, but at clinically achievable concentrations they displayed insufficient efficacy in patients due to severe side effects. The clinical data revealed that 4-aminoquinazoline inhibitors are inappropriate to target the gatekeeper mutant variant of EGFR, as they likewise inhibit wild-type EGFR, accounting for the observed side effects and represent a dose-limiting factor.<a onclick="showRef(event, 'ref20 ref21 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref23 ref24 ref25">(20, 21, 23-25)</a> Hence, a third-generation of EGFR inhibitors (CO-1686 (rociletinib<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>) and AZD9291 (osimertinib<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>)), structurally based on an aminopyrimidine, were developed and seemed to avoid a steric clash with the mutant methionine gatekeeper (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Both covalent inhibitors showed excellent in vivo potency as well as reduced on-target toxicity and could progress into human clinical trials.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> Rociletinib has recently been updated to an objective response rate of 45% to T790M-positive patients. Furthermore, elevated levels of glucose in the blood were observed which could be explained by a noncovalent metabolite that inhibits the insulin-like growth factor 1 and the insulin receptor and, thus, its clinical development was stopped.<a onclick="showRef(event, 'ref28 ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30 ref31 ref32">(28-32)</a> In fact, only one third-generation covalent inhibitor has yet achieved FDA approval. Osimertinib showed excellent results in clinical studies as well as reduced on-target toxicity and was approved by the FDA as Tagrisso in 2015.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative examples of the three generations of EGFR inhibitors. The electrophiles are highlighted in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00515&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Here, we present the expanded structure-guided development and the biochemical as well as cellular evaluation of a pyrazolopyrimidine-based series of covalent inhibitors that target the drug-resistant EGFR mutant T790M in a highly mutant-selective manner. In a previous publication, we presented complex crystal structures of mutant EGFR, which revealed the binding mode of this class of pyrazolopyrimidines and gave a first explanation for the potency and selectivity toward the gatekeeper mutated variant.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> On the basis of these preliminary results, we now further investigated the structure–activity relationship (SAR) and examined the in vitro ADME/DMPK parameters for a representative set of the pyrazolopyrimidines as well as in vivo pharmacokinetics for one candidate that displayed the most promising overall profile.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87546" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87546" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Structure-Guided Development of Pyrazolopyrimidine-Based Inhibitors</h3><div class="NLM_p">Prompted by the failure of second-generation EGFR inhibitors in clinical studies and further stimulated by the significant impact of the first covalent T790M inhibitors beyond 4-aminoquinazolines osimertinib and rociletinib, we sought to identify a new set of covalent inhibitors that specifically target the gatekeeper mutant. Considering the knowledge we gained from first- and second-generation inhibitors as well as from our previous work, our structure-guided design was focused on the following three main criteria, which we expected to be crucial for the development of an effective inhibitor that targets the drug-resistant gatekeeper mutant form of EGFR: (i) a distinct scaffold to specifically target the Met-gatekeeper mutant avoiding steric interference, (ii) mutant-selective inhibition while sparing the wild-type form as an essential requirement to reduce on-target toxicity that is associated with severe side effects, and (iii) an electrophile optimized with respect to geometry and orientation for the efficient alkylation of Cys797 as a critical element to overcome T790M drug resistance.<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35-37)</a> We focused our design efforts on the well-studied 4-amino pyrazolopyrimidine as a core element as this moiety supplies an appropriate hinge-binding element and allows for the rapid and straightforward synthesis of a focused collection of small molecules for exploring the efficiency of potent inhibition of the kinase activity of EGFR-T790M, the selectivity profiles, and covalent binding characteristics.<a onclick="showRef(event, 'ref35 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref35 ref38 ref39 ref40">(35, 38-40)</a> We identified <i>N</i>1 of the pyrazolopyrimidine as a suitable position for the attachment of a Michael acceptor linked to a 3-piperidine as the electrophilic system that has been shown to be appropriate for alkylation of an analogous cysteine to EGFR (Cys481 in Bruton’s tyrosine kinase, BTK) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41, 42)</a> Furthermore, we have learned from previous studies on EGFR inhibitors that a restricted rotational flexibility of the electrophile’s linker, which enables a preferred orientation toward Cys797, has a major effect on the kinetics of the covalent bond formation that may drive the inhibitory potency.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> As 4-amino pyrazolopyrimidines, with a PP1<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> derived substitution pattern, provide this potential, we focused our design on the SARs of various substitutions at the 3-position to investigate in what way a change in size, orientation, and electronic properties will affect the activity and selectivity on the different EGFR mutant variants (<a class="ref internalNav" href="#fig2" aria-label="Figures 2">Figures 2</a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). We initially designed derivatives that contained rather simple moieties at 3-position that differed in their electronic properties (e.g., containing a halogen, ethyne, or cyclopropyl). To further investigate the tolerable size of C-3 substitutions, we included benzyl and phenyl moieties with different types of halogen substitutions in the <i>meta</i> and <i>para</i> positions. Ultimately, we designed derivatives with sterically advanced bicyclic moieties at C-3 to exploit the maximum tolerable size of lipophilic extensions into the pocket adjacent to the gatekeeper residue Met790.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic representation of a structure-based design approach to develop a new series of EGFR inhibitors to target the T790M gatekeeper mutant of EGFR. The design strategy is based on a 4-amino pyrazolopyrimidine scaffold and is focused on the particular derivatization of the 3-position of the pyrazolopyrimidine and the <i>N</i>3-position of the piperidine moiety (each highlighted in pink). The 4-amino pyrazolopyrimidine binding mode is adopted (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4hct">4hct</a>) and was modeled into the active site of EGFR-T790M (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ika">3ika</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00515&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Rational design of the pyrazolopyrimidines to covalently address the methionine gatekeeper mutant of EGFR. Schematic illustration of the pyrazolopyrimidine core structure derived from the nonselective kinase inhibitor PP1 and proposed substitutions to investigate the interplay with Met790 (R<sup>1</sup>) and to gain valuable insights into the covalent bond formation with Cys797 (R<sup>2</sup>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00515&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis of a Focused Library of Covalent Pyrazolopyrimidines</h3><div class="NLM_p">We synthesized a small, focused library of covalent pyrazolopyrimidines in which we paid particular attention to the derivatization of the 3-position of the pyrazolopyrimidine core to elucidate on the maximal tolerable size for the pocket near the methionine gatekeeper (Met790) and the potential for beneficial interactions while retaining the crucial direct hinge contact. Further efforts were directed to exploring covalent bonding to Cys797 by altering the type of Michael acceptors and to producing reversible counterparts for comparative evaluation. We employed a general synthetic route for synthesizing pyrazolopyrimidines <b>1d</b>–<b>z</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Iodination of the commercially available 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>2</b>) at the 3-position resulted in the formation of compound <b>3</b>. Subsequent Mitsunobu coupling was performed with <i>N</i>-Boc-protected (<i>S</i>)-3-hydroxypiperidine to generate chiral compound <b>4</b>, which served as a generic intermediate for rapid library generation. Suzuki coupling with various aryl, benzyl, and heteroaryl boronic acids or esters as well as Sonogashira coupling with cyclopentane-equipped alkynes led to intermediate <b>5</b>. Subsequent Boc deprotection with TFA resulted in secondary amine <b>6</b>, which was decorated with a Michael acceptor using acryloyl chloride, resulting in structures <b>1d</b>, <b>1g</b>, <b>1i</b>, <b>1k</b>, <b>1n</b>, <b>1p</b>–<b>t</b>, <b>1v</b>, and <b>1y</b>–<b>z</b> or with 4-(dimethylamino)-2-butenoic acid to generate amides <b>1f</b> and <b>1m</b> via standard amide coupling. Reversible counterparts (<b>1e</b>, <b>1h</b>, <b>1j</b>, <b>1l</b>, and <b>1o</b>) were synthesized with propionyl chloride. Compounds <b>1a</b>–<b>c</b> were synthesized through a slightly altered synthetic approach presented in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_001.pdf" class="ext-link">Schemes S1–S3</a>). The entire chemical data of compounds <b>1u</b>, <b>1x</b>, and <b>1w</b> have been previously described.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of a Subset of Pyrazolopyripimidine Derivatives (<b>1d</b>–<b>z</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00515&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NIS, DMF, 80 °C; (ii) <i>N</i>-Boc-(<i>S</i>)-3-hydroxypiperidine, DIAD, PPh<sub>3</sub>, THF, rt; (iii) boronic acid/ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, satd Na<sub>2</sub>CO<sub>3</sub>, DME/EtOH (3:1, v/v), 90 °C; (iv) CuI, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, TEA, rt; (v) TFA in DCM, rt; (vi) acryloyl or propionyl chloride, DIPEA, THF, 0 °C; (vii) (<i>E</i>)-4-(dimethylamino)but-2-enoic acid, EDC, HOBt, DIPEA, DCM, rt.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Covalent Pyrazolopyrimidines Effectively Inhibit the Kinase Activity of the Drug-Resistant EGFR Mutant</h3><div class="NLM_p">We used an activity-based assay to evaluate the inhibitory activity of pyrazolopyrimidines <b>1a</b>–<b>z</b> on wild-type, activating (L858R), and drug-resistant (L858R/T790M) EGFR (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Notably, structure <b>1a</b> inhibited the wild-type, L858R, and L858R/T790M variants of EGFR (IC<sub>50</sub> = 6.9, 2.5, and 1.6 μM, respectively) and shows a reasonable selectivity toward the drug-resistant mutant of EGFR (ratio WT:T790M = 4.3). Because compound <b>1a</b> possesses a hydrogen atom at C-3 that is not suitable for beneficial interaction with Met790, the observed activity is directly linked to the inhibitory effect of the acrylamide piperidine-decorated 4-amino pyrazolopyrimidine core, rendering it potentially useful for covalently targeting EGFR-T790M. The introduction of small lipophilic moieties showed an interesting effect on all variants of EGFR. While an ethyne at the 3-position (compound <b>1c</b>) led to an increased activity on all EGFR variants but a loss of selectivity (ratio WT:T790M = 2), the introduction of iodine (compound <b>1b</b>) resulted in an even lower kinase activity but a very good selectivity toward the double mutant of EGFR (EGFR-WT IC<sub>50</sub> = 0.3 μM, EGFR-L858R/T790M IC<sub>50</sub> = 0.02 μM, and ratio WT:T790M = 14, respectively). For structure <b>1d</b>, which is equipped with a phenyl group at the 3-position, we could observe a loss in activity and selectivity compared to <b>1b</b>, indicating an insufficient interaction within the lipophilic subpocket that is in line with the X-ray-based modeling studies (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). Phenyl derivatives with an additional fluorine or trifluoromethyl group in the <i>meta</i> or <i>para</i> position (<b>1g</b>, <b>1i</b>, <b>1l</b>, and <b>1n</b>, respectively) or the introduction of the bioisosteric cyclopropyl moiety (<b>1p</b>) tended to follow the same inhibitory profile. Notably, introduction of a 4-phenol moiety increased the inhibition of L858R (IC<sub>50</sub> = 0.003 μM) and L858R/T790M (IC<sub>50</sub> = 0.04 μM) but led to a complete loss of T790M selectivity (ratio WT:T790M = 0.5). The phenol moiety seemed to have a major influence on the activity, most probably due to a contact with an adjacent glutamate residue (Glu762) of the helix C (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Collection of Pyrazolopyrimidine-Based Derivatives and Determination of Corresponding IC<sub>50</sub> Values<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0006.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0007.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0008.gif" alt="" id="GRAPHIC-d7e740-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values are expressed as the mean ± standard deviation of three independent experiments in duplicates using a kinase activity-based assay as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>; na, not applicable, additional data on LLE (EGFR-L858R/T790M) and clogD values can be found in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_001.pdf" class="ext-link">Table S2</a>.</p></div></div><div></div></div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Model of <b>1d</b> (A), <b>1q</b> (B), <b>1r</b> (C), and <b>1y</b> (D) in EGFR-T790M (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5j9y">5j9y</a>). The models provide a reasonable explanation for the observed SAR. <b>1y</b> with its potential of steric repulsion between Met766 and Glu762 are in line with the rather moderate activity in the biochemical assay. In contrast, <b>1d</b> with a comparable activity lacks sufficient hydrophobic interactions in the back pocket of EGFR-L858R/T790M. With its intrinsic flexibility, the benzyl moiety of <b>1r</b> is capable of adapting a position stacked in between Met790 and Lys745, comparable to the more potent bicyclic derivatives. The phenol derivate (<b>1q</b>) seems to be able to form an additional hydrogen bond with Glu762 and therefore gain selectivity compared to the other monocyclic derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00515&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further investigate the potential benefits of the penetration in the subpocket near the gatekeeper residue, we attached ethynyl- and prop-1-ynyl bridged cyclopentane moieties (<b>1s</b> and <b>1t</b>, respectively) to restrict the substituents in an orientation facing the gatekeeper residue. In contrast to compound <b>1c</b> (terminal alkyne), compounds <b>1s</b> (IC<sub>50</sub> = 1.4 μM) and <b>1t</b> (IC<sub>50</sub> = 0.9 μM) displayed less inhibitory activity against L858R/T790M and more strongly inhibited activating mutant L858R (IC<sub>50</sub> = 0.06 and 0.1 μM, respectively), sustainably indicating that the extended substitutions underwent steric repulsion with Met790. Notably, the benzyl-equipped compound <b>1r</b> demonstrated potent kinase inhibition of the relevant mutant variants of EGFR displaying a 24-fold increased inhibition against EGFRL858R/T790M compared to the phenyl derivative (<b>1d</b>). The more flexible benzyl group probably adopts an orientation toward Met790 and particularly Lys745 that allows a more beneficial interaction (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C). Triggered by this observation, we sought to increase the size of the substituents and attached bicyclic aromatic moieties (compounds <b>1u</b>–<b>z</b>). Therefore, we incorporated 1-naphthyl (compound <b>1x</b>) and 2-naphthyl (compound <b>1u</b>) moieties at the 3-position of the pyrazolopyrimidine scaffold. These alterations increased the inhibition of the activating mutation (3-fold increase on L858R compared to <b>1r</b>) and particularly of the drug-resistant (L858R/T790M; <b>1x</b> IC<sub>50</sub> = 0.002 μM; <b>1u</b> IC<sub>50</sub> < 0.001 μM) mutants of EGFR, leading to a superior selectivity over EGFR-WT (ratio WT:T790M; <b>1x</b> = 30; <b>1u</b> > 20). Conversion of naphthyl into an azaindole (compound <b>1v</b>) or a methylindole (compound <b>1w</b>) yielded comparable trends with IC<sub>50</sub> values in the single-digit nanomolar range. As these inhibitors showed preferential inhibition of the gatekeeper mutated form of EGFR, the highly lipophilic and sterically demanding moieties seemed to induce crucial interactions while avoiding adverse interference with the gatekeeper residue (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_001.pdf" class="ext-link">Figure S1</a>). In addition to their high potency, the bicyclic aromatic substitutions reduced the inhibition of wild-type EGFR, with up to 30-fold mutant selectivity for the T790M mutant. As an exception, the 7-azaindole containing compound <b>1v</b> displayed 10-fold reduced mutant selectivity, which is possibly caused by an additional interaction with the threonine gatekeeper residue, leading to increased inhibition of wild-type.</div><div class="NLM_p last">While the selectivity for the T790M mutant for <b>1y</b> and <b>1z</b> remains virtually the same (around 3.5), a 10-fold decrease in activity for all EGFR variants could be observed by the introduction of the bulky dimethylamino group at the 4-position of the naphthyl compared to the fluorine group. According to the model of <b>1y</b> in EGFR-T790M, the decrease in activity stems supposedly from steric properties (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>D). The introduction of a more sterically demanding Michael acceptor (dimethylamino butenamide) led to compounds <b>1f</b> and <b>1m</b> and resulted in a roughly 30-fold less activity against the EGFR variant L858R/T790M (compared to acrylamide-containing counterparts <b>1d</b> and <b>1k</b>, respectively, suggesting that acrylamide linked to a piperidine is the more favored electrophile for these specific pyrazolopyrimidines). The observed difference in activity between these two Michael acceptors again illustrates the relevance of the development and optimization of an electrophilic system (Michel acceptor and linker) for each covalent inhibitor scaffold. Remarkably, the reversible counterparts of our pyrazolopyrimidine inhibitors (compounds <b>1e</b>, <b>1h</b>, <b>1j</b>, <b>1l</b>, and <b>1o</b>) did not significantly inhibit mutant L858R/T790M. Mass spectrometry of EGFR-T790M treated with compounds <b>1u</b>, <b>1x</b>, or <b>1w</b> confirmed covalent modification consistent with a complete labeling of the targeted protein. Nano-LC-MS/MS analysis precisely verified a single alkylation of Cys797.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Mutant-Selective Inhibitory Effects on Drug-Resistant NSCLC Cell Line H1975</h3><div class="NLM_p">We evaluated the inhibitory efficacy of pyrazolopyrimidine-based compounds <b>1a</b>–<b>z</b> on a cell line with an EGFR activating mutation (HCC827, EGFR-delE746_A750) and on the drug-resistant NSCLC cell line H1975, which harbors EGFR-L858R/T790M. To investigate mutant-selective characteristics, we also tested the compounds’ effect on a cancer cell line harboring wild-type EGFR (A431,  <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Additionally, we tested on KRAS-mutated cell lines (A549, and H358; <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_001.pdf" class="ext-link">Table S1</a>, respectively) to exclude the possibility of off-target toxicity. Cells were treated with compounds <b>1a</b>–<b>z</b> (0–30 μM) for 96 h. Gefitinib, afatinib, <i>N</i>-(3-((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)acrylamide (<b>7</b>, WZ4002<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a>), osimertinib, rociletinib, and ibrutinib served as references. Compounds <b>1u</b>–<b>x</b> demonstrated excellent inhibitory effects on HCC827 (EC<sub>50</sub> = <0.01–0.50 μM) and on H1975 cells (EC<sub>50</sub> = 0.1–0.5 μM) without significantly impacting EGFR wild-type cell lines (A431, EC<sub>50</sub> = 1.4–29 μM; A549, EC<sub>50</sub> = 3.5–23 μM; H358, EC<sub>50</sub> = 2.3–20 μM or no inhibition). Remarkably, the 2-naphthyl-containing compound <b>1u</b> was the most active inhibitor (EC<sub>50</sub> = 0.1 μM against H1975 cells), while very high selectivity for the drug-resistant over the WT cell line was achieved with compounds <b>1w</b> and <b>1x</b> (30-fold and 60-fold, respectively). Compound <b>1v</b> evoked an inhibitory effect in EGFR wild-type cells (EC<sub>50</sub> = 1.4, 3.5, and 2.3 μM in A431, A549, and H358, respectively), consistent with its strong in vitro inhibition of wild-type EGFR. Compound <b>1y</b>, which contains a dimethylamine at the 4-position of the naphthyl moiety, exhibited less activity in H1975 cells (EC<sub>50</sub> = 2.7 μM), in line with our activity-based data. Also consistent with our activity-based assay, compounds with less-lipophilic extensions at the pyrazolopyrimidine C-3 (compounds <b>1c, 1d</b>, <b>1g</b>, <b>1i</b>, <b>1k</b>, and <b>1p</b>) had less effect on H1975 cells (EC<sub>50</sub> = 1.8–16 μM), while the unsubstituted derivative <b>1a</b> did not display inhibitory activity. Notably, compounds <b>1q</b> (4-phenol substitution at C-3) and <b>1b</b> (iodine substitution at C-3) strongly inhibited the T790M mutant in the biochemical setting (IC<sub>50</sub> = 0.04 and 0.02 μM, respectively, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) but were less potent against H1975 cells (EC<sub>50</sub> = 1.84 and 3.9 μM, respectively). In accordance with our activity-based data, reversible inhibitors <b>1e</b>, <b>1h</b>, <b>1j</b>, <b>1l</b>, and <b>1o</b> did not affect any of the tested cancer cell lines, in contrast to their covalent counterparts (compounds <b>1d</b>, <b>1g</b>, <b>1i</b>, <b>1k</b>, and <b>1n</b>), highlighting how crucial a maximized drug–target residence time (characteristics of covalent inhibition) is to target T790M drug resistance. Further, the dimethylamino butenamide Michael acceptor equipped inhibitors <b>1f</b> and <b>1m</b> demonstrated significantly less inhibitory potency against H1975 cells (EC<sub>50</sub> = 30 μM for compound <b>1f</b> and EC<sub>50</sub> = 21 μM for compound <b>1m</b>) than their respective acrylamide analogues (compound <b>1d</b>, EC<sub>50</sub> = 3.7 μM; compound <b>1k</b>, EC<sub>50</sub> = 4.2 μM), also consistent with our activity-based assay data.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Cellular Growth Inhibition (EC<sub>50</sub>) of Reference Compounds and Pyrazolopyrimidines against the Cancer Cell Lines A431, HCC827, H1975, and A549</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="6" align="center">cancer cell lines EC<sub>50</sub> [μM]</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">A431 (EGFR-WT)</th><th class="colsep0 rowsep0" align="center">HCC827 (EGFR-delE746_A750)</th><th class="colsep0 rowsep0" align="center">H1975 (EGFR-L858R/T790M)</th><th class="colsep0 rowsep0" align="center">A549 (KRAS-G12S)</th><th class="colsep0 rowsep0" align="center">ratio A431:H1975</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1a</b></td><td class="colsep0 rowsep0" align="center">ni<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">9.90 ± 1.02</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">na</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1b</b></td><td class="colsep0 rowsep0" align="center">18.2 ± 7.06</td><td class="colsep0 rowsep0" align="center">0.589 ± 0.13</td><td class="colsep0 rowsep0" align="center">3.89 ± 0.94</td><td class="colsep0 rowsep0" align="center">23.4 ± 7.26</td><td class="colsep0 rowsep0" align="center">4.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1c</b></td><td class="colsep0 rowsep0" align="center">29.6 ± 0.69</td><td class="colsep0 rowsep0" align="center">2.05 ± 0.375</td><td class="colsep0 rowsep0" align="center">16.2 ± 2.87</td><td class="colsep0 rowsep0" align="center">28.3 ± 3.03</td><td class="colsep0 rowsep0" align="center">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1d</b></td><td class="colsep0 rowsep0" align="center">12.7 ± 4.37</td><td class="colsep0 rowsep0" align="center">0.07 ± 0.02</td><td class="colsep0 rowsep0" align="center">3.67 ± 0.10</td><td class="colsep0 rowsep0" align="center">21.7 ± 7.44</td><td class="colsep0 rowsep0" align="center">3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1e</b></td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">na</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1f</b></td><td class="colsep0 rowsep0" align="center">29.8 ± 0.39</td><td class="colsep0 rowsep0" align="center">1.19 ± 0.48</td><td class="colsep0 rowsep0" align="center">29.9 ± 0.26</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1g</b></td><td class="colsep0 rowsep0" align="center">11.7 ± 3.81</td><td class="colsep0 rowsep0" align="center">0.07 ± 0.35</td><td class="colsep0 rowsep0" align="center">3.37 ± 0.85</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1h</b></td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">22.3 ± 4.85</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">na</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1i</b></td><td class="colsep0 rowsep0" align="center">17.0 ± 5.92</td><td class="colsep0 rowsep0" align="center">0.08 ± 0.03</td><td class="colsep0 rowsep0" align="center">1.84 ± 0.36</td><td class="colsep0 rowsep0" align="center">27.6 ± 4.2</td><td class="colsep0 rowsep0" align="center">9.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1j</b></td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">25.9 ± 3.58</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">na</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1k</b></td><td class="colsep0 rowsep0" align="center">16.0 ± 2.81</td><td class="colsep0 rowsep0" align="center">0.65 ± 0.13</td><td class="colsep0 rowsep0" align="center">4.16 ± 0.77</td><td class="colsep0 rowsep0" align="center">22.2 ± 3.83</td><td class="colsep0 rowsep0" align="center">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1l</b></td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">na</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1m</b></td><td class="colsep0 rowsep0" align="center">13.7 ± 1.57</td><td class="colsep0 rowsep0" align="center">6.39 ± 1.62</td><td class="colsep0 rowsep0" align="center">20.6 ± 2.98</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">0.7.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1n</b></td><td class="colsep0 rowsep0" align="center">8.87 ± 4.38</td><td class="colsep0 rowsep0" align="center">0.16 ± 0.08</td><td class="colsep0 rowsep0" align="center">1.38 ± 0.31</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">6.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1o</b></td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">23.6 ± 6.96</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">na</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1p</b></td><td class="colsep0 rowsep0" align="center">28.1 ± 4.06</td><td class="colsep0 rowsep0" align="center">0.31 ± 0.12</td><td class="colsep0 rowsep0" align="center">5.83 ± 1.84</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">4.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1q</b></td><td class="colsep0 rowsep0" align="center">4.17 ± 2.20</td><td class="colsep0 rowsep0" align="center">0.07 ± 0.02</td><td class="colsep0 rowsep0" align="center">1.84 ± 0.56</td><td class="colsep0 rowsep0" align="center">20.0 ± 4.75</td><td class="colsep0 rowsep0" align="center">2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1r</b></td><td class="colsep0 rowsep0" align="center">19.9 ± 9.59</td><td class="colsep0 rowsep0" align="center">0.15 ± 0.02</td><td class="colsep0 rowsep0" align="center">0.69 ± 0.17</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">28.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1s</b></td><td class="colsep0 rowsep0" align="center">10.9 ± 2.32</td><td class="colsep0 rowsep0" align="center">1.15 ± 0.14</td><td class="colsep0 rowsep0" align="center">8.27 ± 0.30</td><td class="colsep0 rowsep0" align="center">27.1 ± 2.88</td><td class="colsep0 rowsep0" align="center">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1t</b></td><td class="colsep0 rowsep0" align="center">8.77 ± 2.88</td><td class="colsep0 rowsep0" align="center">3.15 ± 0.55</td><td class="colsep0 rowsep0" align="center">6.93 ± 1.14</td><td class="colsep0 rowsep0" align="center">19.9 ± 4.20</td><td class="colsep0 rowsep0" align="center">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1u</b></td><td class="colsep0 rowsep0" align="center">3.60 ± 1.52</td><td class="colsep0 rowsep0" align="center"><0.014</td><td class="colsep0 rowsep0" align="center">0.14 ± 0.05</td><td class="colsep0 rowsep0" align="center">11.6 ± 5.18</td><td class="colsep0 rowsep0" align="center">25.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1v</b></td><td class="colsep0 rowsep0" align="center">1.39 ± 0.59</td><td class="colsep0 rowsep0" align="center"><0.014</td><td class="colsep0 rowsep0" align="center">0.28 ± 0.03</td><td class="colsep0 rowsep0" align="center">3.45 ± 1.05</td><td class="colsep0 rowsep0" align="center">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1w</b></td><td class="colsep0 rowsep0" align="center">6.78 ± 4.45</td><td class="colsep0 rowsep0" align="center">0.09 ± 0.08</td><td class="colsep0 rowsep0" align="center">0.23 ± 0.06</td><td class="colsep0 rowsep0" align="center">23.3 ± 7.77</td><td class="colsep0 rowsep0" align="center">29.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1x</b></td><td class="colsep0 rowsep0" align="center">29.4 ± 1.67</td><td class="colsep0 rowsep0" align="center">0.50 ± 0.04</td><td class="colsep0 rowsep0" align="center">0.49 ± 0.32</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">60.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1y</b></td><td class="colsep0 rowsep0" align="center">24.5 ± 5.76</td><td class="colsep0 rowsep0" align="center">2.13 ± 0.513</td><td class="colsep0 rowsep0" align="center">2.67 ± 1.64</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">9.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1z</b></td><td class="colsep0 rowsep0" align="center">12.8 ± 4.63</td><td class="colsep0 rowsep0" align="center">0.43 ± 0.10</td><td class="colsep0 rowsep0" align="center">0.36 ± 0.19</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">35.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ibrutinib</td><td class="colsep0 rowsep0" align="center">2.38 ± 1.66</td><td class="colsep0 rowsep0" align="center">0.45 ± 0.39</td><td class="colsep0 rowsep0" align="center">0.64 ± 0.30</td><td class="colsep0 rowsep0" align="center">ni</td><td class="colsep0 rowsep0" align="center">3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gefitinib</td><td class="colsep0 rowsep0" align="center">1.71 ± 0.79</td><td class="colsep0 rowsep0" align="center"><0.014</td><td class="colsep0 rowsep0" align="center">10.7 ± 2.55</td><td class="colsep0 rowsep0" align="center">18.7 ± 11.9</td><td class="colsep0 rowsep0" align="center">0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">afatinib</td><td class="colsep0 rowsep0" align="center">0.2 ± 0.07</td><td class="colsep0 rowsep0" align="center"><0.014</td><td class="colsep0 rowsep0" align="center">0.6 ± 0.8</td><td class="colsep0 rowsep0" align="center">1.49 ± 0.43</td><td class="colsep0 rowsep0" align="center">0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="center">2.21 ± 0.44</td><td class="colsep0 rowsep0" align="center">0.020 ± 0.006</td><td class="colsep0 rowsep0" align="center">0.09 ± 0.01</td><td class="colsep0 rowsep0" align="center">3.99 ± 0.54</td><td class="colsep0 rowsep0" align="center">24.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">osimertinib</td><td class="colsep0 rowsep0" align="center">0.67 ± 0.23</td><td class="colsep0 rowsep0" align="center"><0.014</td><td class="colsep0 rowsep0" align="center"><0.014</td><td class="colsep0 rowsep0" align="center">1.83 ± 0.26</td><td class="colsep0 rowsep0" align="center">>48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rociletinib</td><td class="colsep0 rowsep0" align="center">1.66 ± 0.12</td><td class="colsep0 rowsep0" align="center">0.045 ± 0.011</td><td class="colsep0 rowsep0" align="center">0.10 ± 0.03</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">16.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">ni, no inhibitory effect at 30 μM compound concentration; na, not applicable.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> ADME/DMPK Parameters of a Subset of Pyrazolopyrimidines</h3><div class="NLM_p">For a representative subset of pyrazolopyrimidines, the physicochemical and in vitro ADME parameters such as kinetic solubility and permeability as well as plasma and metabolic stability were examined (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Despite the increased lipophilicity of the most active derivatives reflected by their higher clogP and clogD<sub>7.4</sub> values, the compounds displayed high aqueous kinetic solubility (SolRank) with values of 248–461 μM in buffer at pH 7.4, with the exception of <b>1x</b> (kinetic solubility concentration = 38 μM) that contains a 1-naphthyl moiety.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Calculated, Physical, and in Vitro Pharmacokinetic Parameters for a Subset of Pyrazolopyrimidines (<b>1d</b>, <b>1k</b>, <b>1u</b>, <b>1v</b>, <b>1w</b>, and <b>1x</b>) and the Reference Compounds Rociletinib, Osimertinib, and Ibrutinib</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0009.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>1d</b></th><th class="colsep0 rowsep0" align="center"><b>1k</b></th><th class="colsep0 rowsep0" align="center"><b>1u</b></th><th class="colsep0 rowsep0" align="center"><b>1v</b></th><th class="colsep0 rowsep0" align="center"><b>1w</b></th><th class="colsep0 rowsep0" align="center"><b>1x</b></th><th class="colsep0 rowsep0" align="center">osimertinib</th><th class="colsep0 rowsep0" align="center">rociletinib</th><th class="colsep0 rowsep0" align="center">ibrutinib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">clogP<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">2.1</td><td class="colsep0 rowsep0" align="center">3.0</td><td class="colsep0 rowsep0" align="center">3.1</td><td class="colsep0 rowsep0" align="center">1.4</td><td class="colsep0 rowsep0" align="center">2.5</td><td class="colsep0 rowsep0" align="center">3.1</td><td class="colsep0 rowsep0" align="center">4.5</td><td class="colsep0 rowsep0" align="center">4.1</td><td class="colsep0 rowsep0" align="center">3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">clogD (pH 7.4)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">2.1</td><td class="colsep0 rowsep0" align="center">3.0</td><td class="colsep0 rowsep0" align="center">3.1</td><td class="colsep0 rowsep0" align="center">1.4</td><td class="colsep0 rowsep0" align="center">2.5</td><td class="colsep0 rowsep0" align="center">3.1</td><td class="colsep0 rowsep0" align="center">3.0</td><td class="colsep0 rowsep0" align="center">4.1</td><td class="colsep0 rowsep0" align="center">3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LLE (cell<sub>H1975</sub>)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">3.3</td><td class="colsep0 rowsep0" align="center">2.4</td><td class="colsep0 rowsep0" align="center">3.7</td><td class="colsep0 rowsep0" align="center">5.2</td><td class="colsep0 rowsep0" align="center">4.2</td><td class="colsep0 rowsep0" align="center">3.2</td><td class="colsep0 rowsep0" align="center">4.8</td><td class="colsep0 rowsep0" align="center">2.9</td><td class="colsep0 rowsep0" align="center">2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SolRank (μM)</td><td class="colsep0 rowsep0" align="center">461</td><td class="colsep0 rowsep0" align="center">427</td><td class="colsep0 rowsep0" align="center">248</td><td class="colsep0 rowsep0" align="center">457</td><td class="colsep0 rowsep0" align="center">364</td><td class="colsep0 rowsep0" align="center">38</td><td class="colsep0 rowsep0" align="center">265</td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PAMPA (% flux)</td><td class="colsep0 rowsep0" align="center">59</td><td class="colsep0 rowsep0" align="center">76</td><td class="colsep0 rowsep0" align="center">73</td><td class="colsep0 rowsep0" align="center">27</td><td class="colsep0 rowsep0" align="center">66</td><td class="colsep0 rowsep0" align="center">82</td><td class="colsep0 rowsep0" align="center">112</td><td class="colsep0 rowsep0" align="center">88</td><td class="colsep0 rowsep0" align="center">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 (<i>P</i><sub>app</sub> A–B) (× 10<sup>–8</sup> cm/s)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">51</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">30</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">8.4</td><td class="colsep0 rowsep0" align="center">5.0</td><td class="colsep0 rowsep0" align="center">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 (<i>P</i><sub>app</sub> B–A) (× 10<sup>–8</sup> cm/s)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">29</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">6.0</td><td class="colsep0 rowsep0" align="center">6.8</td><td class="colsep0 rowsep0" align="center">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 (ratio <i>P</i><sub>app</sub> B–A/A–B)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">0.3</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">0.7</td><td class="colsep0 rowsep0" align="center">1.4</td><td class="colsep0 rowsep0" align="center">0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma stability mouse (%)</td><td class="colsep0 rowsep0" align="center">91</td><td class="colsep0 rowsep0" align="center">99</td><td class="colsep0 rowsep0" align="center">86</td><td class="colsep0 rowsep0" align="center">96</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">90</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">75</td><td class="colsep0 rowsep0" align="center">96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma stability human (%)</td><td class="colsep0 rowsep0" align="center">97</td><td class="colsep0 rowsep0" align="center">96</td><td class="colsep0 rowsep0" align="center">94</td><td class="colsep0 rowsep0" align="center">98</td><td class="colsep0 rowsep0" align="center">95</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">78</td><td class="colsep0 rowsep0" align="center">80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>f</i><sub>u100%</sub> (mouse plasma)</td><td class="colsep0 rowsep0" align="center">0.33</td><td class="colsep0 rowsep0" align="center">0.09</td><td class="colsep0 rowsep0" align="center">0.02</td><td class="colsep0 rowsep0" align="center">0.37</td><td class="colsep0 rowsep0" align="center">0.12</td><td class="colsep0 rowsep0" align="center">0.15</td><td class="colsep0 rowsep0" align="center">0.03</td><td class="colsep0 rowsep0" align="center">0.01</td><td class="colsep0 rowsep0" align="center">0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MLM Cl<sub>int</sub> (μL min<sup>–1</sup> mg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="center">924</td><td class="colsep0 rowsep0" align="center">2773</td><td class="colsep0 rowsep0" align="center">2311</td><td class="colsep0 rowsep0" align="center">495</td><td class="colsep0 rowsep0" align="center">1980</td><td class="colsep0 rowsep0" align="center">2773</td><td class="colsep0 rowsep0" align="center">51</td><td class="colsep0 rowsep0" align="center">81</td><td class="colsep0 rowsep0" align="center">1980</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HLM Cl<sub>int</sub> (μL min<sup>–1</sup> mg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="center">122</td><td class="colsep0 rowsep0" align="center">578</td><td class="colsep0 rowsep0" align="center">770</td><td class="colsep0 rowsep0" align="center">108</td><td class="colsep0 rowsep0" align="center">462</td><td class="colsep0 rowsep0" align="center">770</td><td class="colsep0 rowsep0" align="center">4.1</td><td class="colsep0 rowsep0" align="center">5.1</td><td class="colsep0 rowsep0" align="center">420</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">clogP as well as clogD values were calculated with Seurat (consensus model using ChemAxon and Klopman’s models and the PhysProp database).</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Ligand lipophilicity efficiency (LLE) was calculated from pEC<sub>50</sub>(H1975) – clogD<sub>7.4</sub>.</p></div></div></div><div class="NLM_p">As the lipophilicity of the most promising pyrazolopyrimidines was significantly raised in the course of the optimization cycles, the determination of the ligand-lipophilicity efficiency (LLE; defined as pIC<sub>50</sub> – clogP/D and describing how efficient a ligand exploits its lipophilicity) became of interest to substantiate a specific target interaction.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The most promising compounds being effective on H1975 drug-resistant cell lines (<b>1u</b>, <b>1v</b>, <b>1w</b>, and <b>1x</b>) displayed LLE values regarding H1975 between 3.2–5.2 that are in an acceptable range (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_001.pdf" class="ext-link">Figure S2</a>).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">Moreover, all compounds tested showed high penetration in the artificial membrane permeation assay (PAMPA) (59–82% flux), except for the more polar azaindole derivative (<b>1v</b>) (27% flux).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a><b>1u</b> and <b>1w</b> were further measured in the Caco-2 cell permeability assay as a cellular model to examine intestinal drug absorption. Both compounds demonstrated a high cellular apical (A) to basolateral (B) permeability with low efflux ratios of 0.3 (<b>1u</b>) and 1.0 (<b>1w</b>) predicting good oral absorption.</div><div class="NLM_p">All tested covalent pyrazolopyrimidines seemed to be extremely stable in both mouse and human plasma (>86%). With respect to plasma protein binding, the 2-naphthyl containing derivative was the only compound that showed a somewhat lower free fraction (<i>f</i><sub>u100%</sub> = 0.02) compared to the other derivatives of the series that revealed satisfactory <i>f</i><sub>u100%</sub> values ranging from 0.09 to 0.37, which are significantly higher than the fraction unbound levels determined for osimertinib, rociletinib, and ibrutinib (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). As expected, the intrinsic clearance (Cl<sub>int</sub>) of the compounds was very high in both mouse and human liver microsomes, thus being similarly unstable as the structure-related clinical reference ibrutinib. Nevertheless, the overall profile encouraged us to investigate the pharmacokinetics of this compound class in vivo.</div><div class="NLM_p">We selected <b>1w</b> for a first in vivo experiment and administered the compound by the intravenous (IV), intraperitoneal (IP), and oral (PO) route to CD-1 mice (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) at doses of 2 mg/kg (IV), 20 mg/kg (IP), and 20 mg/kg (PO). We observed no adverse effects, indicating that the compound was generally well tolerated. In line with the in vitro ADME data, we observed relatively low exposure (AUC) combined with a high volume of distribution and a high clearance of the compound after intravenous administration. This resulted in a short half-life of only 0.6 h. For the intraperitoneal route, however, we measured a disproportionately high exposure of 1888 h·ng/mL, indicating a good IP bioavailability. The highest concentration measured in plasma (<i>C</i><sub>max, total</sub>) of 4539 ng/mL (= 11.32 μM) represents a nearly 50-fold cover of the cellular EC<sub>50</sub> of 0.23 μM obtained in H1975 cells, while the highest free plasma concentration was still nearly 6-fold above this value (<i>C</i><sub>max, free</sub> = 1.36 μM). Thus, despite the relatively short half-life of 0.2 h, the total plasma concentration was above the H1975 EC<sub>50</sub> for approximately 75 min, and the free plasma concentration was above the EC<sub>50</sub> for about 30 min, which could be sufficient to see efficacy in a proof-of-concept study in vivo (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_001.pdf" class="ext-link">Figure S3</a>). In contrast, administration by oral gavage resulted in a very low exposure of 28.6 h·ng/mL, indicative of a poor oral bioavailability, despite the promising permeability values obtained in the Caco-2 assay. It remains to be determined whether this could be a consequence of metabolism during intestinal absorption or whether the Caco-2 assay did not correctly reflect the in vivo situation. Nevertheless, the intraperitoneal route seems to be the most appropriate route of administration to further profile <b>1w</b> in preclinical in vivo studies.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. in Vivo Pharmacokinetic Parameters for <b>1w</b> in Mice</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IV</th><th class="colsep0 rowsep0" align="center">(2 mg/kg)</th><th class="colsep0 rowsep0" align="center">IP</th><th class="colsep0 rowsep0" align="center">(20 mg/kg)</th><th class="colsep0 rowsep0" align="center">PO</th><th class="colsep0 rowsep0" align="center">(20 mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.60</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.24</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>0</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">138</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">4539</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (h·ng/mL)</td><td class="colsep0 rowsep0" align="left">121</td><td class="colsep0 rowsep0" align="left">AUC (h·ng/mL)</td><td class="colsep0 rowsep0" align="left">1888</td><td class="colsep0 rowsep0" align="left">AUC (h·ng/mL)</td><td class="colsep0 rowsep0" align="left">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (L/h/kg)</td><td class="colsep0 rowsep0" align="left">16.6</td><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">156</td><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">12.4</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65172" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65172" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Patients that suffer from advanced NSCLC are treated with cytotoxic chemotherapy, which dramatically decreases the patient health-related quality of life and fails to exert sustainable therapeutic effects. For this reason, selective drugs must be developed, for example, TKIs may achieve impressive effects in NSCLC patients that harbor specific activating mutations in EGFR. Although therapy is beneficial in these patients, treatment is limited due to the acquisition of drug-resistance mutations. Third-generation EGFR inhibitors irreversibly target the oncogenic and drug-resistant T790M variant by alkylating a rare cysteine (Cys797). Rociletinib and osimertinib were the most promising clinical candidates for the treatment of advanced NSCLC, of which only osimertinib (Tagrisso) has been FDA approved, whereas the clinical development of rociletinib has recently been stopped by Clovis Oncology.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The latest progress and the fact that there are only very few approved drugs for this indication to date shows the persistent interest for the development of new T790M-targeting drugs.</div><div class="NLM_p">Here, we report the structure-guided development of a series of covalent pyrazolopyrimidines that selectively target T790M drug-resistant EGFR without affecting the wild-type protein. Our design relied on the classical hinge-binding motif 4-amino pyrazolopyrimidine as the starting point, to which we introduced a 3-piperidine linker for attaching a Michael acceptor for covalent modification of Cys797. On the basis of modeling studies, we focused our chemical efforts on derivatization of C-3 of the pyrazolopyrimidine core, which we considered as the hot spot for beneficial interactions with the methionine gatekeeper. Recently, we studied the interactions of substituted indazoles with the back pocket of the active site.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> To investigate the alkylation reaction, we varied the electrophilic system. A focused small-molecule library contained a series of EGFR inhibitors that displayed excellent (subnanomolar) inhibitory effects against the drug-resistant variant L858R/T790M and reduced inhibition of wild-type EGFR in activity-based studies. The most promising compounds, <b>1u</b>, <b>1w</b>, <b>1x</b>, and <b>1z</b>, equipped with aromatic bicyclic moieties, demonstrated a mutant-selective profile during biochemical characterization, with excellent inhibitory effects on H1975 cells (EC<sub>50</sub> up to 0.1 μM) but not on cancer cells harboring wild-type EGFR.</div><div class="NLM_p">In our collection of compounds, the C-3 substitution of the pyrazolopyrimidine was the hot spot for increased inhibitory potency and selectivity toward the T790M mutant. Of note, bicyclic moieties with a strong lipophilic character were highly active against H1975 cells, as these motifs avoid steric interference but rather directly interact with the Met790 gatekeeper residue as well as the alkyl side chain of Lys745.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In contrast, compounds with less lipophilic substituents at the 3-position were less effective as inhibitors due to the weakening of favorable interactions. Variation of the Michael acceptor demonstrated that an acrylamide is the preferred electrophile for these types of pyrazolopyrimidines. Reversible counterparts that cannot undergo Michael addition to form a covalent bond with Cys797 were inactive in both biochemical and cellular studies, substantiating the need of covalent inhibition of drug-resistant EGFR. It is crucial to differentiate between the two distinct binding events that occur with covalent ligands. The initial binding of the inhibitor is almost completely based on the intrinsic affinity of the inhibitor to the target and reversible. After the reversible binding, the electrophilic warhead can form a covalent bond with the target kinase if it is properly positioned to a suitable nucleophile.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> For this reason, it is important to differentiate these two binding steps in a series of kinetic measurements, which has been done for a selected set of the herein presented compounds in Engel and Becker et al.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The structure–activity relationship of the entire series of pyrazolopyrimidines observed in the activity-based assay translated nicely into a cellular setting for mutant as well as wild-type EGFR.</div><div class="NLM_p last">The in vitro ADME profile of <b>1w</b> represented the most promising overall profile, displaying a high aqueous kinetic solubility as well as an excellent cellular permeability with a low efflux ratio. The high stability in both mouse and human plasma together with a satisfactory free fraction in mouse plasma stimulated an in vivo pharmacokinetic study in mice that revealed a high exposure by the intraperitoneal route. The total plasma concentration was above the H1975 EC<sub>50</sub> for approximately 75 min that could be sufficient to see efficacy in a proof-of-concept study in vivo.</div></div><div id="sec99" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76013" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76013" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we identified a novel class of covalent and mutant-selective third-generation EGFR inhibitors that exhibited strong effects on the drug-resistant H1975 cell line while displaying marginal inhibitory activity on EGFR wild-type cell lines, a characteristic that may ultimately overcome issues of on-target toxicity. The first in vivo experiment of <b>1w</b> revealed good exposure by the intraperitoneal route that seems to be the most appropriate route of administration to further profile <b>1w</b> in in vivo studies. The discovery of this class of inhibitors may stimulate further development of therapeutics to overcome drug resistance in NSCLC.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13347" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13347" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Activity-Based Assay for IC<sub>50</sub> Determination</h3><div class="NLM_p last">IC<sub>50</sub> determinations for EGFR and its mutants (Carna Biosciences, lot13CBS-0005K for EGFR-WT; Invitrogen, lot279551C for EGFR-L858R, and Invitrogen, lot350247C for EGFR-L858R/T790M) were performed with the HTRF KinEASE-TK assay from Cisbio according to the manufacturer’s instructions. Briefly, the amount of EGFR in each reaction well was set to 0.60 ng of EGFR-WT (0.67 nM), 0.10 ng of EGFR-L858R (0.11 nM), or 0.07 ng of EGFR-L858R/T790M (0.08 nM). An artificial substrate peptide (TK-substrate from Cisbio) was phosphorylated by EGFR. After completion of the reaction (reaction times: 25 min for WT, 15 min for L858R, and 20 min for L858R/T790M), the reaction was stopped by addition of buffer containing EDTA as well as, an antiphosphotyrosine antibody labeled with europium cryptate and streptavidin labeled with the fluorophore XL665. FRET between europium cryptate and XL665 was measured after an additional hour of incubation to quantify the phosphorylation of the substrate peptide. ATP concentrations were set at their respective <i>K</i><sub>m</sub> values (9.5 μM for EGFR-WT, 25 μM for EGFR-L858R, and 20 μM for EGFR-L858R/T790M) in conjunction with substrate concentrations of 1 μM, 225 nM, and 275 nM, respectively. Kinase and inhibitor were preincubated for 30 min before the reaction was started by addition of ATP and substrate peptide. An EnVision multimode plate reader (PerkinElmer) was used to measure the fluorescence of the samples at 620 nm (Eu-labeled antibody) and 665 nm (XL665 labeled streptavidin) 50 μs after excitation at 320 nm. The quotient of both intensities for reactions made with eight different inhibitor concentrations was then analyzed using the Quattro Software Suite for IC<sub>50</sub> determination. Each reaction was performed in duplicate, and at least three independent determinations of each IC<sub>50</sub> were made.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Cell Culture</h3><div class="NLM_p last">A431, HCC827, H1975, A549, and H358 cells were obtained from the American Type Culture Collection (ATCC). A431 cells were cultured in DMEM high glucose media (Life Technologies, Germany), and HCC827, H1975, A549, as well as H358 cells were cultured in RPMI media (Life Technologies, Germany), both containing <span class="smallcaps smallerCapital">l</span>-glutamine and supplemented with 10% FBS (PAN-Biotech, Germany) and 1% PenStrep (Life Technologies, Germany) in a humidified incubator at 37 °C and 5% CO<sub>2</sub>. Cell line authentication was performed last in October 2014 by STR profiling of 16 alleles.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Viability Assay</h3><div class="NLM_p last">Cells were seeded on day 1 at cell numbers that ensure linearity and optimal signal intensity (100–300 cells/well, 25 μL). After culturing for 24 h in serum- and antibiotic-containing media in humidified chambers at 37 °C/5% CO<sub>2</sub>, the cells were incubated for 96 h with EGFR inhibitors in serial dilutions (14 nM to 30 μM) with DMSO and staurosporine as control. Compound dilutions were generated using the acoustic dispensing system ECHO 520 liquid handler from Labcyte (Sunnyvale, CA) and the according dose–response software Echo Dose-Response v1.5.4. Viability studies were carried out on day 5 using CellTiterGlo Assay (Promega, U.S.), which is a homogeneous method of determining the number of viable cells in culture. It is based on quantification of ATP, indicating the presence of metabolically active cells. For these studies, CellTiterGlo Reagent was prepared according to the instructions of the kit and diluted 1:1 with the complete growth medium suitable for the corresponding cell line. Then reagent and assay plates were equilibrated at room temperature for 20 min. Equal volumes of the reagent were added to the volume of culture medium present in each well (25 μL). The plates were shaken for 2 min on an orbital shaker to induce cell lysis. The microplates were then incubated at room temperature for 20 min for stabilization of the luminescent signal. Following incubation, the luminescence was recorded on an EnVision microplate reader (PerkinElmer) using 500 ms integration time. The data were then analyzed using the Quattro Software Suite for EC<sub>50</sub> determination. As quality control, the <i>Z</i>′-factor was calculated from 16 positive and negative control values. Only assay results showing a <i>Z</i>′-factor ≥0.5 were used for further analysis. All experimental points were measured in duplicates for each plate and were replicated in at least two plates.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> ADME/DMPK Parameters</h3><div class="NLM_p">For determining kinetic solubility, the compound was diluted from a 10 mM stock in DMSO to a final concentration of 500 μM in 50 mM Hepes buffer, pH 7.4. Following an incubation of 90 min at room temperature on a shaker, the aqueous dilution was filtered through a 0.2 μm PVDF filter, and the optical density between 250 and 500 nm was measured at intervals of 10 nm. The kinetic solubility was calculated from the area under the curve (AUC) between 250 and 500 nm and normalized to absorption of a dilution of the compound in acetonitrile.</div><div class="NLM_p">Absorption was assessed using parallel artificial membrane permeability assay (PAMPA) and Caco-2 cell culture. For PAMPA, the compound was diluted from a 10 mM stock in DMSO to a final concentration of 500 μM in 50 mM Hepes buffer pH 7.4 and transferred onto a transwell membrane covered with a membrane-forming solution of 10% 1.2-dioleyl-<i>sn</i>-glycer-3-phosphocholine (Sigma-Aldrich) and 0.5% (w/v) cholesterol (Sigma-Aldrich) in dodecane. Following an incubation of 20 h at room temperature in a wet chamber, the optical density of the solution in the receiver well was measured between 250 and 500 nm in intervals of 10 nm. The percent flux was calculated from the AUC between 250 and 500 nm and normalized to the absorption of the compound following a 20 h incubation in a parallel transwell containing a membrane covered with 50% methanol in 50 mM Hepes buffer pH 7.4.</div><div class="NLM_p">For Caco-2 cell culture, a 10 mM DMSO stock of the compound was diluted to a final concentration of 5 μM in HBSS buffer pH 7.4 and incubated for 2 h at 37 °C and 5% CO<sub>2</sub> on a monolayer of Caco-2 cells (ATCC) that had been grown on a transwell membrane (Millipore, Schwalbach, Germany) for 21 d. The compound concentration was measured in the receiver as well as the donor well. Apparent permeability (<i>P</i><sub>app</sub>) from either the apical to basolateral direction or vice versa was calculated by the equation: <i>P</i><sub>app</sub> = 1/<i>AC</i><sub>0</sub> (d<i>Q</i>/d<i>t</i>), where <i>A</i> is the membrane surface area, <i>C</i><sub>0</sub> is the donor drug concentration at <i>t</i> = 0, and d<i>Q</i>/d<i>t</i> is the amount of drug transported within the given time period of 2 h.</div><div class="NLM_p">Plasma stability was measured by LC-MS-based determination of % remaining of selected compounds at a concentration of 5 μM after incubation in 100% plasma obtained from different species for 1 h at 37 °C.</div><div class="NLM_p">Assessment of plasma protein binding was measured by equilibrium dialysis by incubating the compound of interest at a concentration of 5 μM for 6 h at 37 °C in 50% plasma in buffer (v/v) followed by LC-MS-based determination of final compound concentrations. The resulting fraction unbound at 50% plasma (<i>f</i><sub>u50</sub>%) was extrapolated to the fraction unbound at 100% plasma (<i>f</i><sub>u100</sub>%) using the following equation: <i>f</i><sub>u100</sub>% = <i>f</i><sub>u50</sub>%/(2 −<i>f</i><sub>u50</sub> %).</div><div class="NLM_p">Metabolic stability under oxidative conditions was measured in liver microsomes from different species by LC-MS-based measuring of depletion of compound at a concentration of 3 μM over time up to 50 min at 37 °C. On the basis of compound half-life <i>t</i><sub>1/2</sub>, in vitro intrinsic clearance Cl<sub>int</sub> was calculated.</div><div class="NLM_p last">To determine the pharmacokinetics of <b>1w</b> totally 24 male RjOrl:SWISS (CD1) mice, age 8–10 weeks, body weight (bw) between 29 and 31 g, were purchased from Janvier, Saint-Berthevin Cedex, France. Mice were fed ad libitum with Allein-Futter für Ratten-/Mäusehaltung from Sniff Special Diets GmbH, Germany. They had free access to water and were kept in a 12 h day/night rhythm. All experiments were approved by the local authorities. Pharmacokinetics were studied for the oral, intraperitoneal (ip), and intravenous (iv) route of administration. For the oral and intraperitoneal routes, a stock solution of 8 mg of <b>1w</b> in 4 mL of a solution consisting of 10% of DMSO and to 90% of an aqueous solution of 30% 2-hydroxypropyl-β-cyclodextrin was prepared. To reach doses of 20 mg/kg bw, 300 μL were administered per 30 g of mouse bw. For the intravenous route of administration, a 2 mg/mL DMSO solution was prepared and 30 μL were applied to a 30 g mouse to reach a concentration of 2 mg/kg·bw. Mice were sacrificed 5, 15, 45, and 135 min after administration of the test compound, and approximately 100 μL of blood was taken from the left heart chamber. Three mice were analyzed per time point and route of administration (oral, ip, and (iv), respectively. Immediately after sampling, blood was centrifuged at 16200<i>g</i> for 10 min at 4 °C and plasma was stored at −80 °C until LC/MS analysis of <b>1w</b>. Prior to LC-MS/MS analysis, plasma proteins were precipitated with acetonitrile containing an internal standard, and samples were filtered. A calibration curve was obtained from spiked blank plasma samples. <b>1w</b> was measured using a Shimadzu UPLC system connected to a QTrap 4000 hybrid triple quadrupole/linear ion trap mass spectrometer (AB Sciex). The regression equation of the calibration curve was used to calculate plasma concentrations. Pharmacokinetic parameters were calculated using the PKSolver software2.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Chemistry</h3><div class="NLM_p">Unless otherwise noted, all reagents and solvents were purchased from Acros, Fluka, Sigma-Aldrich, or Merck and used without further purification. Dry solvents were purchased as anhydrous reagents from commercial suppliers. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance DRX 400 or Bruker Avance DRX 500 spectrometer at 400, 500, 600, or 700 and 101, 126, or 176 MHz, respectively. <sup>1</sup>H chemical shifts are reported in δ (ppm) as s (singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quartet), m (multiplet), and bs (broad singlet) and are referenced to the residual solvent signal DMSO-<i>d</i><sub>6</sub> (2.50). Coupling constants (<i>J</i>) are expressed in hertz (Hz). <sup>13</sup>C spectra are referenced to the residual solvent signal DMSO-<i>d</i><sub>6</sub> (39.52). High-resolution electrospray ionization mass spectra (ESI-FTMS) were recorded on a Thermo LTQ Orbitrap (high-resolution mass spectrometer from Thermo Electron) coupled to an Accela HPLC system supplied with a Hypersil GOLD column (Thermo Electron). Analytical TLC was carried out on Merck 60 F245 aluminum-backed silica gel plates. Compounds were purified by column chromatography using Baker silica gel (40–70 μm particle size) or flash chromatography on a Biotage Isolera One using Biotage SNAP, SNAP Ultra, ZIP Sphere, or ZIP KP-Sil columns (25, 10, 5, or 120 g, respectively) monitored by UV at λ = 254 and 280 nm. Preparative HPLC was conducted on an Agilent HPLC system (1200 series) with a VP 125/21 Nucleodur C18 column from Macherey-Nagel and monitored by UV at λ = 210 nm, 254 nm. All final compounds were purified to >95% purity as determined by high-performance liquid chromatography (HPLC). Purity was measured using Agilent 1200 series HPLC systems with UV detection at 210 nm (system: Agilent Eclipse XDB-C18 4.6 mm × 150 mm, 5 μM, 10–100% CH<sub>3</sub>CN in H<sub>2</sub>O, with 0.1% TFA, for 15 min at 1.0 mL/min).</div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> General Procedure A</h4><div class="NLM_p last">Suzuki cross-coupling of iodinated pyrazolopyrimidines (<b>3</b>) with various boronic acids: <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>3</b>), and the corresponding boronic acid were dissolved in a mixture of DME and ethanol (4 mL, 3/1, v/v) and treated with saturated sodium carbonate solution. The reaction mixture was flushed with argon for 5 min. After that, tetrakis(triphenylphosphine)palladium(0) was added. The mixture was heated to 90 °C and stirred for 12 h under argon atmosphere. The reaction mixture was filtered through a plug of Celite and after that washed using saturated sodium hydrogen carbonate solution and extracted three times with ethyl acetate, washed with water, and saturated sodium chloride solution. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness. The resulting crude product was purified via column chromatography or flash chromatography (normal and reversed phase).</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> General Procedure B</h4><div class="NLM_p last">Deprotection of the secondary amine: The protected pyrazolopyrimidines (<b>5a</b>–<b>o</b>) were dissolved in 3 mL of DCM and cooled to 0 °C. To this stirred solution, 3 mL of a solution of TFA in DCM (25/75, v/v) was added dropwise. The reaction mixture was warmed to room temperature and stirred for 1 h. The reaction mixture was diluted with DCM and the pH adjusted to 8 with satd sodium hydrogen carbonate solution and extracted five times with a solution of 10% MeOH in DCM. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness. The deprotected amines were taken up in THF and cooled to 0 °C. The solution was treated with DIPEA and stirred for 15 min at 0 °C under argon atmosphere. A solution of acryolyl chloride or propionyl chloride in THF was added dropwise at this temperature and stirred until the reaction was complete (15–45 min) at 0 °C. The reaction mixture was quenched with satd sodium hydrogen carbonate solution and extracted three times with ethyl acetate and washed with water and saturated sodium chloride solution. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness. The resulting crude product was purified by column chromatography, flash chromatography (normal and reversed phase), or preparative HPLC.</div></div><div id="sec4_5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (<i>R</i>)-1-(3-(4-Amino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1a</b>)</h4><div class="NLM_p last">Compound <b>1a</b> was prepared according to general procedure B using <b>5a</b> (50 mg, 0.2 mmol, 1.0 equiv), DIPEA (269 μL, 1.6 mmol, 10.0 equiv), and acryolyl chloride (14 μL, 0.2 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–3/97 v/v)). Yield: 15 mg (0.1 mmol, 38% over two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.33 (s, 1H), 8.26 (d, <i>J</i> = 14.5 Hz, 1H), 6.89–6.64 (m, 1H), 6.15–6.04 (m, 1H), 5.73–5.59 (m, 1H), 4.70–4.59 (m, 1H), 4.52 (d, <i>J</i> = 12.4 Hz, 0.5H), 4.27–4.21 (m, 0.5H), 4.19–4.13 (m, 0.5H), 4.11–4.05 (m, 0.5H), 3.63 (m, 0.5H), 3.20–3.11 (m, 1H), 2.98–2.92 (m, 0.5H), 2.25–2.16 (m, 1H), 2.12–2.05 (m, 1H), 1.94–1.87 (m, 1H), 1.65–1.53 (m, 1H). HRMS (ESI-MS): calcd 273.15 for C<sub>13</sub>H<sub>18</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, found 273.15.</div></div><div id="sec4_5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>R</i>)-1-(3-(4-Amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1b</b>)</h4><div class="NLM_p last">Compound <b>1b</b> was prepared according to general procedure B using <b>4</b> (80 mg, 0.2 mmol, 1.0 equiv), DIPEA (204 μL, 1.2 mmol, 1.2 equiv), and acryolyl chloride (28 μL, 0.3 mmol, 1.9 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–2/98 v/v)). Yield: 12 mg (0.03 mmol, 17% over two steps). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.21 (s, 1H), 7.90 (bs, 1H), 6.89–6.69 (m, 1H), 6.63 (bs, 1H), 6.15–6.05 (m, 1H), 5.73–5.59 (m, 1H), 4.65–4.54 (m, 1H), 4.54–4.48 (m, 0.5H), 4.30–4.24 (m, 0.5H), 4.20–4.14 (m, 0.5H), 4.09–4.03 (m, 0.5H), 3.62–3.56 (m, 0.5H), 3.19–3.07 (m, 1H), 2.92–2.86 (m, 0.5H), 2.22–2.15 (m, 1H), 2.08–2.02 (m, 1H), 1.91–1.83 (m, 1H), 1.61–1.47 (m, 1H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.4, 164.9, 158.2, 156.5, 153.7, 153.6, 128.8, 128.7, 128.0, 127.9, 103.7, 103.6, 89.8, 89.7, 53.9, 53.1, 49.6, 46.2, 45.5, 41.9, 30.1, 30.0, 25.4, 23.9. LC-MS (ESI-MS): calcd 399.04 for C<sub>13</sub>H<sub>16</sub>IN<sub>6</sub>O [M + H]<sup>+</sup>, found 399.04.</div></div><div id="sec4_5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (<i>R</i>)-1-(3-(4-Amino-3-ethynyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1c</b>)</h4><div class="NLM_p last">Compound <b>1c</b> was prepared according to general procedure B using <b>11</b> (400 mg, 1.2 mmol, 1.0 equiv), DIPEA (995 μL, 5.9 mmol, 5.0 equiv), and acryolyl chloride (129 μL, 1.6 mmol, 1.4 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–3/97 v/v). Yield: 147 mg (0.5 mmol, 43% over two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.24 (s, 1H), 8.05 (bs, 1H), 6.88–6.68 (m, 1H), 6.54 (bs, 1H), 6.54 (bs, 1H), 6.15–6.05 (m, 1H), 4.66 (s, 1H), 4.65–4.59 (m, 1H), 4.51 (d, <i>J</i> = 11.3 Hz, 0.5H), 4.29–4.16 (m, 1H), 4.07 (d, <i>J</i> = 13.4 Hz, 0.5H), 3.64–3.58 (m, 0.5H), 3.19–3.09 (m, 1H), 2.95–2.89 (m, 0.5H), 2.22–2.15 (m, 1H), 2.10–2.05 (m, 1H), 1.93–1.85 (m, 1H), 1.60–1.52 (m, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.6, 164.5, 157.7, 156.5, 152.8, 152.7, 128.3, 128.2, 127.6, 127.5, 125.1, 125.0, 101.0, 100.9, 86.2, 75.2, 53.4, 52.5, 49.1, 45.6, 45.1, 41.5, 29.5, 29.4, 24.9, 23.4. HRMS (ESI-MS): calcd 297.14647 for C<sub>15</sub>H<sub>17</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, found 297.14584.</div></div><div id="sec4_5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>R</i>)-1-(3-(4-Amino-3-phenyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1d</b>)</h4><div class="NLM_p last">Compound <b>1d</b> was prepared according to general procedure B using <b>5b</b> (286 mg, 0.7 mmol, 1.0 equiv), and 100 mg (0.3 mmol, 1.0 equiv) of the deprotected compound were then used according to general procedure B with DIPEA (340 μL, 2.0 mmol, 5.9 equiv) and acryolyl chloride (30 μL, 0.4 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v)) and subsequent preparative HPLC (H<sub>2</sub>O/ACN (20/80, v/v) + 0.2% TFA as additive). Yield: 18 mg (0.05 mmol, 15%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.31 (s, 1H), 7.68 (d, <i>J</i> = 7.2 Hz, 2H), 7.59–7.53 (m, 2H), 7.52–7.47 (m, 1H), 7.04 (bs, 2H), 6.94–6.63 (m, 1H), 6.23–6.02 (m, 1H), 5.73–5.56 (m, 1H), 4.81–4.66 (m, 1H), 4.56 (d, <i>J</i> = 10.9 Hz, 0.5H), 4.20 (d, <i>J</i> = 11.2 Hz, 1H), 4.07 (d, <i>J</i> = 12.3 Hz, 0.5H), 3.77–3.67 (m, 0.5H), 3.29–3.16 (m, 1H), 3.07–2.99 (m, 0.5H), 2.34–2.22 (m, 1H), 2.17–2.10 (m, 1H), 1.98–1.90 (m, 1H), 1.67–1.52 (m, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.4, 158.4, 154.6, 155.3, 144.7, 133.6, 130.0, 129.6, 129.3, 129.1, 128.3, 128.0, 98.2, 53.6, 52.9, 49.8, 46.5, 47.0, 42.5, 30.2, 30.5, 25.7, 24.0. LC-MS (ESI-MS): calcd 349.18 for C<sub>19</sub>H<sub>21</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, found 349.18.</div></div><div id="sec4_5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (<i>R</i>)-1-(3-(4-Amino-3-phenyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)propan-1-one (<b>1e</b>)</h4><div class="NLM_p last">Compound <b>1e</b> was prepared according to general procedure B using <b>5b</b> (286 mg, 0.7 mmol, 1.0 equiv), and 70 mg (0.2 mmol, 1.0 equiv) of the deprotected compound were then used according to general procedure B with DIPEA (243 μL, 1.4 mmol, 6.0 equiv) and propionyl chloride (23 μL, 0.3 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v) and subsequent preparative HPLC (H<sub>2</sub>O/ACN + 0.1% TFA as additive). Yield: 43 mg (0.1 mmol, 50% over two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (d, <i>J</i> = 11.6 Hz, 1H), 7.67 (d, <i>J</i> = 7.3 Hz, 2H), 7.55 (dd, <i>J</i> = 7.4 Hz, 2H), 7.52–7.47 (m, 1H), 8.85 (bs, 2H), 4.79–4.60 (m, 1H), 4.57–4.51 (m, 0.5H) 4.22 (d, <i>J</i> = 13.0 Hz, 0.5H), 4.06–4.00 (m, 0.5H), 3.87 (d, <i>J</i> = 13.3 Hz, 0.5H), 3.62–3.55 (m, 0.5H), 3.16–3.07 (m, 1H), 2.90–2.82 (m, 0.5H), 2.42–2.19 (m, 3H), 2.16–2.07 (m, 1H), 1.94–1.84 (m, 1H), 1.69–1.47 (m, 1H), 1.04–0.94 (m, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.4, 171.3, 158.1, 155.6, 155.5, 154.0, 153.9, 143.7, 143.6, 132.9, 129.0, 128.6, 128.2, 97.4, 97.4, 52.7, 52.1, 49.1, 45.3, 44.8, 41.1, 29.6, 29.3, 25.6, 24.6, 23.4, 9.4. HRMS (ESI-MS): calcd 351.19349 for C<sub>19</sub>H<sub>23</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, found 351.19279.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (<i>R</i>,<i>E</i>)-1-(3-(4-Amino-3-phenyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-4-(dimethylamino)but-2-en-1-one (<b>1f</b>)</h4><div class="NLM_p last">Compound <b>1f</b> was prepared according to general procedure B using <b>5b</b> (286 mg, 0.7 mmol, 1.0 equiv), and 50 mg (0.2 mmol, 1.0 equiv) of the deprotected compound were then dissolved in 2 mL of DCM and treated with (<i>E</i>)-4-(dimethylamino)but-2-enoic acid hydrochloride (42 mg, 0.3 mmol, 1.5 equiv), 3-(ethyliminomethyleneamino)-<i>N</i>,<i>N</i>-dimethylpropan-1-amine hydrochloride (49 mg, 0.3 mmol, 1.5 equiv), benzotriazol-1-ol (34 mg, 0.3 mmol, 1.5 equiv), and DIPEA (173 μL, 1.0 mmol, 6.0 equiv). The reaction mixture was stirred for 12 h at room temperature. The reaction mixture was diluted with DCM and the pH adjusted to 8 with satd sodium hydrogen carbonate solution and extracted four times with a solution of 10% MeOH in DCM. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness. The crude product was purified by column chromatography (MeOH/DCM (2/98 v/v–10/90 v/v) and subsequent preparative HPLC (H<sub>2</sub>O/ACN + 0.1% TFA as additive). Yield: 19 mg (0.05 mmol, 29%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (d, <i>J</i> = 3.8 Hz, 1H), 7.70–7.64 (m, 2H), 7.62 (bs, 2H), 7.58–7.53 (m, 2H), 7.52–7.48 (m, 1H), 7.05–6.85 (m, 1H), 6.71–6.58 (m, 1H), 4.79–4.67 (m, 1H), 4.54 (d, <i>J</i> = 12.0 Hz, 0.5H), 4.28–4.17 (m, 1H), 4.08 (d, <i>J</i> = 13.4 Hz, 0.5H), 3.87 (d, <i>J</i> = 6.9 Hz, 1H), 3.74 (d, <i>J</i> = 6.9 Hz, 1H), 3.77–3.70 (m, <i>J</i> = 8.9 Hz, 0.5H), 3.28–3.20 (m, 1H), 3.03–2.96 (m, 0.5), 2.72 (s, 3H), 2.65 (s, 3H), 2.31–2.21 (m, 1H), 2.16–2.09 (m, 1H), 1.98–1.87 (m, 1H), 1.69–1.53 (m, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.5, 158.2, 155.8, 155.7, 154.1, 154.0, 143.9, 143.8, 132.9, 132.9, 132.4, 132.1, 129.2, 129.2, 129.0, 128.8, 128.3, 128.3, 97.4, 56.7, 52.8, 52.0, 49.4, 45.9, 45.3, 41.8, 41.6, 29.7, 29.6, 24.9, 23.4. HRMS (ESI-MS): calcd 406.23599 for C<sub>22</sub>H<sub>28</sub>N<sub>7</sub>O [M + H]<sup>+</sup>, found 406.23499.</div></div><div id="sec4_6_0_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>R</i>)-1-(3-(4-Amino-3-(3-fluorophenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1g</b>)</h4><div class="NLM_p last">Compound <b>1g</b> was prepared according to general procedure B using <b>5c</b> (239 mg, 0.6 mmol, 1.0 equiv), and 44 mg (0.1 mmol, 1.0 equiv) of the deprotected compound were then used according to general procedure B with DIPEA (246 μL, 1.4 mmol, 10.2 equiv) and acryolyl chloride (13.0 μL, 0.2 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v). Yield: 15.0 mg (0.04 mmol, 29%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (s, 1H), 7.60–7.41 (m, 3H), 7.36–7.27 (m, 1H), 6.90–6.61 (m, 1H), 6.09 (dd, <i>J</i> = 35.8, 16.9 Hz, 1H), 5.74–5.53 (m, 1H), 4.73 (s, 1H), 4.17 (s, 1H), 3.77–3.66 (m, 1H), 3.24 (dd, <i>J</i> = 11.7 Hz, 1H), 2.04–1.88 (m, 2H), 1.59 (s, 1H), 1.32–1.19 (m, 2H). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>) δ −74.34 (s, <i>J</i> = 293.7 Hz). HRMS (ESI-MS): calcd 367.16771 for C<sub>19</sub>H<sub>19</sub>ON<sub>6</sub>F [M + H]<sup>+</sup>, found 367.16812.</div></div><div id="sec4_6_0_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>R</i>)-1-(3-(4-Amino-3-(3-fluorophenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)propan-1-one (<b>1h</b>)</h4><div class="NLM_p last">Compound <b>1h</b> was prepared according to general procedure B using <b>5c</b> (239 mg, 0.6 mmol, 1.0 equiv), and 181 mg (0.4 mmol, 1.0 equiv) of the deprotected compound were then used according to general procedure B with DIPEA (249 μL, 1.4 mmol, 3.3 equiv) and propionyl chloride (56 μL, 0.6 mmol, 1.5 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v). Yield: 36 mg (0.1 mmol, 23%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.30 (d, <i>J</i> = 8.4 Hz, 1H), 7.62–7.56 (m, 1H), 7.50 (d, <i>J</i> = 7.6 Hz, 1H), 7.47–7.41 (m, 1H), 7.35–7.30 (m, 1H), 7.17 (bs, 2H), 4.80–4.61 (m, 1H), 4.54–4.48 (m, 0.5H), 4.20 (d, <i>J</i> = 13.0 Hz, 0.5H), 4.05–3.99 (m, 0.5H), 3.87 (d, <i>J</i> = 13.5 Hz, 0.5H), 3.61–3.55 (m, 0.5H), 3.17–3.09 (m, 1H), 2.93–2.82 (m, 0.5H), 2.42–2.18 (m, 3H), 2.15–2.07 (m, 1H), 1.94–1.83 (m, 1H), 1.69–1.46 (m, 1H), 1.03–0.94 (m, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.4, 163.5, 161.5, 157.6, 155.1, 153.8, 142.7, 134.9, 131.1, 124.4, 115.6, 115.4, 97.3, 52.8, 52.3, 49.0, 45.3, 44.7, 41.1, 29.5, 29.3, 25.6, 24.5, 23.5, 9.4. <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>) δ −73.70 (s, <i>J</i> = 299.4 Hz). HRMS (ESI-MS): calcd 369.18336 for C<sub>19</sub>H<sub>21</sub>ON<sub>6</sub>F [M + H]<sup>+</sup>, found 369.18390.</div></div><div id="sec4_6_0_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>R</i>)-1-(3-(4-Amino-3-(4-fluorophenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1i</b>)</h4><div class="NLM_p last">Compound <b>1i</b> was prepared according to general procedure B using <b>5d</b> (78 mg, 0.2 mmol, 1.0 equiv), DIPEA (326 μL, 1.9 mmol, 9.8 equiv), and acryolyl chloride (16.8 μL, 0.2 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–3/97 v/v)). Yield: 44 mg (0.1 mmol, 63% over two steps). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8,39 (s, 1H), 7.67 (m, 2H), 7.23 (t, 2H), 6.58 (m, 1H), 6.29 (d, 1H), 5.68 (d, 1H), 5.40 (s, 2H), 2.36 (m, 1H), 2.24 (m, 1H), 2.02 (m, 1H), 1.74 (m, 1H), 1.27 (m, 5H). HRMS calcd: 367.16 for C<sub>19</sub>H<sub>20</sub>FN<sub>6</sub>O [M + H]<sup>+</sup>, found 367.17.</div></div><div id="sec4_6_0_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>R</i>)-1-(3-(4-Amino-3-(4-fluorophenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)propan-1-one (<b>1j</b>)</h4><div class="NLM_p last">Compound <b>1j</b> was prepared according to general procedure B using <b>5d</b> (389 mg, 0.9 mmol, 1.0 equiv), DIPEA (1.87 mL, 11.0 mmol, 11.7 equiv), and propionyl chloride (101 μL, 1.2 mmol, 1.3 equiv). The crude product was purified by preperative HPLC (MeOH/DCM (25/75, v/v + 0.2% TFA as additive). Yield: 111 mg (0.3 mmol, 29%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.25 (t, <i>J</i> = 9.2 Hz, 1H), 7.69 (ddd, <i>J</i> = 7.9, 5.3, 2.2 Hz, 2H), 7.37 (td, <i>J</i> = 8.8, 2.2 Hz, 2H), 4.80–4.58 (m, 1H), 4.57–4.19 (m, 1H), 3.97 (ddd, <i>J</i> = 67.3, 27.7, 10.3 Hz, 1H), 3.54 (dt, <i>J</i> = 26.0, 13.0 Hz, 1H), 3.16–3.05 (m, 1H), 2.83 (t, <i>J</i> = 10.9 Hz, 1H), 2.41–2.19 (m, 2H), 2.13–2.03 (m, 1H), 1.94–1.82 (m, 1H), 1.57 (dddd, <i>J</i> = 27.9, 14.8, 11.1, 3.4 Hz, 1H), 0.98 (dt, <i>J</i> = 21.5, 7.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.4, 163.4, 161.4, 158.2, 155.8 (d, <i>J</i> = 9.0 Hz), 154.0, 142.9, 130.5, 129.3, 116.1, 97.4, 52.7, 52.1, 49.1, 45.4, 44.8, 29.5, 25.6, 24.7, 23.5, 9.5. <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>) δ −73.43 (s, <i>J</i> = 299.4 Hz). HRMS calcd: 369.18 for C<sub>19</sub>H<sub>22</sub>FN<sub>6</sub>O [M + H]<sup>+</sup>, found 369.18.</div></div><div id="sec4_6_0_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>R</i>)-1-(3-(4-Amino-3-(3-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1k</b>)</h4><div class="NLM_p last">Compound <b>1k</b> was prepared according to general procedure B using <b>5e</b> (415 mg, 0.9 mmol, 1.0 equiv), and 100 mg (0.3 mmol, 1.0 equiv) of the deprotected compound were then used according to general procedure B with DIPEA (289 μL, 1.7 mmol, 6.1 equiv) and acryolyl chloride (25 μL, 0.3 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v). Yield: 46 mg (0.1 mmol, 39%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (s, 1H), 7.98–7.93 (m, 2H), 7.86–7.74 (m, 2H), 7.03 (bs, 2H), 6.91–6.66 (m, 1H), 6.18–6.02 (m, 1H), 5.75–5.54 (m, 1H), 4.83–4.68 (m, 1H), 4.53 (d, <i>J</i> = 11.2 Hz, 0.5H), 4.24–4.12 (m, 1H), 4.05 (d, <i>J</i> = 12.4 Hz, 0.5H), 3.81–3.71 (m, 0.5H), 3.41–3.17 (m, 1H), 3.14–3.03 (m, 0.5H), 2.33–2.23 (m, 1H), 2.18–2.09 (m,, 1H), 1.99–1.87 (m, 1H), 1.67–1.53 (m, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.5 158.2, 155.7, 154.0, 142.4, 133.8, 132.2, 130.1, 129.7, 129.5, 128.3, 127.3, 127.1, 125.2, 125.0, 124.6, 123.0, 97.5, 52.8, 52.1, 49.0, 45.6, 45.1, 41.5, 29.5, 29.2, 24.7, 23.1. <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>) δ −60.98 (s, <i>J</i> = 225.9 Hz). HRMS (ESI-MS): calcd 417.16316 for C<sub>20</sub>H<sub>20</sub>F<sub>3</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, found 417.16452.</div></div><div id="sec4_6_0_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>R</i>)-1-(3-(4-Amino-3-(3-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)propan-1-one (<b>1l</b>)</h4><div class="NLM_p last">Compound <b>1l</b> was prepared according to general procedure B using <b>5e</b> (415 mg, 0.9 mmol, 1.0 equiv), and 75 mg (0.2 mmol, 1.0 equiv) of the deprotected compound were then used according to general procedure B with DIPEA (211 μL, 0.8 mmol, 3.6 equiv) and propionyl chloride (20 μL, 0.2 mmol, 1.1 equiv). The crude product was purified by flash chromatography (MeOH/DCM (1/99 v/v–4/96 v/v) and subsequent preparative HPLC (H<sub>2</sub>O/ACN + 0.1% TFA as additive). Yield: 61 mg (0.2 mmol, 71%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (d, <i>J</i> = 11.5 Hz, 1H), 7.99–7.94 (m, 2H), 7.85–7.75 (m, 2H), 7.03 (bs, 2H), 4.81–4.62 (m, 1H), 4.55–4.47 (m, 0.5H), 4.20 (d, <i>J</i> = 12.3 Hz, 0.5H), 4.05–4.00 (m, 0.5H), 3.86 (d, <i>J</i> = 13.3 Hz, 0.5H), 3.64–3.57 (m, 0.5H), 3.20–3.11 (m, 1H), 2.92–2.84 (m, 0.5H), 2.42–2.19 (m, 3H), 2.17–2.08 (m, 1H), 1.96–1.82 (m, 1H), 1.69–1.48 (m, 1H), 1.03–0.94 (m, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.4, 171.3, 158.2, 155.7, 155.6, 154.3, 154.1, 142.3, 142.2, 134.0, 133.8, 132.2, 130.1, 129.9, 129.8, 129.5, 127.3, 125.2, 125.0, 124.6, 123.0, 97.6, 97.4, 52.8, 52.2, 49.0, 45.3, 44.8, 41.0, 29.5, 29.3, 25.6, 24.4, 23.3, 9.3. HRMS (ESI-MS): calcd 419.18127 for C<sub>20</sub>H<sub>22</sub>F<sub>3</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, found 419.18017.</div></div><div id="sec4_6_0_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>R</i>,<i>E</i>)-1-(3-(4-Amino-3-(3-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-4-(dimethylamino)but-2-en-1-one (<b>1m</b>)</h4><div class="NLM_p last">Compound <b>1m</b> was prepared according to general procedure B using <b>5e</b> (415 mg, 0.9 mmol, 1.0 equiv), and 50 mg, 0.1 mmol, 1.0 equiv) of the deprotected compound were then solved in 2 mL of DCM and treated with (<i>E</i>)-4-(dimethylamino)but-2-enoic acid hydrochloride (35 mg, 0.2 mmol, 1.5 equiv), 3-(ethyliminomethyleneamino)-<i>N</i>,<i>N</i>-dimethylpropan-1-amine hydrochloride (40 mg, 0.2 mmol, 1.5 equiv), benzotriazol-1-ol (28 mg, 0.2 mmol, 1.5 equiv), and DIPEA (141 μL, 0.8 mmol, 5.9 equiv). The reaction mixture was stirred for 12 h at room temperature. The reaction mixture was diluted with DCM and the pH adjusted to 8 with satd sodium hydrogen carbonate solution and extracted four times with a solution of 10% MeOH in DCM. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness. The crude product was purified by column chromatography (MeOH/DCM (2/98 v/v–10/90 v/v)) and subsequent preparative HPLC (H<sub>2</sub>O/ACN + 0.1% TFA as additive). Yield: 23 mg (0.05 mmol, 36%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (s, 1H), 7.98–7.93 (m, 2H), 7.87–7.74 (m, 2H), 7.21 (s, 2H), 6.72–6.42 (m, 2H), 4.83–4.65 (m, 2H), 4.55–4.49 (m, 0.5H), 4.17–4.11 (m, 0.5H), 4.09–4.02 (m, 1H), 4.09–4.02 (m, 0.5H), 3.27–3.19 (m, 1H), 3.17–3.11 (m, 0.5H), 3.05 (d, <i>J</i> = 5.2 Hz, 0.5H), 2.88 (d, <i>J</i> = 4.9 Hz, 0.5H), 2.32–2.21 (m, 1H), 2.16 (s, 3H), 2.18–2.07 (m, 1H), 2.05 (s, 3H), 2.01–1.88 (m, 1H), 1.67–1.52 (m, 1H). HRMS (ESI-MS): calcd 474.22348 for C<sub>23</sub>H<sub>27</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup>, found 474.22237.</div></div><div id="sec4_6_0_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>R</i>)-1-(3-(4-Amino-3-(4-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1n</b>)</h4><div class="NLM_p last">Compound <b>1r</b> was prepared according to general procedure B using <b>5f</b> (439 mg, 1.0 mmol, 1.0 equiv), DIPEA (1.7 μL, 10.0 mmol, 10.5 equiv), and acryolyl chloride (89.8 μL, 1.1 mmol, 1.2 equiv). The crude product was purified by reverse-phase flash chromatography (H<sub>2</sub>O/ACN (20/80, v/v) with 0.2% TFA as additive) and subsequent preparative HPLC (H<sub>2</sub>O/ACN (30/70, v/v) + 0.2% TFA as additive). Yield: 123 mg (0.3 mmol, 31% over two steps). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (s, 1H), 7.89 (s, 4H), 6.96–6.66 (m, 1H), 6.08 (dt, <i>J</i> = 34.5, 17.4 Hz, 1H), 5.63 (dt, <i>J</i> = 60.8, 11.9 Hz, 1H), 4.72 (dd, <i>J</i> = 31.2, 20.2 Hz, 1H), 4.15 (dt, <i>J</i> = 33.0, 13.4 Hz, 2H), 3.27–3.01 (m, 2H), 2.31–2.20 (m, 1H), 2.16 (d, <i>J</i> = 15.7 Hz, 1H), 1.98–1.89 (m, 1H), 1.61 (d, <i>J</i> = 12.8 Hz, 1H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.6, 158.2, 155.8, 136.8, 129.0, 126.0, 97.5, 70.0–69.57, 53.00–52.63, 49.51–49.04, 45.70, 29.70–29.48, 24.87. <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>) δ −60.98 (s, <i>J</i> = 225.9 Hz). HRMS (ESI-MS): calcd 417.16452 for C<sub>20</sub>H<sub>20</sub>N<sub>6</sub>OF<sub>3</sub> [M + H]<sup>+</sup> and 439.14647 for C<sub>20</sub>H<sub>19</sub>N<sub>6</sub>OF<sub>3</sub>Na [M + Na]<sup>+</sup>, found 417.16392 and 439.14578.</div></div><div id="sec4_6_0_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>R</i>)-1-(3-(4-Amino-3-(4-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)propan-1-one (<b>1o</b>)</h4><div class="NLM_p last">Compound <b>1o</b> was prepared according to general procedure B using <b>5f</b> (246 mg, 0.5 mmol, 1.0 equiv), and 102 mg (0.3 mmol, 1.0 equiv) of the deprotected compound were then used according to general procedure B with DIPEA (483 μL, 2.8 mmol, 10.0 equiv) and propionyl chloride (27 μL, 0.3 mmol, 1.1 equiv). The crude product was purified by flash chromatography (DCM/EtOAc (95/5, v/v + 1% ammonia as additive). Yield: 46 mg (0.1 mmol, 39%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.42 (s, 1H), 7.88–7.77 (m, 2H), 4.08 (d, <i>J</i> = 11.6 Hz, 1H), 3.90 (d, <i>J</i> = 13.7 Hz, 1H), 3.70–3.60 (m, 1H), 3.31 (t, <i>J</i> = 11.7 Hz, 1H), 3.16 (t, <i>J</i> = 12.0 Hz, 1H), 2.77 (t, <i>J</i> = 11.8 Hz, 1H), 2.42 (dt, <i>J</i> = 15.1, 7.6 Hz, 1H), 2.45–2.36 (m, 1H), 2.03–1.92 (m, 1H), 1.65 (d, <i>J</i> = 30.5 Hz, 2H), 1.16 (dd, <i>J</i> = 17.8, 7.5 Hz, 2H). HRMS calcd: 419.18017 for C<sub>20</sub>H<sub>22</sub>F<sub>3</sub>N<sub>6</sub>O [M + H]<sup>+</sup> and 441.16212 for C<sub>20</sub>H<sub>21</sub>F<sub>3</sub>N<sub>6</sub>ONa [M + Na]<sup>+</sup>, found 419.17997 and 441.16178.</div></div><div id="sec4_6_0_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>R</i>)-1-(3-(4-Amino-3-cyclopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1p</b>)</h4><div class="NLM_p last">Compound <b>1p</b> was prepared according to general procedure B using <b>5g</b> (236 mg, 0.7 mmol, 1.0 equiv), and 50 mg (0.2 mmol, 1.0 equiv) of the deprotected compound were then used according to general procedure B with DIPEA (194 μL, 1.1 mmol, 6.0 equiv) and acryolyl chloride (17 μL, 0.2 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v) and EtOAc (with 1% ammonia as additive) and subsequent preparative HPLC (H<sub>2</sub>O/ACN (20/80, v/v) + 0.1% TFA as additive). Yield: 17 mg (0.05 mmol, 26%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.13 (bs, 1H), 7.28 (bs, 2H), 6.91–6.60 (m, 1H), 6.14–6.01 (m, 1H), 5.73–5.54 (m, 1H), 4.58–4.44 (m, 1H), 4.40 (d, <i>J</i> = 11.9 Hz, 0.5H), 4.17–4.09 (m, 0.5H), 4.08–4.00 (m, 1H), 3.64–3.56 (m, 0.5H), 3.21–3.05 (m, 1H), 3.04–2.96 (m, 0.5H), 2.45–2.38 (m, 1H), 2.19–2.10 (m, 1H), 2.02–1.96 (m, 1H), 1.91–1.82 (m, 1H), 1.58–1.45 (m, 1H), 0.93 (d, <i>J</i> = 7.6 Hz, 2H), 0.86 (bs, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.5, 164.4, 158.3, 155.6, 153.7, 153.6, 145.7, 145.6, 128.4, 128.3, 127.5, 127.2, 99.1, 99.1, 52.3, 51.8, 49.2, 45.7, 45.1, 41.6, 29.5, 29.3, 24.9, 23.2, 8.6, 7.7. HRMS (ESI-MS): calcd 313.17791 for C<sub>16</sub>H<sub>21</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, found 313.17714.</div></div><div id="sec4_6_0_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>R</i>)-1-(3-(4-Amino-3-(4-hydroxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1q</b>)</h4><div class="NLM_p last">Compound <b>1q</b> was prepared according to general procedure B using <b>5h</b> (88 mg, 0.2 mmol, 1.0 equiv), DIPEA (371 μL, 2.2 mmol, 9.8 equiv), and acryolyl chloride (19.3 μL, 0.2 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v)). Yield: 51 mg (0.1 mmol, 64% over two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.45 (s, 1H), 7.46 (d, 2H), 7.27 (s, 2H), 6.95 (d 2H), 4.74 (s, 1H), 4.20 (m, 1H), 3.97 (m, 1H), 3.20 (m, 1H), 2.25 (m, 1H), 2.11 (m, 1H), 1.98 (m, 1H), 1.56 (m, 2H). HRMS calcd: 365.17 for C<sub>19</sub>H<sub>21</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, found 365.17.</div></div><div id="sec4_6_0_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>R</i>)-1-(3-(4-Amino-3-benzyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1r</b>)</h4><div class="NLM_p last">Compound <b>1r</b> was prepared according to general procedure B using <b>5i</b> (58 mg, 0.1 mmol, 1.0 equiv), DIPEA (223 μL, 1.3 mmol, 9.2 equiv), and acryolyl chloride (12 μL, 0.1 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v). Yield: 27 mg (0.07 mmol, 50% over two steps). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.36 (s, 1H), 8.16 (s, 2H), 7.57–7.30 (m, 5H), 6.55 (d, <i>J</i> = 43.0 Hz, 1H), 6.33 (d, <i>J</i> = 16.5 Hz, 1H), 5.74 (d, <i>J</i> = 10.3 Hz, 1H), 5.50 (s, 1H), 4.84 (s, 1H), 2.33 (d, <i>J</i> = 7.6 Hz, 2H), 2.25 (d, <i>J</i> = 9.1 Hz, 2H), 2.06 (d, <i>J</i> = 13.6 Hz, 3H), 1.71 (dt, <i>J</i> = 43.7, 16.0 Hz, 2H). HRMS (ESI-MS): calcd 363.19279 for C<sub>20</sub>H<sub>23</sub>ON<sub>6</sub> [M + H]<sup>+</sup> and 385.17473 for C<sub>20</sub>H<sub>22</sub>ON<sub>6</sub>Na [M + Na]<sup>+</sup>, found 363.19288 and 385.17471.</div></div><div id="sec4_6_0_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>R</i>)-1-(3-(4-Amino-3-(cyclopentylethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1s</b>)</h4><div class="NLM_p last">Compound <b>1s</b> was prepared according to general procedure B using <b>5j</b> (125 mg, 0.3 mmol, 1.0 equiv), and 109 mg (0.3 mmol, 1.0 equiv) of the deprotected compound were then used according to general procedure B with DIPEA (604 μL, 3.5 mmol, 11.3 equiv) and acryolyl chloride (31 μL, 0.4 mmol, 1.3 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–3/97 v/v). Yield: 22 mg (0.06 mmol, 19%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (s, 1H), 6.94–6.57 (m, 1H), 6.19–5.99 (m, 1H), 5.77–5.52 (m, 1H), 4.67–4.58 (m, 1H), 4.52 (d, <i>J</i> = 11.3 Hz, 0.5H), 4.32–4.24 (m, 0.5H), 4.21–4.14 (m, 0.5H), 4.09–4.04 (m, 0.5H), 3.64–3.56 (m, 0.5H), 3.21–3.06 (m, 1H), 3.06–2.97 (m, 1H), 2.93–2.83 (m, 0.5H), 2.24–2.13 (m, 1H), 2.10–1.98 (m, 3H), 1.94–1.83 (m, 1H), 1.78–1.65 (m, 4H), 1.64–1.51 (m, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.9, 156.5, 154.6, 152.2, 128.3, 127.2, 100.3, 71.4, 52.6, 48.9, 44.9, 41.0, 33.1, 30.2, 29.1, 24.5, 22.9. HRMS (ESI-MS): calcd 365.20844 for C<sub>20</sub>H<sub>25</sub>ON<sub>6</sub> [M + H]<sup>+</sup> and 387.19038 for C<sub>20</sub>H<sub>24</sub>ON<sub>6</sub>Na [M + Na]<sup>+</sup>, found 365.20857 and 387.19038.</div></div><div id="sec4_6_0_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>R</i>)-1-(3-(4-Amino-3-(3-cyclopentylprop-1-yn-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1t</b>)</h4><div class="NLM_p last">Compound <b>1t</b> was prepared according to general procedure B using <b>5k</b> (66 mg, 0.2 mmol, 1.0 equiv), DIPEA (270 μL, 1.6 mmol, 9.8 equiv), and acryolyl chloride (15 μL, 0.2 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v). Yield: 38 mg (0.1 mmol, 63% over two steps). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.20 (s, 1H), 6.75 (s, 2H), 6.59 (m, 1H), 6.32 (d,1H), 5.75 (d, 1H), 4.81 (d, 1H), 4.03 (d, 1H), 3.72 (m, 1H), 3.24 (m,2H), 2.19 (m, 2H), 1.88 (dt, 2H), 1.68 (m, 4H), 1.60 (m, 3H), 1.31 (dt, 3H), 1.25 (m, 1H). <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ 166.1, 153.8, 153.8, 150.5, 146.6, 129.0, 129.0, 127.3, 86.7, 53.6, 46.2, 45.9, 38.80, 38.78, 25.5, 25.5, 25.3, 25.2. HRMS (ESI-MS): calcd 379.22 for C<sub>21</sub>H<sub>27</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, found 379.22.</div></div><div id="sec4_6_0_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (<i>R</i>)-1-(3-(4-Amino-3-(naphthalen-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1u</b>)</h4><div class="NLM_p last">Compound <b>1u</b> was prepared according to general procedure B using <b>5l</b> (37 mg, 0.1 mmol, 1.0 equiv), DIPEA (85 μL, 0.5 mmol, 6.3 equiv), and acryolyl chloride (7.4 μL, 0.1 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v)) and subsequent preparative HPLC (H<sub>2</sub>O/ACN (20/80, v/v) + 0.2% TFA as additive). Yield: 9 mg (0.02 mmol, 22% over two steps). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (bs, 1H), 8.20 (d, <i>J</i> = 7.8 Hz, 1H), 8.08 (d, <i>J</i> = 8.3 Hz, 1H), 8.06–7.99 (m, 2H), 7.82 (d, <i>J</i> = 8.1 Hz, 1H), 7.61–7.57 (m, 2H), 6.93–6.71 (m, 1H), 6.18–6.06 (m, 1H), 5.74–5.59 (m, 1H), 4.80–4.70 (m, 1H), 4.58 (d, <i>J</i> = 12.5 Hz, 0.5H), 4.27–4.22 (m, 1H), 4.13–4.07 (m, 0.5H), 3.78–3.72 (m, 0.5H), 3.28–3.19 (m, 1H), 3.05–2.99 (m, 0.5H), 2.35–2.26 (m, 1H), 2.19–2.15 (m, 1H), 2.00–1.95 (m, 1H), 1.66–1.55 (m, 1H). HRMS (ESI-MS): calcd 399.19395 for C<sub>23</sub>H<sub>23</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, found 399.19279.</div></div><div id="sec4_6_0_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>R</i>)-1-(3-(4-Amino-3-(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1v</b>)</h4><div class="NLM_p last">Compound <b>1v</b> was prepared according to general procedure B using <b>5m</b> (24 mg, 0.1 mmol, 1 0.0 equiv), DIPEA (28 μL, 0.2 mmol, 3.0 equiv), and acryolyl chloride (4.9 μL, 0.1 mmol, 1.20 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v). Yield: 17 mg (0.04 mmol, 80% over two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.82 (s, 1H), 8.48 (s, 1H), 8.27 (s, 1H), 8.19 (s, 1H), 7.57–7.56 (m, 1H), 6.94 (bs, 2H), 6.91–6.68 (m, 2H), 6.59–6.53 (m, 1H), 6.18–6.02 (m, 1H), 5.73–5.55 (m, 1H), 4.81–4.65 (m, 1H), 4.57 (d, <i>J</i> = 10.8 Hz, 0.5H), 4.26–4.15 (m, 1H), 4.07 (d, <i>J</i> = 12.5 Hz, 0.5H), 3.79–3.68 (m, 0.5H), 3.28–3.18 (m, 1H), 3.08–2.97 (m, 0.5H), 2.37–2.24 (m, 1H), 2.20–2.08 (m, 1H), 2.00–1.87 (m, 1H), 1.68–1.49 (m, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.6, 158.3, 155.6, 154.0, 148.4, 142.4, 128.3, 127.8, 127.3, 127.1, 120.8, 119.5, 100.4, 97.7, 52.8, 52.0, 49.3, 45.7, 45.1, 41.5, 29.7, 29.4, 24.8, 23.2. HRMS (ESI-MS): calcd 389.18450 for C<sub>20</sub>H<sub>21</sub>N<sub>8</sub>O [M + H]<sup>+</sup>, found 389.18328.</div></div><div id="sec4_6_0_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (<i>R</i>)-1-(3-(4-Amino-3-(1-methyl-1<i>H</i>-indol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1w</b>)</h4><div class="NLM_p last">Compound <b>1w</b> was prepared according to general procedure B using <b>5n</b> (85 mg, 0.2 mmol, 1.0 equiv), DIPEA (196 μL, 1.2 mmol, 6.3 equiv), and acryolyl chloride (17 μL, 0.2 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v). Yield: 48 mg (0.1 mmol, 63% over two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) δ 8.24 (d, 1H), 7.87 (d, <i>J</i> = 7.9 Hz, 1H), 7.71 (d, <i>J</i> = 9.0 Hz, 1H), 7.54 (d, <i>J</i> = 8.3 Hz, 1H), 7.26 (dd, <i>J</i> = 7.5 Hz, 1H), 7.15 (dd, <i>J</i> = 7.4 Hz, 1H), 6.98 (bs, 2H), 6.91–6.70 (m, 1H), 6.17–6.04 (m, 1H), 5.73–5.57 (m, 1H), 4.75–4.65 (m, 1H), 4.57 (d, <i>J</i> = 11.1 Hz, 0.5H), 4.31–4.20 (m, 1H), 4.08 (d, <i>J</i> = 13.4 Hz, 0.5H), 3.88 (s, 3H), 3.74–3.68 (m, 0.5H), 3.29–3.18 (m, 1H), 3.01–2.94 (m, 0.5H), 2.34–2.25 (m, 1H), 2.18–2.11 (m, 1H), 1.98–1.91 (m, 1H), 1.66–1.55 (m, 1H). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 373 K) δ 8.24 (s, 1H), 7.84 (d, <i>J</i> = 7.9 Hz, 1H), 7.67 (s, 1H), 7.52 (d, <i>J</i> = 8.2 Hz, 1H), 7.27 (dd, <i>J</i> = 7.6 Hz, 1H), 7.15 (dd, <i>J</i> = 7.5 Hz, 1H), 6.72 (dd, <i>J</i> = 16.8, 10.6 Hz, 1H), 6.57 (s, 2H), 6.06 (d, <i>J</i> = 16.8 Hz, 1H), 5.62 (d, <i>J</i> = 10.5 Hz, 1H), 4.78–4.71 (m, 1H), 4.42 (bs, 1H), 4.17–4.07 (m, 1H), 3.90 (s, 3H), 3.55 (bs, 1H), 3.21–3.13 (m, 1H), 2.40–2.30 (m, 1H), 2.24–2.17 (m, 1H), 2.03–1.97 (m, 1H), 1.69–1.60 (m, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.6, 164.5, 158.4, 155.6, 153.6, 153.5, 138.68, 138.6, 136.9, 129.8, 128.4, 128.3, 127.6, 127.4, 126.2, 122.1, 120.5, 120.0, 110.1, 106.7, 97.9, 97.8, 52.7, 51.8, 49.4, 45.89, 45.2, 41.6, 32.8, 29.7, 29.5, 25.0, 23.5. HRMS (ESI-MS): calcd 402.20466 for C<sub>22</sub>H<sub>24</sub>N<sub>7</sub>O [M + H]<sup>+</sup>, found 402.20368.</div></div><div id="sec4_6_0_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (<i>R</i>)-1-(3-(4-Amino-3-(naphthalen-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1x</b>)</h4><div class="NLM_p last">Compound <b>1x</b> was prepared according to general procedure B using <b>5o</b> (68 mg, 0.2 mmol, 1.0 equiv), DIPEA (153 μL, 1.0 mmol, 6.0 equiv), and acryolyl chloride (14 μL, 0.2 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v)). Yield: 44 mg (0.1 mmol, 73% over two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.30 (d, <i>J</i> = 5.5 Hz, 1H), 8.07 (dd, <i>J</i> = 15.3, 8.0 Hz, 2H), 7.91–7.85 (m, 1H), 7.69–7.49 (m, 4H), 6.93–6.71 (m, 1H), 6.18–6.04 (m, 1H), 5.74–5.58 (m, 1H), 5.39 (bs, 2), 4.84–4.72 (m, 1H), 4.59 (d, <i>J</i> = 11.7 Hz, 0.5H), 4.32–4.16 (m, 1H), 4.06 (d, <i>J</i> = 13.6 Hz, 0.5H), 3.79–3.70 (m, 0.5H), 3.32–3.18 (m, 1H), 3.05–2.96 (m, 0.5H), 2.33–2.23 (m, 1H), 2.22–2.16 (m, 1H), 1.98–1.91 (m, 1H), 1.67–1.53 (m, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.6, 164.5, 158.0, 155.9, 153.6, 153.5, 142.1, 142.0, 133.6, 131.4, 130.0, 129.4, 128.4, 128.39, 128.35, 128.2, 127.7, 127.5, 127.0, 126.9, 126.4, 125.7, 125.5, 99.2, 52.9, 52.1, 49.4, 45.9, 45.2, 41.7, 29.7, 29.5, 25.0, 23.4. HRMS (ESI-MS): calcd 399.19345 for C<sub>23</sub>H<sub>23</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, found 399.19279.</div></div><div id="sec4_6_0_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>R</i>)-1-(3-(4-Amino-3-(4-(dimethylamino)naphthalen-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1y</b>)</h4><div class="NLM_p last">Compound <b>1y</b> was prepared according to general procedure B using <b>5p</b> (100 mg, 0.2 mmol, 1.0 equiv), DIPEA (354 μL, 2.1 mmol, 9.8 equiv), and acryolyl chloride (19 μL, 0.2 mmol, 1.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v)). Yield: 22 mg (0.05 mmol, 24% over two steps). <sup>1</sup>H NMR (700 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (d, <i>J</i> = 7.1 Hz, 1H), 8.26 (d, <i>J</i> = 8.5 Hz, 1H), 7.84 (d, <i>J</i> = 8.0 Hz, 1H), 7.56 (dd, <i>J</i> = 18.7, 10.8 Hz, 1H), 7.54–7.48 (m, <i>J</i> = 15.0, 7.7 Hz, 2H), 7.22 (d, <i>J</i> = 7.7 Hz, 1H), 6.86 (dd, <i>J</i> = 16.4, 10.6 Hz, 1H), 6.73 (dd, <i>J</i> = 16.3, 10.7 Hz, 1H), 6.10 (dd, <i>J</i> = 48.3, 16.5 Hz, 1H), 5.71 (d, <i>J</i> = 10.2 Hz, 1H), 5.59 (d, <i>J</i> = 10.5 Hz, 1H), 4.81–4.71 (m, 1H), 4.58 (d, <i>J</i> = 11.2 Hz, 1H), 4.23 (dd, <i>J</i> = 45.2, 12.6 Hz, 1H), 4.04 (dd, <i>J</i> = 17.6, 10.4 Hz, 1H), 3.77–3.71 (m, 1H), 2.91 (s, 6H), 2.27 (d, <i>J</i> = 7.0 Hz, 1H), 2.21–2.16 (m, 1H), 2.00–1.92 (m, <i>J</i> = 9.8, 3.4 Hz, 2H). <sup>13</sup>C NMR (176 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.1, 158.4, 156.3, 154.1–153.8, 152.0, 143.32, 133.1, 132.4–131.6, 128.9, 128.8 (d, <i>J</i> = 14.4 Hz), 128.2–127.6, 127.1, 126.4, 125.8, 124.9, 124.4, 114.0, 99.9–99.2, 56.0, 53.8–53.0, 52.4, 49.8, 45.5, 45.1, 30.3–29.9, 25.6–25.1, 24.0–23.6. HRMS (ESI-MS): calcd 442.23499 for C<sub>25</sub>H<sub>28</sub>ON<sub>7</sub> [M + H]<sup>+</sup>, found 442.23528.</div></div><div id="sec4_6_0_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>R</i>)-1-(3-(4-Amino-3-(4-fluoronaphthalen-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1z</b>)</h4><div class="NLM_p last">Compound <b>1z</b> was prepared according to general procedure B using <b>5q</b> (121 mg, 0.3 mmol, 1.0 equiv), DIPEA (452 μL, 2.6 mmol, 10.0 equiv), and acryolyl chloride (23.3 μL, 0.3 mmol, 1.3 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v)). Yield: 39 mg (0.1 mmol, 36% over two steps). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (d, <i>J</i> = 6.0 Hz, 1H), 8.17 (d, <i>J</i> = 8.3 Hz, 1H), 7.89 (d, <i>J</i> = 6.8 Hz, 1H), 7.70 (t, <i>J</i> = 7.5 Hz, 1H), 7.66–7.58 (m, 2H), 7.47 (dd, <i>J</i> = 10.5, 8.0 Hz, 1H), 6.91–6.69 (m, 1H), 6.10 (dd, <i>J</i> = 40.6, 16.6 Hz, 1H), 5.65 (dd, <i>J</i> = 68.6, 10.2 Hz, 1H), 4.75 (ddd, <i>J</i> = 46.9, 23.1, 12.0 Hz, 1H), 4.32–3.96 (m, 2H), 3.38–2.96 (m, 2H), 2.35–2.15 (m, 2H), 2.03–1.88 (m, 2H). HRMS (ESI-MS): calcd 417.18336 for C<sub>23</sub>H<sub>22</sub>ON<sub>6</sub>F [M + H]<sup>+</sup> and 439.16531 for C<sub>23</sub>H<sub>22</sub>ON<sub>6</sub>FNa [M + Na]<sup>+</sup>, found 417.18300 and 439.16488.</div></div><div id="sec4_6_0_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 3-Iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>3</b>)</h4><div class="NLM_p last">4-Amino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]-pyrimidine (<b>2</b>, 5.0 g, 37.0 mmol, 1.0 equiv) and <i>N</i>-iodosuccinimide (12.5 g, 55.5 mmol, 1.5 equiv) were dissolved in 20 mL of DMF, heated to 85 °C, and stirred for 12 h. After completion of the reaction, the mixture was cooled to room temperature to obtain solid precipitate. The precipitate was filtered and thoroughly washed with ice-cold ethanol. The light-gray solid was dried in vacuo to afford compound <b>3</b> (9.4 g, 35.9 mmol, 97% yield). The product was used without further purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.78 (s, 1 H), 8.17 (s, 1 H), 7.09 (bs, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.5, 156.0, 102.5, 89.6. HRMS (ESI-MS): calcd 261.95 for C<sub>5</sub>H<sub>4</sub>IN<sub>5</sub> [M + H]<sup>+</sup>, found 262.14.</div></div><div id="sec4_6_0_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>)</h4><div class="NLM_p last">A solution of 3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>3</b>, 7.5 g, 28.7 mmol, 1.0 equiv) and <i>tert</i>-butyl-(<i>S</i>)-3-hydroxypiperidine-1-carboxylate (8.3 g, 40.2 mmol, 1.4 equiv) in anhydrous THF were stirred at room temperature under argon atmosphere. To the pale-yellow suspension, triphenylphosphine (11.3 g, 43.1 mmol, 1.5 equiv) was added, and the resulting solution was cooled to 0 °C in an ice bath. To this solution, diisopropyl azodicarboxylate (8.5 mL, 43.1 mmol, 1.5 equiv) was added. The reaction mixture was warmed to room temperature and stirred for 18 h under argon atmosphere. After completion of the reaction, the reaction mixture was quenched using saturated sodium hydrogen carbonate and extracted three times with ethyl acetate and washed with water and saturated sodium chloride solution. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness to obtain a yellow oil. The crude product was purified by column chromatography (DCM/EtOAc (60/40, v/v) + 1% MeOH as additive). Compound <b>4</b> was obtained as a pale-yellow solid (5.4 g, 28.7 mmol, 42% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.21 (s, 1H), 7.04 (s, 2H), 4.64–4.57 (m, 1H), 3.99 (d, <i>J</i> = 11.8 Hz, 1H), 3.80 (d, <i>J</i> = 13.2 Hz, 1H), 3.11 (s, 2H), 2.20–2.10 (m, 1H), 2.10–2.02 (m, 1H), 1.94–1.85 (m, 1H), 1.60–1.48 (m, 1H), 1.37 (s, 9H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 154.6, 152.9, 151.5, 145.5, 102.6, 88.9, 80.5, 77.4, 77.3–77.1, 76.9, 32.1, 30.4, 29.8, 28.6, 24.3, 22.8. HRMS (ESI-MS) calcd: 445.08434 for C<sub>15</sub>H<sub>21</sub>IN<sub>6</sub>O<sub>6</sub> [M + H]<sup>+</sup>, found [M + H]<sup>+</sup> 445.08403.</div></div><div id="sec4_6_0_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5a</b>)</h4><div class="NLM_p last">Compound <b>5a</b> was prepared according to general procedure A using <i>tert</i>-butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 100 mg, 0.2 mmol, 1.0 equiv), satd sodium carbonate solution (2.0 mL), and tetrakis(triphenylphosphine)palladium(0) (26.0 mg, 0.02 mmol, 0.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–2/98 v/v)). Yield: 49.7 mg (0.2 mmol, 70%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.17 (s, 1H), 8.09 (s, 1H), 7.71 (bs, 2H), 4.61–4.53 (m, 1H), 4.15–3.71 (m, 2H), 3.52–3.39 (m, 0.5H), 3.22–3.05 (m, 0.5H), 3.01–2.81 (m, 1H), 2.20–2.09 (m, 1H), 2.06–1.99 (m, 1H), 1.95–1.80 (m, 1H), 1.60–1.49 (m, 1H), 1.38 (bs, 9H).</div></div><div id="sec4_6_0_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-phenyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5b</b>)</h4><div class="NLM_p last">Compound <b>5b</b> was prepared according to general procedure A using <i>tert</i>-butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 392 mg, 0.9 mmol, 1.0 equiv), benzeneboronic acid (150 mg, 1.2 mmol, 1.4 equiv), satd sodium carbonate solution (2.0 mL), and tetrakis(triphenylphosphine)palladium(0) (101 mg, 0.1 mmol, 0.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–2/98 v/v)). Yield: 341 mg (0.9 mmol, 97%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.70–7.64 (m, 2H), 7.58–7.51 (m, 2H), 7.51–7.45 (m, 1H), 6.89 (bs, 2H), 4.75–4.65 (m, 1H), 4.22–3.65 (m, 3H), 3.09–2.92 (m, 1H), 2.28–2.16 (m, 1H), 2.13–2.04 (m, 1H), 2.03–1.79 (m, 1H), 1.61–1.49 (m, 1H), 1.32 (bs, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.1, 155.5, 154.0, 153.7, 143.5, 132.89, 129.0, 128.6, 128.2, 97.4, 78.8, 52.1, 47.5, 43.2, 29.0, 27.9, 23.7. LC-MS (ESI-MS): calcd 395.21 for C<sub>21</sub>H<sub>27</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, found 395.11.</div></div><div id="sec4_6_0_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-(3-fluorophenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5c</b>)</h4><div class="NLM_p last">Compound <b>5c</b> was prepared according to general procedure A using <i>tert</i>-butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 105 mg, 0.2 mmol, 1.0 equiv), 3-fluorophenyl boronic acid (47 mg, 0.3 mmol, 1.5 equiv), satd sodium carbonate solution (2.0 mL), and tetrakis(triphenylphosphine)palladium(0) (27 mg, 0.02 mmol, 0.1 equiv). The crude product was purified by flash chromatography (MeOH/DCM (1/99 v/v–4/96 v/v)). Yield: 59.0 mg (0.1 mmol, 61%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.40 (s, 1H), 7.56–7.40 (m, 3H), 7.24–7.14 (m, 1H), 5.68 (bs, 2H), 4.90–4.80 (m, 1H), 4.46–3.99 (m, 2H), 3.57–3.27 (m, 1H), 2.92–2.79 (m, 1H), 2.31–2.18 (m, 1H), 1.97–1.85 (m, 1H), 1.83–1.66 (m, 2H), 1.44 (bs, 9H). HRMS (ESI-MS): calcd 413.20958 for C<sub>21</sub>H<sub>26</sub>O<sub>2</sub>N<sub>6</sub>F [M + H]<sup>+</sup>, found 413.20993.</div></div><div id="sec4_6_0_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-(4-fluorophenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5d</b>)</h4><div class="NLM_p last">Compound <b>5d</b> was prepared according to general procedure A using <i>tert</i>-butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 105 mg, 0.2 mmol, 1.0 equiv), 4-fluorophenyl boronic acid (48.2 mg, 0.4 mmol, 1.5 equiv), satd sodium carbonate solution (2.0 mL), and tetrakis(triphenylphosphine)palladium(0) (27 mg, 0.02 mmol, 0.10 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–2/98 v/v)). Yield: 78.0 mg (0.2 mmol, 83%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 7.68 (dd, <i>J</i> = 8.4, 5.6 Hz, 2H), 7.37 (t, <i>J</i> = 8.9 Hz, 2H), 4.68 (s, 1H), 3.96 (dd, <i>J</i> = 181.6, 51.1 Hz, 2H), 3.35–2.90 (m, 2H), 2.24 (dd, <i>J</i> = 40.7, 8.8 Hz, 1H), 2.13–2.05 (m, 1H), 1.91 (dd, <i>J</i> = 81.6, 28.2 Hz, 1H), 1.63–1.49 (m, 1H), 1.20 (dd, <i>J</i> = 47.2, 11.0 Hz, 9H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.7, 162.03, 158.7, 156.1, 154.5, 154.2, 143.5–142.9, 130.9, 129.8, 116.5, 97.9, 79.7–79.1, 70.4–70.1, 52.5, 29.8–28.8, 28.4. <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>) δ −73.41 (s, <i>J</i> = 299.4 Hz). HRMS (ESI-MS): calcd 413.20 for C<sub>21</sub>H<sub>26</sub>FN<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, found 413.21.</div></div><div id="sec4_6_0_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-(3-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5e</b>)</h4><div class="NLM_p last">Compound <b>5e</b> was prepared according to general procedure A using <i>tert</i>-butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 450 mg, 1.0 mmol, 1.0 equiv), 3-(trifluoromethylbenzene boronic acid (266 mg, 1.4 mmol, 1.4 equiv), satd sodium carbonate solution (2.0 mL), and tetrakis(triphenylphosphine)palladium(0) (116 mg, 0.1 mmol, 0.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (0.25/99.75 v/v–2/98 v/v)). Yield: 439 mg (1.0 mmol, 95%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (s, 1H), 7.99–7.93 (m, 2H), 7.86–7.81 (m, 1H), 7.80–7.74 (m, 1H), 7.02 (bs, 2H), 4.81–4.63 (m, 1H), 4.38–3.50 (m, 3H), 3.11–2.93 (m, 1H), 2.30–2.17 (m, 1H), 2.14–2.06 (m, 1H), 2.04–1.85 (m, 1H), 1.63–1.53 (m, 1H), 1.32 (bs, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.2, 155.6, 154.2, 153.7, 142.1, 133.8, 132.2, 130.1, 129.7, 129.5, 125.2, 125.0, 124.6, 123.0, 97.5, 78.8, 56.0, 52.1, 46.9, 43.2, 29.1, 27.9, 23.3. <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>) δ −61.21 (s <i>J</i> = 299.4 Hz). LC-MS (ESI-MS): calcd 463.20 for C<sub>22</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, found 463.09.</div></div><div id="sec4_6_0_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-(4-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5f</b>)</h4><div class="NLM_p last">Compound <b>5f</b> was prepared according to general procedure A using <i>tert</i>-butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 556 mg, 1.1 mmol, 1.0 equiv), 4-(trifluoromethyl) benzene boronic acid (343 mg, 1.7 mmol, 1.5 equiv), satd sodium carbonate solution (2.0 mL), and tetrakis(triphenylphosphine)palladium(0) (131 mg, 0.1 mmol, 0.1 equiv). The crude product was purified by flash chromatography (MeOH/DCM (1/99 v/v–4/96 v/v)). Yield: 432 mg (0.9 mmol, 82%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (s, 1H), 7.62 (ddd, <i>J</i> = 13.2, 7.9, 4.3 Hz, 2H), 7.58–7.52 (m, 2H), 4.68 (d, <i>J</i> = 38.6 Hz, 1H), 4.24–3.45 (m, 2H), 3.32 (s, 2H), 2.28–2.15 (m, 1H), 2.15–2.07 (m, 1H), 1.97 (dd, <i>J</i> = 34.1, 25.5 Hz, 1H), 1.56 (tt, <i>J</i> = 20.6, 10.3 Hz, 1H), 1.37–1.15 (m, 9H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.2, 155.7, 154.2, 154.1–153.6, 136.8, 133.1, 132.4, 132.0, 131.5, 131.4, 129.0, 128.8, 128.7, 128.5, 126.0, 125.2, 123.4, 97.5, 52.1, 29.0, 27.9, 22.2–22.0.</div></div><div id="sec4_6_0_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-cyclopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5g</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 100 mg, 0.2 mmol, 1.0 equiv) was dissolved in a mixture of dioxane/H<sub>2</sub>O (2.5 mL, 3/1, v/v) and treated with cyclopropyl-2-boronic acid pinacol ester (58 μL, 0.3 mmol, 1.4 equiv) and cesium carbonate (220 mg, 0.7 mmol, 3.0 equiv). The mixture was degassed for 30 min, and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) in complex with dichloromethane (19 mg, 0.02 mmol, 0.1 equiv) was added to the reaction mixture. The mixture was heated to 100 °C and stirred for 12 h under argon atmosphere. The reaction mixture was filtered through a plug of Celite and after that washed using saturated sodium hydrogen carbonate solution and extracted three times with ethyl acetate and washed with water and saturated sodium chloride solution. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness. The crude product was purified by column chromatography (MeOH/DCM (0.5/99.5 v/v–2/98 v/v)). Yield: 57 mg (0.2 mmol, 70%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.12 (s, 1H), 7.34 (bs, 2H), 4.52–4.41 (m, 1H), 4.02–3.91 (m, 0.5H), 3.89–3.66 (m, 1H), 3.14–3.02 (m, 0.5H), 2.98–2.81 (m, 1H), 2.42–2.34 (m, 1H), 2.12–2.01 (m, 1H), 1.98–1.90 (m, 1H), 1.90–1.75 (m, 1H), 1.53–1.44 (m, 1H), 1.42–1.22 (m, 9H), 1.21–1.18 (m, 1H). 0.96–0.89 (m, 2H), 0.88–0.81 (m, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.2, 155.4, 153.7, 153.6, 145.5, 99.1, 78.8, 51.8, 47.6, 43.4, 28.9, 27.9, 23.68, 8.5, 7.5. LC-MS (ESI-MS): calcd 358.21 for C<sub>18</sub>H<sub>27</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, found 359.08.</div></div><div id="sec4_6_0_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-(4-hydroxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5h</b>)</h4><div class="NLM_p last">Compound <b>5h</b> was prepared according to general procedure A using <i>tert</i>-butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 100 mg, 0.2 mmol, 1.0 equiv), 4-hydroxyphenyl boronic acid pinacol ester (74.2 mg, 0.3 mmol, 1.5 equiv), satd sodium carbonate solution (2.0 mL), and tetrakis(triphenylphosphine)palladium(0) (27 mg, 0.02 mmol, 0.1 equiv). The crude product was purified by flash chromatography (MeOH/DCM (1/99 v/v–6/94 v/v)). Yield: 88 mg (0.2 mmol, 91%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.76 (s, 1H), 8.23 (s, 1H), 7.47 (d, <i>J</i> = 8.6 Hz, 2H), 6.92 (d, <i>J</i> = 8.7 Hz, 2H), 6.73 (bs, 2H), 4.70–4.61 (m, 1H), 4.19–3.66 (m, 2H), 3.60–3.16 (m, 1H), 3.09–2.90 (m, 1H), 2.27–2.14 (m, 1H), 2.11–2.03 (m, 1H), 2.01–1.84 (m, 1H), 1.60–1.49 (m, 1H), 1.32 (bs, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.1, 158.0, 155.4, 153.8, 143.7, 129.6, 123.6, 115.9, 97.4, 78.9, 52.0, 47.3, 43.1, 29.1, 27.9, 23.7. LC-MS (ESI-MS): calcd 411.21 for C<sub>21</sub>H<sub>27</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>, found 411.21.</div></div><div id="sec4_6_0_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-benzyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5i</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 100 mg, 0.2 mmol, 1.0 equiv) was dissolved in a mixture of dioxane/H<sub>2</sub>O (2.5 mL, 3/1, v/v) and treated with benzyl-2-boronic acid pinacol ester (75 μL, 0.3 mmol, 1.5 equiv) and cesium carbonate (220 mg, 0.7 mmol, 3.0 equiv). The mixture was degassed for 30 min, and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) in complex with dichloromethane (17 mg, 0.02 mmol, 0.1 equiv) was added to the reaction mixture. The mixture was heated to 145 °C and stirred for 20 h under microwave irradiation. The reaction mixture was filtered through a plug of Celite and after that washed using saturated sodium hydrogen carbonate solution and extracted three times with ethyl acetate and washed with water and saturated sodium chloride solution. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness. The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–2/98 v/v)). Yield: 58 mg (0.1 mmol, 63%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (s, 1H), 7.34–7.23 (m, 4H), 7.20 (t, <i>J</i> = 7.1 Hz, 1H), 5.76 (s, 2H), 4.62 (s, 1H), 4.45–4.36 (m, 2H), 3.85 (m, 3H), 2.93 (m, 1H), 2.22–2.09 (m, <i>J</i> = 20.4, 11.4 Hz, 1H), 2.09–1.99 (m, 1H), 1.92–1.80 (m, 1H), 1.53 (dt, <i>J</i> = 32.9, 16.3 Hz, 1H), 1.27 (d, <i>J</i> = 50.6, 39.0 Hz, 9H). HRMS (ESI-MS): calcd 409.23465 for C<sub>22</sub>H<sub>28</sub>O<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup>, found 409.23448.</div></div><div id="sec4_6_0_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-(cyclopentylethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5j</b>)</h4><div class="NLM_p last">A solution of <b>4</b> (200 mg, 0.5 mmol, 1.0 equiv) and cyclopentylacetylene (62 mg, 0.6 mmol, 1.4 equiv) in 4 mL of THF was treated with copper(I) iodide (4 mg, 0.02 mmol, 0.05 equiv), bis(triphenylphosphin)palladium(II)dichloride (16 mg, 0.02 mmol, 0.05 equiv) and TEA (314 μL, 2.3 mmol, 5.0 equiv) and stirred at room temperature for 12 h. The reaction mixture was filtered through a plug of Celite and after that washed using saturated sodium hydrogen carbonate solution and extracted three times with ethyl acetate and washed with water and saturated sodium chloride solution. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness. The crude product was purified by reverse-phase flash chromatography (H<sub>2</sub>O/ACN (20/80, v/v) + 0.2% TFA as additive). Yield: 144 mg (0.4 mmol, 78%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (d, <i>J</i> = 12.5 Hz, 1H), 7.62 (s, 2H), 4.56 (d, <i>J</i> = 52.2 Hz, 1H), 4.11–3.67 (m, 2H), 3.01 (dt, <i>J</i> = 14.6, 7.4 Hz, 2H), 2.16–2.07 (m, 1H), 2.01 (d, <i>J</i> = 7.5 Hz, 2H), 1.91 (t, <i>J</i> = 14.9 Hz, 1H), 1.78–1.65 (m, 4H), 1.60 (dd, <i>J</i> = 10.5, 7.4 Hz, 2H), 1.53 (dd, <i>J</i> = 24.5, 11.4 Hz, 1H), 1.32 (dd, <i>J</i> = 55.7, 36.7 Hz, 11H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.8, 156.3, 153.7, 152.7, 133.1, 132.4, 132.0, 131.5, 131.5, 128.8, 128.7, 100.5, 99.8, 79.1–78.6, 72.0, 52.3, 33.1, 30.1, 28.0, 24.7. HRMS (ESI-MS): calcd 411.25030 for C<sub>22</sub>H<sub>30</sub>O<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup>, found 411.25017.</div></div><div id="sec4_6_0_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-(3-cyclopentylprop-1-yn-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5k</b>)</h4><div class="NLM_p last">A solution of <b>4</b> (100 mg, 0.2 mmol, 1.0 equiv) and cyclopentylacetylene (41.2 μL, 0.3 mmol, 1.4 equiv) in 4 mL of THF was treated with copper(I) iodide (2.1 mg, 0.01 mmol, 0.05 equiv), bis(triphenylphosphin)palladium(II)dichloride (7.9 mg, 0.01 mmol, 0.05 equiv), and TEA (156.9 μL, 1.1 mmol, 5.0 equiv) and stirred at room temperature for 12 h. The reaction mixture was filtered through a plug of Celite and after that washed using saturated sodium hydrogen carbonate solution and extracted three times with ethyl acetate and washed with water and saturated sodium chloride solution. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness. The crude product was purified by reverse-phase flash chromatography (H<sub>2</sub>O/ACN (20/80, v/v) + 0.2% TFA as additive). Yield: 63 mg (0.2 mmol, 69%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.21 (s, 1H), 4.56 (d, <i>J</i> = 41.1 Hz, 1H), 4.11–3.63 (m, 1H), 3.22–2.83 (m, 1H), 2.54 (t, <i>J</i> = 10.0 Hz, 2H), 2.19–2.07 (m, 2H), 2.02 (dt, <i>J</i> = 21.0, 8.2 Hz, 1H), 1.88 (dd, <i>J</i> = 17.9, 11.0 Hz, 1H), 1.79 (td, <i>J</i> = 11.8, 7.0 Hz, 2H), 1.68–1.58 (m, 2H), 1.57–1.48 (m, 3H), 1.46–1.19 (m, 13H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d6</i>) δ 158.3, 156.8, 154.3–154.1, 153.1, 132.5, 132.0, 131.9, 129.3, 129.2, 126.7–126.5, 101.1, 96.1, 79.5–79.3, 72.8, 52.8, 38.7, 32.1, 28.4, 25.22–25.18, 25.1. LC-MS: calcd 425.27 for C<sub>23</sub>H<sub>33</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, found 425.27.</div></div><div id="sec4_6_0_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-(naphthalen-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5l</b>)</h4><div class="NLM_p last">Compound <b>5l</b> was prepared according to general procedure A using <i>tert</i>-butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 50 mg, 0.1 mmol, 1.0 equiv), naphthalen-2-ylboronic acid (39 mg, 0.2 mmol, 2.1 equiv), satd sodium carbonate solution (2.0 mL), and tetrakis(triphenylphosphine)palladium(0) (12 mg, 0.01 mmol, 0.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–2/98 v/v)). Yield: 37 mg (0.1 mmol, 73%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.30 (s, 1H), 8.19 (s, 1H), 8.08 (d, <i>J</i> = 8.5 Hz, 1H), 8.04 (dd, <i>J</i> = 6.0, 3.4 Hz, 1H), 8.00 (dd, <i>J</i> = 6.0, 3.4 Hz, 1H), 7.82 (dd, <i>J</i> = 8.4, 1.4 Hz, 1H), 7.61–7.56 (m, 2H), 6.80 (bs, 2H) 4.77–4.69 (m, 1H), 4.24–3.53 (m, 3H), 3.10–2.91 (m, 1H), 2.30–2.21 (m, 1H), 2.15–2.08 (m, 1H), 2.05–1.83 (m, 1H), 1.64–1.54 (m, 1H), 1.31 (bs, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.2, 155.6, 154.1, 153.8, 143.8, 133.0, 132.8, 130.3, 128.7, 128.4, 127.7, 127.6, 126.7, 126.7, 126.0, 97.6, 79.1, 52.2, 48.1, 47.2, 43.9, 43.0, 29.4, 28.8, 28.0, 24.1, 23.4. LC-MS (ESI-MS): calcd 445.23 for C<sub>25</sub>H<sub>29</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, found 445.21.</div></div><div id="sec4_6_0_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5m</b>)</h4><div class="NLM_p last">Compound <b>5m</b> was prepared according to general procedure A using <i>tert</i>-butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 118 mg, 0.3 mmol, 1 0.0 equiv), 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl) boronic acid pinacolester (162 mg, 0.7 mmol, 2.5 equiv), satd sodium carbonate solution (2.0 mL), and tetrakis(triphenylphosphine)palladium(0) (31 mg, 0.03 mmol, 0.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–4/96 v/v)). Yield: 92 mg (0.2 mmol, 78%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.84 (s, 1H), 8.48 (s, 1H), 8.27 (s, 1H), 8.19 (s, 1H), 7.57 (s, 1H), 7.03 (bs, 2H), 6.57 (s, 1H), 4.74–4.64 (m, 1H), 4.20–3.50 (m, 3H), 3.01 (s, 1H), 2.31–2.16 (m, 1H), 2.15–2.06 (m, 1H), 2.04–1.83 (m, 1H), 1.66–1.50 (m, 1H), 1.31 (s, 9H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.3, 155.5, 153.9, 153.7, 148.4, 142.4, 127.8, 127.1, 120.8, 119.5, 100.5, 97.7, 78.9, 52.1, 47.4, 43.0, 28.9, 27.9, 23.8. LC-MS (ESI-MS): calcd 435.22 for C<sub>22</sub>H<sub>27</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, found 435.12.</div></div><div id="sec4_6_0_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-(1-methyl-1<i>H</i>-indol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5n</b>)</h4><div class="NLM_p last">Compound <b>5n</b> was prepared according to general procedure A using <i>tert</i>-butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 500 mg, 1.1 mmol, 1.0 equiv), <i>N</i>-methylindole-3-boronic acid pinacol ester (412 mg, 1.6 mmol, 1.4 equiv), satd sodium carbonate solution (2.0 mL), and tetrakis(triphenylphosphine)palladium(0) (127 mg, 0.1 mmol, 0.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–3/97 v/v)). Yield: 418 mg (0.9 mmol, 82%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.24 (s, 1H), 7.87 (d, <i>J</i> = 7.9 Hz, 1H), 7.69 (s, 1H), 7.53 (d, <i>J</i> = 8.2 Hz, 1H), 7.26 (t, <i>J</i> = 7.5 Hz, 1H), 7.15 (t, <i>J</i> = 7.4 Hz, 1H), 6.93 (bs, 2H), 4.75–4.64 (m, 1H), 4.21–3.42 (m, 3H), 3.88 (s, 3H), 3.11–2.86 (m, 1H), 2.32–2.19 (m, 1H), 2.17–2.09 (m, 1H), 2.08–1.88 (m, 1H), 1.65–1.52 (m, 1H), 1.31 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.3, 155.4, 153.8, 153.4, 136.8, 129.6, 126.1, 122.0, 120.4, 119.9, 110.0, 106.7, 97.9, 78.8, 51.9, 32.7, 27.9. LC-MS (ESI-MS): calcd 448.24 for C<sub>24</sub>H<sub>30</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, found 448.15.</div></div><div id="sec4_6_0_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-(naphthalen-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5o</b>)</h4><div class="NLM_p last">Compound <b>5o</b> was prepared according to general procedure A using <i>tert</i>-butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 382 mg, 0.9 mmol, 1.0 equiv), naphthalen-1-ylboronic acid (206 mg, 1.2 mmol, 1.4 equiv), satd sodium carbonate solution (2.0 mL), and tetrakis(triphenylphosphine)palladium(0) (99 mg, 0.1 mmol, 0.1 equiv). The crude product was purified by column chromatography (MeOH/DCM (1/99, v/v - 2/98, v/v)). Yield: 331 mg (0.7 mmol, 86%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.30 (s, 1H), 8.06 (dd, <i>J</i> = 14.8, 7.9 Hz, 2H), 7.91 (d, <i>J</i> = 7.5 Hz, 1H), 7.71–7.49 (m, 4H), 5.46 (s, 2H), 4.81–4.69 (m, 1H), 4.33–3.51 (m, 3H), 3.14–2.87 (m, 1H), 2.31–2.19 (m, 1H), 2.19–2.10 (m, 1H), 2.05–1.82 (m, 1H), 1.63–1.52 (m, 1H), 1.33 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.9, 155.7, 153.8, 153.6, 141.7, 133.5, 131.3, 129.8, 129.2, 128.3, 128.2, 126.8, 126.2, 125.6, 125.4, 99.2, 78.8, 52.2, 47.6, 43.2, 28.9, 27.9, 23.6. LC-MS (ESI-MS): calcd 445.23 for C<sub>25</sub>H<sub>29</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, found 445.13.</div></div><div id="sec4_6_0_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-(4-(dimethylamino)naphthalen-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5p</b>)</h4><div class="NLM_p last">Compound <b>5p</b> was prepared according to general procedure A using <i>tert</i>-butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 700 mg, 1.5 mmol, 1.0 equiv), <i>N</i>,<i>N</i>-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-amine (<b>9</b>, 676 mg, 2.1 mmol, 1.3 equiv), satd sodium carbonate solution (6.0 mL), and tetrakis(triphenylphosphine)palladium(0) (184 mg, 0.2 mmol, 0.1 equiv) in 12 mL of solvent mixture. The crude product was purified by reverse-phase flash column chromatography (H<sub>2</sub>O/ACN (5/95, v/v) + 5 mM ammonium acetate as additive). Yield: 300 mg (615 mmol, 39%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.31–8.23 (m, 2H), 7.87 (s, 1H), 7.60–7.54 (m, 1H), 7.50 (dd, <i>J</i> = 14.6, 7.3 Hz, 2H), 7.22 (d, <i>J</i> = 7.6 Hz, 1H), 4.73 (s, 1H), 3.97–3.60 (m, 2H), 2.90 (s, 6H), 2.29–2.06 (m, 2H), 1.49–1.19 (m, 13H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.3–155.5, 132.8–132.4, 128.7–128.1, 127.0–126.4, 125.7–124.9, 124.4 113.6, 99.7–98.6, 59.8, 52.2, 44.8, 28.0, 20.8, 14.1.</div></div><div id="sec4_6_0_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-(4-fluoronaphthalen-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>5q</b>)</h4><div class="NLM_p last">Compound <b>5q</b> was prepared according to general procedure A using <i>tert</i>-butyl-(<i>R</i>)-3-(4-amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>4</b>, 150 mg, 0.3 mmol, 1.0 equiv), 4-fluoronaphthalene-1-boronic acid (98 mg, 0.5 mmol, 1.3 equiv), satd sodium carbonate solution (2.0 mL), and tetrakis(triphenylphosphine)palladium(0) (39 mg, 0.03 mmol, 0.1 equiv). The reaction was carried out for 20 min at 130 °C under microwave irradiation. The crude product was purified by column chromatography (MeOH/DCM (1/99 v/v–2/98 v/v)). Yield: 121 mg (0.3 mmol, 77%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.41 (s, 1H), 8.24 (d, <i>J</i> = 8.2 Hz, 1H), 7.92 (d, <i>J</i> = 8.3 Hz, 1H), 7.71–7.53 (m, 4H), 7.48 (td, <i>J</i> = 7.5, 2.9 Hz, 1H), 7.33–7.28 (m, 1H), 5.61–5.01 (m, 2H), 5.01–4.78 (m, 1H), 4.41 (d, <i>J</i> = 80.5 Hz, 1H), 4.14 (s, 1H), 2.86 (td, <i>J</i> = 13.1, 2.6 Hz, 1H), 2.37–2.20 (m, 2H), 1.80–1.67 (m, 1H), 1.52–1.43 (m, 9H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 158.7, 157.8, 156.1, 154.8, 154.0, 142.0, 132.3, 132.2, 128.7, 128.6, 128,4, 127.2, 127.1, 126.3, 125.6, 124.4, 124.3, 121.2, 109.6, 109.4, 80.1, 53.1, 30.4, 28.6.</div></div><div id="sec4_6_0_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>N</i>,<i>N</i>-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-amine (<b>9</b>)</h4><div class="NLM_p last">A solution of 4-bromo-<i>N</i>,<i>N</i>-dimethylnaphthalen-1-amine (<b>7</b>, 500 mg, 2.0 mmol, 1.0 equiv) in 8 mL of THF was cooled to −78 °C. At this temperature, <i>n</i>-butyl lithium (1.3 mL, 2.4 mmol, 1.2 equiv) was added dropwise and stirred for 45 min, and then bis(pinacolato)diboron (<b>8</b>, 1.5 g, 6.0 mmol, 3.0 equiv) was added and again stirred for 2 h at −78 °C. The reaction mixture was warmed to room temperature and stirred for 18 h. After completion, the volatiles were removed in vacuo and the remaining solid was taken up in 30 mL of 0.1 M HCl and extracted with DCM. The pH value of the aqueous phase was adjusted to 8 with satd sodium hydrogen carbonate and again extracted with DCM. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness to obtain a pale-gray solid. The crude product was used without further purification. Yield: 438 mg (14.7 mmol, 73%). LC-MS (ESI-MS): calcd 297.20 for C<sub>18</sub>H<sub>24</sub>BNO<sub>2</sub> [M + H]<sup>+</sup>, found 298.30.</div></div><div id="sec4_6_0_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-((trimethylsilyl)ethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>10</b>)</h4><div class="NLM_p last"><b>4</b> (284 mg, 0.6 mmol, 1.0 equiv) was dissolved in 5 mL of anhydrous DMF and treated with triethylamine (355 μL, 2.6 mmol, 4.0 equiv) and copper(I) iodide (24 mg, 0.1 mmol, 0.2 equiv). Trimethylsilylacetylene (1.8 mL, 12.8 mmol, 20 equiv) was added dropwise at 0 °C, and tetrakis(triphenylphosphine)palladium(0) (74 mg, 0.1 mmol, 0.1 equiv) was added under argon atmosphere. The reaction mixture was stirred for 2 h at room temperature. The reaction mixture was filtered through a plug of Celite and the volatiles removed in vacuo. The crude product was taken up in DCM and quenched with water. The aqueous phase was then extracted three times with a solution of 10% MeOH in DCM. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness. The resulting crude product was used without further purification. LC-MS (ESI-MS): calcd 415.22 for C<sub>20</sub>H<sub>31</sub>N<sub>6</sub>O<sub>2</sub>Si [M + H]<sup>+</sup>, found 415.13.</div></div><div id="sec4_6_0_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>tert</i>-Butyl-(<i>R</i>)-3-(4-amino-3-ethynyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>11</b>)</h4><div class="NLM_p last">To a solution of <b>10</b> (283 mg, 0.7 mmol, 1.0 equiv) in 5 mL of MeOH potassium carbonate (23.0 mg, 0.2 mmol, 0.3 equiv) was added. The reaction mixture was stirred for 1 h at room temperature. The reaction mixture was quenched in water and extracted three times with a solution of 10% MeOH ind DCM. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness. The crude product was purified by column chromatography (EtOAc/DCM (30/70 v/v–70/30 v/v)). Yield: 126 mg (0.4 mmol, 58% over two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.24 (s, 1H), 8.04 (bs, 1H), 6.69 (bs, 1H), 4.65 (s, 1H), 4.64–4.60 (m, 1H), 4.14–3.58 (m, 3H), 3.19–2.88 (m, 1H), 2.20–2.08 (m, 1H), 2.08–2.00 (m, 1H), 1.99–1.81 (m, 1H), 1.57–1.49 (m, 1H), 1.45–1.23 (m, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.7, 156.4, 153.7, 152.8, 124.9, 101.0, 86.1, 79.0, 75.3, 52.5, 47.9, 47.0, 44.0, 43.0, 28.9, 27.9, 24.0, 23.2. LC-MS (ESI-MS): calcd 343.18 for C<sub>17</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, found 343.09.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-5"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00515">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12752" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12752" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00515" class="ext-link">10.1021/acs.jmedchem.7b00515</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic routes used to generate presented compounds; crystal structure and interaction map of <b>1w</b> and <b>1x</b> in EGFR<sup>L858R/T790M</sup>; plot of pEC50 against clogD for entire series of pyrazolopyrimidines; plasma concentration/time profile of <b>1w</b>; cellular growth inhibition (EC<sub>50</sub>) of <b>1a</b>–<b>z</b> against H358; collection of pyrazolopyrimidine-based derivatives calcd LLE and clogD values (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_001.pdf">jm7b00515_si_001.pdf (911.68 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_002.csv">jm7b00515_si_002.csv (7.5 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00515" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12670" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12670" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Rauh</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry
and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1970-7642" title="Orcid link">http://orcid.org/0000-0002-1970-7642</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1a7e7b74737f7634687b6f725a6e6f377e75686e776f747e347e7f"><span class="__cf_email__" data-cfemail="d4b0b5babdb1b8faa6b5a1bc94a0a1f9b0bba6a0b9a1bab0fab0b1">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julian Engel</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry
and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Smith</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry
and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonas Lategahn</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry
and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hannah L. Tumbrink</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry
and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Goebel</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry
and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Becker</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry
and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elisabeth Hennes</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry
and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marina Keul</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry
and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anke Unger</span> - <span class="hlFld-Affiliation affiliation">Lead Discovery Center GmbH, Otto-Hahn-Straße 15, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heiko Müller</span> - <span class="hlFld-Affiliation affiliation">Lead Discovery Center GmbH, Otto-Hahn-Straße 15, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthias Baumann</span> - <span class="hlFld-Affiliation affiliation">Lead Discovery Center GmbH, Otto-Hahn-Straße 15, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carsten Schultz-Fademrecht</span> - <span class="hlFld-Affiliation affiliation">Lead Discovery Center GmbH, Otto-Hahn-Straße 15, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Georgia Günther</span> - <span class="hlFld-Affiliation affiliation">Leibniz Research Centre for Working Environment and Human Factors
(IfADo), TU Dortmund University, D-44139 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jan G. Hengstler</span> - <span class="hlFld-Affiliation affiliation">Leibniz Research Centre for Working Environment and Human Factors
(IfADo), TU Dortmund University, D-44139 Dortmund, Germany</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>J.E. and S.S. authors contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6170-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75125" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75125" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was cofunded by the German Federal Ministry for Education and Research (NGFNPlus and e:Med) (grant no. BMBF 01GS08104, 01ZX1303C), the Deutsche Forschungsgemeinschaft (DFG), the German federal state North Rhine-Westphalia (NRW) and the European Union (European Regional Development Fund: Investing In Your Future) (EFRE-800400), NEGECA (PerMed NRW), and EMODI.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i78" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i78"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i79" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i79"> Abbreviations Used</h2><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton tyrosine kinase</p></td></tr><tr><td class="NLM_term">CTG</td><td class="NLM_def"><p class="first last">CellTiter Glo</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung cancer</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82304" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82304" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 49 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small Cell Lung Cancer to Gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">–</span> <span class="NLM_lpage">2139</span><span class="refDoi"> DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+Mutations+in+the+Epidermal+Growth+Factor+Receptor+Underlying+Responsiveness+of+Non-Small+Cell+Lung+Cancer+to+Gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lhWJRte0YVWJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520Mutations%2520in%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Underlying%2520Responsiveness%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkaria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupfer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">EGF Receptor Gene Mutations are Common in Lung Cancers from ″Never Smokers″ and are Associated with Sensitivity of Tumors to Gefitinib and Erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">–</span> <span class="NLM_lpage">13311</span><span class="refDoi"> DOI: 10.1073/pnas.0405220101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1073%2Fpnas.0405220101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=15329413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+Receptor+Gene+Mutations+are+Common+in+Lung+Cancers+from+%E2%80%B3Never+Smokers%E2%80%B3+and+are+Associated+with+Sensitivity+of+Tumors+to+Gefitinib+and+Erlotinib&doi=10.1073%2Fpnas.0405220101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib</span></div><div class="casAuthors">Pao, William; Miller, Vincent; Zakowski, Maureen; Doherty, Jennifer; Politi, Katerina; Sarkaria, Inderpal; Singh, Bhuvanesh; Heelan, Robert; Rusch, Valerie; Fulton, Lucinda; Mardis, Elaine; Kupfer, Doris; Wilson, Richard; Kris, Mark; Varmus, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">13306-13311</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly assocd. with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor.  In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21).  We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004).  Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clin. relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003).  Because most mutation-pos. tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime ("never smokers"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers.  Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001).  Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concns. of drug.  Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently contg. mutations within the TK domain of EGFR that are assocd. with gefitinib and erlotinib sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovevWonTGqELVg90H21EOLACvtfcHk0lij3YCjl0usUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D&md5=38f491968552501b7463a688fa0e62ff</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405220101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405220101%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520Receptor%2520Gene%2520Mutations%2520are%2520Common%2520in%2520Lung%2520Cancers%2520from%2520%25E2%2580%25B3Never%2520Smokers%25E2%2580%25B3%2520and%2520are%2520Associated%2520with%2520Sensitivity%2520of%2520Tumors%2520to%2520Gefitinib%2520and%2520Erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311%26doi%3D10.1073%2Fpnas.0405220101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Maemondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugawara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oizumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiwara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nukiwa, T.</span><span> </span><span class="NLM_article-title">North-East Japan Study Group. Gefitinib or Chemotherapy for Non-Small Cell Lung Cancer with Mutated EGFR</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">2380</span><span class="NLM_x">–</span> <span class="NLM_lpage">2388</span><span class="refDoi"> DOI: 10.1056/NEJMoa0909530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa0909530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=20573926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=2380-2388&author=M.+Maemondoauthor=A.+Inoueauthor=K.+Kobayashiauthor=S.+Sugawaraauthor=S.+Oizumiauthor=H.+Isobeauthor=A.+Gemmaauthor=M.+Haradaauthor=H.+Yoshizawaauthor=I.+Kinoshitaauthor=Y.+Fujitaauthor=S.+Okinagaauthor=H.+Hiranoauthor=K.+Yoshimoriauthor=T.+Haradaauthor=T.+Oguraauthor=M.+Andoauthor=H.+Miyazawaauthor=T.+Tanakaauthor=Y.+Saijoauthor=K.+Hagiwaraauthor=S.+Moritaauthor=T.+Nukiwa&title=North-East+Japan+Study+Group.+Gefitinib+or+Chemotherapy+for+Non-Small+Cell+Lung+Cancer+with+Mutated+EGFR&doi=10.1056%2FNEJMoa0909530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span></div><div class="casAuthors">Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, Satoshi; Isobe, Hiroshi; Gemma, Akihiko; Harada, Masao; Yoshizawa, Hirohisa; Kinoshita, Ichiro; Fujita, Yuka; Okinaga, Shoji; Hirano, Haruto; Yoshimori, Kozo; Harada, Toshiyuki; Ogura, Takashi; Ando, Masahiro; Miyazawa, Hitoshi; Tanaka, Tomoaki; Saijo, Yasuo; Hagiwara, Koichi; Morita, Satoshi; Nukiwa, Toshihiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2380-2388</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of std. chemotherapy.  We randomly assigned 230 patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy to receive gefitinib or carboplatin-paclitaxel.  The primary end point was progression-free survival; secondary end points included overall survival, response rate, and toxic effects.  In the planned interim anal. of data for the first 200 patients, progression-free survival was significantly longer in the gefitinib group than in the std.-chemotherapy group (hazard ratio for death or disease progression with gefitinib, 0.36; P<0.001), resulting in early termination of the study.  The gefitinib group had a significantly longer median progression-free survival (10.8 mo, vs. 5.4 mo in the chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; P<0.001), as well as a higher response rate (73.7% vs. 30.7%, P<0.001).  The median overall survival was 30.5 mo in the gefitinib group and 23.6 mo in the chemotherapy group (P = 0.31).  The most common adverse events in the gefitinib group were rash (71.1%) and elevated aminotransferase levels (55.3%), and in the chemotherapy group, neutropenia (77.0%), anemia (64.6%), appetite loss (56.6%), and sensory neuropathy (54.9%).  One patient receiving gefitinib died from interstitial lung disease.  First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with std. chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1G31xQ-ZFWLVg90H21EOLACvtfcHk0lij3YCjl0usUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D&md5=603963e646bf20ecfd936fc98467f5fd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0909530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0909530%26sid%3Dliteratum%253Aachs%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DSugawara%26aufirst%3DS.%26aulast%3DOizumi%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DH.%26aulast%3DGemma%26aufirst%3DA.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DYoshizawa%26aufirst%3DH.%26aulast%3DKinoshita%26aufirst%3DI.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DOkinaga%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DH.%26aulast%3DYoshimori%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DMiyazawa%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSaijo%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DK.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DNukiwa%26aufirst%3DT.%26atitle%3DNorth-East%2520Japan%2520Study%2520Group.%2520Gefitinib%2520or%2520Chemotherapy%2520for%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520with%2520Mutated%2520EGFR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D2380%26epage%3D2388%26doi%3D10.1056%2FNEJMoa0909530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Mok, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunpaweravong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margono, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiwaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chewaskulyong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffield, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuoka, M.</span><span> </span><span class="NLM_article-title">Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">–</span> <span class="NLM_lpage">957</span><span class="refDoi"> DOI: 10.1056/NEJMoa0810699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa0810699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=19692680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=947-957&author=T.+S.+Mokauthor=Y.+L.+Wuauthor=S.+Thongprasertauthor=C.+H.+Yangauthor=D.+T.+Chuauthor=N.+Saijoauthor=P.+Sunpaweravongauthor=B.+Hanauthor=B.+Margonoauthor=Y.+Ichinoseauthor=Y.+Nishiwakiauthor=Y.+Oheauthor=J.+J.+Yangauthor=B.+Chewaskulyongauthor=H.+Jiangauthor=E.+L.+Duffieldauthor=C.+L.+Watkinsauthor=A.+A.+Armourauthor=M.+Fukuoka&title=Gefitinib+or+Carboplatin-Paclitaxel+in+Pulmonary+Adenocarcinoma&doi=10.1056%2FNEJMoa0810699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span></div><div class="casAuthors">Mok, Tony S.; Wu, Yi-Long; Thongprasert, Sumitra; Yang, Chih-Hsin; Chu, Da-Tong; Saijo, Nagahiro; Sunpaweravong, Patrapim; Han, Baohui; Margono, Benjamin; Ichinose, Yukito; Nishiwaki, Yutaka; Ohe, Yuichiro; Yang, Jin-Ji; Chewaskulyong, Busyamas; Jiang, Haiyi; Duffield, Emma L.; Watkins, Claire L.; Armour, Alison A.; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-957</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.  METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calcd. to produce an area under the curve of 5 or 6 mg per mL per min) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients).  The primary end point was progression-free survival.  RESULTS: The 12-mo rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel.  The study met its primary objective of showing the noninferiority of gefitinib and also showed its superiority, as compared with carboplatin-paclitaxel, with respect to progression-free survival in the intention-to-treat population (hazard ratio for progression or death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P < 0.001).  In the subgroup of 261 patients who were pos. for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P < 0.001), whereas in the subgroup of 176 patients who were neg. for the mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel (hazard ratio for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P < 0.001).  The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel group.  CONCLUSIONS: Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia.  The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKhpFOiEQu7Vg90H21EOLACvtfcHk0li0ZC2XnMXUWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK&md5=31ce0983eedb9f248dcf0726adf18b88</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810699%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%2BS.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DChu%26aufirst%3DD.%2BT.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DSunpaweravong%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DMargono%26aufirst%3DB.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DDuffield%26aufirst%3DE.%2BL.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DArmour%26aufirst%3DA.%2BA.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520or%2520Carboplatin-Paclitaxel%2520in%2520Pulmonary%2520Adenocarcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D947%26epage%3D957%26doi%3D10.1056%2FNEJMoa0810699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span><span class="refDoi"> DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+J%C3%A4nneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+Mutations+in+Lung+Cancer%3A+Correlation+with+Clinical+Response+to+Gefitinib+Therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0li0ZC2XnMXUWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520Mutations%2520in%2520Lung%2520Cancer%253A%2520Correlation%2520with%2520Clinical%2520Response%2520to%2520Gefitinib%2520Therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, M. J.</span><span> </span><span class="NLM_article-title">EGFR Mutations in Circulating Tumour DNA</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">973</span><span class="refDoi"> DOI: 10.1016/S1470-2045(12)70369-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1016%2FS1470-2045%2812%2970369-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=23026821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVCjsbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=971-973&author=R.+Rosellauthor=M.+A.+Molinaauthor=M.+J.+Serrano&title=EGFR+Mutations+in+Circulating+Tumour+DNA&doi=10.1016%2FS1470-2045%2812%2970369-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutations in circulating tumour DNA</span></div><div class="casAuthors">Rosell, Rafael; Molina, Miguel Angel; Serrano, Maria Jose</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">971-973</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  This article discusses the data on EGFR mutations in circulating tumor DNA (ctDNA).  It shows that an abundance of EGFR mutations in plasma or serum could offer further information for gauging of response and monitoring of disease progression and could be utilized to det. the presence of new acquired mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6T_Flo7pD7rVg90H21EOLACvtfcHk0ljy7WJrbBI4cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVCjsbjN&md5=9887e936b4460d94902a48958c210a84</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970369-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970369-8%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DSerrano%26aufirst%3DM.%2BJ.%26atitle%3DEGFR%2520Mutations%2520in%2520Circulating%2520Tumour%2520DNA%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D971%26epage%3D973%26doi%3D10.1016%2FS1470-2045%2812%2970369-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">–</span> <span class="NLM_lpage">1167</span><span class="refDoi"> DOI: 10.1126/science.1101637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1126%2Fscience.1101637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=15284455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163-1167&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-Sensitizing+EGFR+Mutations+in+Lung+Cancer+Activate+Anti-Apoptotic+Pathways&doi=10.1126%2Fscience.1101637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways</span></div><div class="casAuthors">Sordella, Raffaella; Bell, Daphne W.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5687</span>),
    <span class="NLM_cas:pages">1163-1167</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gefitinib (Iressa, AstraZeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) and induces dramatic clin. responses in nonsmall cell lung cancers (NSCLCs) with activating mutations within the EGFR kinase domain.  The authors report that these mutant EGFRs selectively activate Akt and signal transduction and activator of transcription (STAT) signaling pathways, which promote cell survival, but have no effect on extracellular signal-regulated kinase signaling, which induces proliferation.  NSCLC cells expressing mutant EGFRs underwent extensive apoptosis after small interfering RNA-mediated knockdown of the mutant EGFR or treatment with pharmacol. inhibitors of Akt and STAT signaling and were relatively resistant to apoptosis induced by conventional chemotherapeutic drugs.  Thus, mutant EGFRs selectively transduce survival signals on which NSCLCs become dependent; inhibition of those signals by gefitinib may contribute to the drug's efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrKHDqaSobm7Vg90H21EOLACvtfcHk0ljy7WJrbBI4cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D&md5=e9742920d5e320357b774495746e6581</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.1101637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1101637%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-Sensitizing%2520EGFR%2520Mutations%2520in%2520Lung%2520Cancer%2520Activate%2520Anti-Apoptotic%2520Pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26epage%3D1167%26doi%3D10.1126%2Fscience.1101637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+Mutation+and+Resistance+of+Non-Small-Cell+Lung+Cancer+to+Gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljy7WJrbBI4cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520Mutation%2520and%2520Resistance%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is Associated with a Second Mutation in the EGFR Kinase Domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+Resistance+of+Lung+Adenocarcinomas+to+Gefitinib+or+Erlotinib+is+Associated+with+a+Second+Mutation+in+the+EGFR+Kinase+Domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eYRbFikHh3ub7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520Resistance%2520of%2520Lung%2520Adenocarcinomas%2520to%2520Gefitinib%2520or%2520Erlotinib%2520is%2520Associated%2520with%2520a%2520Second%2520Mutation%2520in%2520the%2520EGFR%2520Kinase%2520Domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Digumarthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turke, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gettinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosper, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhavanfard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heist, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernovsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanuti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">75ra26</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3002003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1126%2Fscitranslmed.3002003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=21430269" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=75ra26&author=L.+V.+Sequistauthor=B.+A.+Waltmanauthor=D.+Dias-Santagataauthor=S.+Digumarthyauthor=A.+B.+Turkeauthor=P.+Fidiasauthor=K.+Bergethonauthor=A.+T.+Shawauthor=S.+Gettingerauthor=A.+K.+Cosperauthor=S.+Akhavanfardauthor=R.+S.+Heistauthor=J.+Temelauthor=J.+G.+Christensenauthor=J.+C.+Wainauthor=T.+J.+Lynchauthor=K.+Vernovskyauthor=E.+J.+Markauthor=M.+Lanutiauthor=A.+J.+Iafrateauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=Genotypic+and+Histological+Evolution+of+Lung+Cancers+Acquiring+Resistance+to+EGFR+Inhibitors&doi=10.1126%2Fscitranslmed.3002003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3002003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3002003%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DWaltman%26aufirst%3DB.%2BA.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DCosper%26aufirst%3DA.%2BK.%26aulast%3DAkhavanfard%26aufirst%3DS.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DTemel%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DVernovsky%26aufirst%3DK.%26aulast%3DMark%26aufirst%3DE.%2BJ.%26aulast%3DLanuti%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DGenotypic%2520and%2520Histological%2520Evolution%2520of%2520Lung%2520Cancers%2520Acquiring%2520Resistance%2520to%2520EGFR%2520Inhibitors%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D75ra26%26doi%3D10.1126%2Fscitranslmed.3002003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raaijmakers, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Otterlo, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Characterization of Irreversible Kinase Inhibitors by Directly Detecting Covalent Bond Formation: a Tool for Dissecting Kinase Drug Resistance</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2557</span><span class="NLM_x">–</span> <span class="NLM_lpage">2566</span><span class="refDoi"> DOI: 10.1002/cbic.201000352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1002%2Fcbic.201000352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=21080395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFahsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=2557-2566&author=S.+Kl%C3%BCterauthor=J.+R.+Simardauthor=H.+B.+Rodeauthor=C.+Gr%C3%BCtterauthor=V.+Pawarauthor=H.+C.+Raaijmakersauthor=T.+A.+Barfauthor=M.+Rabillerauthor=W.+A.+van+Otterloauthor=D.+Rauh&title=Characterization+of+Irreversible+Kinase+Inhibitors+by+Directly+Detecting+Covalent+Bond+Formation%3A+a+Tool+for+Dissecting+Kinase+Drug+Resistance&doi=10.1002%2Fcbic.201000352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Irreversible Kinase Inhibitors by Directly Detecting Covalent Bond Formation: A Tool for Dissecting Kinase Drug Resistance</span></div><div class="casAuthors">Klueter, Sabine; Simard, Jeffrey R.; Rode, Haridas B.; Gruetter, Christian; Pawar, Vijaykumar; Raaijmakers, Hans C. A.; Barf, Tjeerd A.; Rabiller, Matthias; van Otterlo, Willem A. L.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2557-2566</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting protein kinases in cancer therapy with irreversible small-mol. inhibitors is moving to the forefront of kinase-inhibitor research and is thought to be an effective means of overcoming mutation-assocd. drug resistance in epidermal growth factor receptor kinase (EGFR).  We generated a detection technique that allows direct measurements of covalent bond formation without relying on kinase activity, thereby allowing the straightforward investigation of the influence of steric clashes on covalent inhibitors in different resistant kinase mutants.  The obtained results are discussed together with structural biol. and biochem. studies of catalytic activity in both wild-type and gatekeeper mutated kinase variants to draw conclusions about the impact of steric hindrance and increased catalytic activity in drug-resistant kinase variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXBFAgMOxkBLVg90H21EOLACvtfcHk0lh6pDBr5fsznA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFahsLrE&md5=5f48cde54e6bad28b4d4f9d47a4e3e3e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201000352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201000352%26sid%3Dliteratum%253Aachs%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DRaaijmakers%26aufirst%3DH.%2BC.%26aulast%3DBarf%26aufirst%3DT.%2BA.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3Dvan%2BOtterlo%26aufirst%3DW.%2BA.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DCharacterization%2520of%2520Irreversible%2520Kinase%2520Inhibitors%2520by%2520Directly%2520Detecting%2520Covalent%2520Bond%2520Formation%253A%2520a%2520Tool%2520for%2520Dissecting%2520Kinase%2520Drug%2520Resistance%26jtitle%3DChemBioChem%26date%3D2010%26volume%3D11%26spage%3D2557%26epage%3D2566%26doi%3D10.1002%2Fcbic.201000352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Michalczyk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Structural Insights Into How Irreversible Inhibitors Can. Overcome Drug Resistance in EGFR</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3482</span><span class="NLM_x">–</span> <span class="NLM_lpage">3488</span><span class="refDoi"> DOI: 10.1016/j.bmc.2008.02.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1016%2Fj.bmc.2008.02.053" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=3482-3488&author=A.+Michalczykauthor=S.+Kl%C3%BCterauthor=H.+B.+Rodeauthor=J.+R.+Simardauthor=C.+Gr%C3%BCtterauthor=M.+Rabillerauthor=D.+Rauh&title=Structural+Insights+Into+How+Irreversible+Inhibitors+Can.+Overcome+Drug+Resistance+in+EGFR&doi=10.1016%2Fj.bmc.2008.02.053"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.02.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.02.053%26sid%3Dliteratum%253Aachs%26aulast%3DMichalczyk%26aufirst%3DA.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStructural%2520Insights%2520Into%2520How%2520Irreversible%2520Inhibitors%2520Can.%2520Overcome%2520Drug%2520Resistance%2520in%2520EGFR%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D3482%26epage%3D3488%26doi%3D10.1016%2Fj.bmc.2008.02.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.+H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+Profiling+Provides+Insights+into+the+Limited+Activity+of+Irreversible+EGFR+Inhibitors+in+Tumor+Cells+Expressing+the+T790M+EGFR+Resistance+Mutation&doi=10.1158%2F0008-5472.CAN-09-3106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0liQT6j2nDJuYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520Profiling%2520Provides%2520Insights%2520into%2520the%2520Limited%2520Activity%2520of%2520Irreversible%2520EGFR%2520Inhibitors%2520in%2520Tumor%2520Cells%2520Expressing%2520the%2520T790M%2520EGFR%2520Resistance%2520Mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874%26doi%3D10.1158%2F0008-5472.CAN-09-3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span><span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0liQT6j2nDJuYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Carey, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garton, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8163</span><span class="NLM_x">–</span> <span class="NLM_lpage">8171</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-0453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1158%2F0008-5472.CAN-06-0453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=16912195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8163-8171&author=K.+D.+Careyauthor=A.+J.+Gartonauthor=M.+S.+Romeroauthor=J.+Kahlerauthor=S.+Thomsonauthor=S.+Rossauthor=F.+Parkauthor=J.+D.+Haleyauthor=N.+Gibsonauthor=M.+X.+Sliwkowski&title=Kinetic+analysis+of+epidermal+growth+factor+receptor+somatic+mutant+proteins+shows+increased+sensitivity+to+the+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+erlotinib&doi=10.1158%2F0008-5472.CAN-06-0453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib</span></div><div class="casAuthors">Carey, Kendall D.; Garton, Andrew J.; Romero, Maria S.; Kahler, Jennifer; Thomson, Stuart; Ross, Sarajane; Park, Frances; Haley, John D.; Gibson, Neil; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8163-8171</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We show that two commonly occurring epidermal growth factor receptor (EGFR) somatic mutations, L858R and an in-frame deletion mutant, Del(746-750), exhibit distinct enzymic properties relative to wild-type EGFR and are differentially sensitive to erlotinib.  Kinetic anal. of the purified intracellular domains of EGFR L858R and EGFR Del(746-750) reveals that both mutants are active but exhibit a higher KM for ATP and a lower Ki for erlotinib relative to wild-type receptor.  When expressed in NR6 cells, a cell line that does not express EGFR or other ErbB receptors, both mutations are ligand dependent for receptor activation, can activate downstream EGFR signaling pathways, and promote cell cycle progression.  As expected from the kinetic anal., the EGFR Del(746-752) is more sensitive to erlotinib inhibition than the EGFR L858R mutant.  Further characterization shows that these mutations promote ligand-dependent and anchorage-independent growth, and cells harboring these mutant receptors form tumors in immunocompromised mice.  Anal. of tumor lysates reveals that the tumorigenicity of the mutant EGFR cell lines may be due to a differential pattern of mutant EGFR autophosphorylation as compared with wild-type receptor.  Significant inhibition of tumor growth, in mice harboring wild-type EGFR receptors, is only obsd. at doses of erlotinib approaching the max. tolerated dose for the mouse.  In contrast, the growth of mutant tumors is inhibited by erlotinib treatment at approx. one third the max. tolerated dose.  These findings suggest that EGFR somatic mutations directly influence both erlotinib sensitivity and cellular transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-kYT9GVzgo7Vg90H21EOLACvtfcHk0lhzDqorCeoDcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D&md5=0ea102a026666dc0cb9cf60a3de0e944</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0453%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DK.%2BD.%26aulast%3DGarton%26aufirst%3DA.%2BJ.%26aulast%3DRomero%26aufirst%3DM.%2BS.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DF.%26aulast%3DHaley%26aufirst%3DJ.%2BD.%26aulast%3DGibson%26aufirst%3DN.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DKinetic%2520analysis%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520somatic%2520mutant%2520proteins%2520shows%2520increased%2520sensitivity%2520to%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520erlotinib%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8163%26epage%3D8171%26doi%3D10.1158%2F0008-5472.CAN-06-0453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Mulloy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrand, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">2325</span><span class="NLM_x">–</span> <span class="NLM_lpage">2330</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1158%2F0008-5472.CAN-06-4293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=17332364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=2325-2330&author=R.+Mulloyauthor=A.+Ferrandauthor=Y.+Kimauthor=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=K.+S.+Andersonauthor=J.+Settleman&title=Epidermal+growth+factor+receptor+mutants+from+human+lung+cancers+exhibit+enhanced+catalytic+activity+and+increased+sensitivity+to+gefitinib&doi=10.1158%2F0008-5472.CAN-06-4293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to Gefitinib</span></div><div class="casAuthors">Mulloy, Roseann; Ferrand, Audrey; Kim, Youngjoo; Sordella, Raffaella; Bell, Daphne W.; Haber, Daniel A.; Anderson, Karen S.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2325-2330</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Somatic mutations within the epidermal growth factor receptor (EGFR) kinase domain are detected in 10% to 30% of human non-small cell lung cancers and are correlated with striking clin. responses in a subset of patients treated with EGFR kinase inhibitors, such as gefitinib and erlotinib.  Cell-based studies suggest that these mutant EGFRs promote increased autophosphorylating activity on a subset of EGFR COOH-terminal tyrosines and the consequent engagement of a subset of downstream effectors.  Because EGFR function is regulated at multiple levels in vivo, and it is therefore difficult to assess the direct consequences of these mutations on EGFR enzyme function, we measured EGFR catalytic activity in in vitro kinase assays using purified recombinant proteins corresponding to the cytoplasmic domain of wild-type and two frequently detected EGFR mutants (DelL747-P753insS and L858R).  Both mutants exhibit substantially increased autophosphorylating activity relative to wild-type EGFR, and they exhibit distinct reaction kinetics.  In addn., the mutant kinases are more sensitive to kinase inhibition by gefitinib, which seems to reflect their increased drug affinity.  These findings suggest that the altered signaling properties and drug sensitivity of these EGFR mutants that have been obsd. in vivo largely result from differences in the catalytic properties of the kinase.  In addn., we find that the T790M secondary "drug resistance mutation" of EGFR, which frequently arises in relapsed patients that initially responded to treatment, confers enhanced kinase activity to primary activating EGFR alleles and may, therefore, be oncogenic in some contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ3000le0prLVg90H21EOLACvtfcHk0lhzDqorCeoDcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjsLk%253D&md5=6bd63e27b220c89e22f0ba6e8682db17</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4293%26sid%3Dliteratum%253Aachs%26aulast%3DMulloy%26aufirst%3DR.%26aulast%3DFerrand%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DAnderson%26aufirst%3DK.%2BS.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutants%2520from%2520human%2520lung%2520cancers%2520exhibit%2520enhanced%2520catalytic%2520activity%2520and%2520increased%2520sensitivity%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D2325%26epage%3D2330%26doi%3D10.1158%2F0008-5472.CAN-06-4293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lhzDqorCeoDcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4702</span><span class="NLM_x">–</span> <span class="NLM_lpage">4711</span><span class="refDoi"> DOI: 10.1038/onc.2008.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fonc.2008.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=18408761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models&doi=10.1038%2Fonc.2008.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span></div><div class="casAuthors">Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K-K.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4702-4711</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to treatment with small mol. tyrosine kinase inhibitors.  Although first-generation reversible, ATP-competitive inhibitors showed encouraging clin. responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time.  Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3.  Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen.  Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms.  Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib.  These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.  Oncogene (2008) 27, 4702-4711; doi:10.1038/onc.2008.109; published online 14 Apr. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5PQdKep-Sp7Vg90H21EOLACvtfcHk0liCalpfZe8czw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D&md5=24945893e83b4e3d01c267100fdaf57c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711%26doi%3D10.1038%2Fonc.2008.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amato, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhoury, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lettiere, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span> </span><span class="NLM_article-title">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1880</span><span class="NLM_x">–</span> <span class="NLM_lpage">1889</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1158%2F1535-7163.MCT-07-2232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=18606718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1880-1889&author=A.+J.+Gonzalesauthor=K.+E.+Hookauthor=I.+W.+Althausauthor=P.+A.+Ellisauthor=E.+Trachetauthor=A.+M.+Delaneyauthor=P.+J.+Harveyauthor=T.+A.+Ellisauthor=D.+M.+Amatoauthor=J.+M.+Nelsonauthor=D.+W.+Fryauthor=T.+Zhuauthor=C.+M.+Loiauthor=S.+A.+Fakhouryauthor=K.+M.+Schlosserauthor=K.+E.+Sextonauthor=R.+T.+Wintersauthor=J.+E.+Reedauthor=A.+J.+Bridgesauthor=D.+J.+Lettiereauthor=D.+A.+Bakerauthor=J.+Yangauthor=H.+T.+Leeauthor=H.+Tecleauthor=P.+W.+Vincent&title=Antitumor+activity+and+pharmacokinetic+properties+of+PF-00299804%2C+a+second-generation+irreversible+pan-erbB+receptor+tyrosine+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-07-2232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Gonzales, Andrea J.; Hook, Kenneth E.; Althaus, Irene W.; Ellis, Paul A.; Trachet, Erin; Delaney, Amy M.; Harvey, Patricia J.; Ellis, Teresa A.; Amato, Danielle M.; Nelson, James M.; Fry, David W.; Zhu, Tong; Loi, Cho-Ming; Fakhoury, Stephen A.; Schlosser, Kevin M.; Sexton, Karen E.; Winters, R. Thomas; Reed, Jessica E.; Bridges, Alex J.; Lettiere, Daniel J.; Baker, Deborah A.; Yang, Jianxin; Lee, Helen T.; Tecle, Haile; Vincent, Patrick W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1880-1889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types.  Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments.  PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor currently in phase I clin. trials.  PF-00299804 is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members.  Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) assocd. with resistance to gefitinib and erlotinib.  Furthermore, PF-00299804 shows exceptional distribution to human tumor xenografts and excellent pharmacokinetic properties across species. [Mol Cancer Ther 2008;7(7):1880-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbL0hP8K2G37Vg90H21EOLACvtfcHk0liCalpfZe8czw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D&md5=3392275d1e4f4d5d70e3b22d4893e3c8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2232%26sid%3Dliteratum%253Aachs%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DEllis%26aufirst%3DT.%2BA.%26aulast%3DAmato%26aufirst%3DD.%2BM.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DLoi%26aufirst%3DC.%2BM.%26aulast%3DFakhoury%26aufirst%3DS.%2BA.%26aulast%3DSchlosser%26aufirst%3DK.%2BM.%26aulast%3DSexton%26aufirst%3DK.%2BE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DLettiere%26aufirst%3DD.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacokinetic%2520properties%2520of%2520PF-00299804%252C%2520a%2520second-generation%2520irreversible%2520pan-erbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1880%26epage%3D1889%26doi%3D10.1158%2F1535-7163.MCT-07-2232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-Target Residence Time and its Implications for Lead Optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span><span class="refDoi"> DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-Target+Residence+Time+and+its+Implications+for+Lead+Optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0liCalpfZe8czw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-Target%2520Residence%2520Time%2520and%2520its%2520Implications%2520for%2520Lead%2520Optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span> </span><span class="NLM_article-title">Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3417</span><span class="NLM_x">–</span> <span class="NLM_lpage">3420</span><span class="refDoi"> DOI: 10.1200/JCO.2012.43.1825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1200%2FJCO.2012.43.1825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=22915655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3417-3420&author=J.+M.+Heuckmannauthor=D.+Rauhauthor=R.+K.+Thomas&title=Epidermal+Growth+Factor+Receptor+%28EGFR%29+Signaling+and+Covalent+EGFR+Inhibition+in+Lung+Cancer&doi=10.1200%2FJCO.2012.43.1825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor (EGFR) signaling and covalent EGF inhibition in lung cancer</span></div><div class="casAuthors">Heuckmann, Johannes M.; Rauh, Daniel; Thomas, Roman K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3417-3420</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The research of Ramalingam et al. (2012) entitled, 'Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, vs. erlotinib in patients with advanced non-small-cell lung cancer' is reviewed with commentary and refs.  In their paper, a novel irreversible ERBB family inhibitor, dacomitinib, improved progression-free survival compared with erlotinib in unselected patients with non-small-cell lung cancer without prior epidermal growth factor receptor-directed therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8PW4hGdL2k7Vg90H21EOLACvtfcHk0lhmIafxrUCuXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt73O&md5=45192d5ee846d2c25302286226cff733</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.1825%26sid%3Dliteratum%253Aachs%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DEpidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%2520Signaling%2520and%2520Covalent%2520EGFR%2520Inhibition%2520in%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3417%26epage%3D3420%26doi%3D10.1200%2FJCO.2012.43.1825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The Resurgence of Covalent Drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+Resurgence+of+Covalent+Drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lhmIafxrUCuXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520Resurgence%2520of%2520Covalent%2520Drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Katakami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atagi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koboyashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebisawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span> </span><span class="NLM_article-title">LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3335</span><span class="NLM_x">–</span> <span class="NLM_lpage">3341</span><span class="refDoi"> DOI: 10.1200/JCO.2012.45.0981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1200%2FJCO.2012.45.0981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=23816963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KrsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3335-3341&author=N.+Katakamiauthor=S.+Atagiauthor=K.+Gotoauthor=T.+Hidaauthor=T.+Horaiauthor=A.+Inoueauthor=Y.+Ichinoseauthor=K.+Koboyashiauthor=K.+Takedaauthor=K.+Kiuraauthor=K.+Nishioauthor=Y.+Sekiauthor=R.+Ebisawaauthor=M.+Shahidiauthor=N.+Yamamoto&title=LUX-Lung+4%3A+A+Phase+II+Trial+of+Afatinib+in+Patients+With+Advanced+Non-Small-Cell+Lung+Cancer+Who+Progressed+During+Prior+Treatment+With+Erlotinib%2C+Gefitinib%2C+or+Both&doi=10.1200%2FJCO.2012.45.0981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">LUX-lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both</span></div><div class="casAuthors">Katakami, Noboyuki; Atagi, Shinji; Goto, Koichi; Hida, Toyoaki; Horai, Takeshi; Inoue, Akira; Ichinose, Yukito; Koboyashi, Kunihiko; Takeda, Koji; Kiura, Katsuyuki; Nishio, Kazuto; Seki, Yoko; Ebisawa, Ryuichi; Shahidi, Mehdi; Yamamoto, Nobuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3335-3341</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose New mol. targeted agents are needed for patients with non-small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both.  Afatinib, an oral irreversible ErbB family blocker, has preclin. activity in epidermal growth factor receptor (EGFR [ErbB1]) mutant models with EGFR-activating mutations, including T790M.  Patients and Methods This was a Japanese single-arm phase II trial conducted in patients with stage IIIB to IV pulmonary adenocarcinoma who progressed after ≥ 12 wk of prior erlotinib and/or gefitinib.  Patients received afatinib 50 mg per day.  The primary end point was objective response rate (complete response or partial response) by independent review.  Secondary end points included progression-free survival (PFS), overall survival (OS), and safety.  Results Of 62 treated patients, 45 (72.6%) were EGFR mutation pos. in their primary tumor according to local and/or central lab. analyses.  Fifty-one patients (82.3%) fulfilled the criteria of acquired resistance to erlotinib and/or gefitinib.  Of 61 evaluable patients, five (8.2%; 95% CI, 2.7% to 18.1 %) had a confirmed objective response rate (partial response).  Median PFS was 4.4 mo (95% CI, 2.8 to 4.6 mo), and median OS was 19.0 mo (95% CI, 14.9 mo to not achieved).  Two patients had acquired T790M mutations: L858R + T790M, and deletion in exon 19 + T790M; they had stable disease for 9 mo and 1 mo, resp.  The most common afatinib-related adverse events (AEs) were diarrhea (100%) and rash/acne (91.9%).  Treatment-related AEs leading to afatinib discontinuation were experienced by 18 patients (29%), of whom four also had progressive disease.  Conclusion Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM0F6fZnWKTbVg90H21EOLACvtfcHk0lhmIafxrUCuXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KrsrzK&md5=1666aeb642dbc953dd9bcc818bab9098</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.45.0981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.45.0981%26sid%3Dliteratum%253Aachs%26aulast%3DKatakami%26aufirst%3DN.%26aulast%3DAtagi%26aufirst%3DS.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DHorai%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DKoboyashi%26aufirst%3DK.%26aulast%3DTakeda%26aufirst%3DK.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DY.%26aulast%3DEbisawa%26aufirst%3DR.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DN.%26atitle%3DLUX-Lung%25204%253A%2520A%2520Phase%2520II%2520Trial%2520of%2520Afatinib%2520in%2520Patients%2520With%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%2520Who%2520Progressed%2520During%2520Prior%2520Treatment%2520With%2520Erlotinib%252C%2520Gefitinib%252C%2520or%2520Both%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3335%26epage%3D3341%26doi%3D10.1200%2FJCO.2012.45.0981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadranel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span> </span><span class="NLM_article-title">Afatinib versus Placebo for Patients with Advanced, Metastatic Non-Small Cell Lung Cancer After Failure of Erlotinib, Gefitinib, or both, and One or Two Lines of Chemotherapy (LUX-Lung 1): A Phase 2b/3 Randomised Trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">528</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span><span class="refDoi"> DOI: 10.1016/S1470-2045(12)70087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.+M.+Chenauthor=K.+Parkauthor=S.+W.+Kimauthor=C.+Zhouauthor=W.+C.+Suauthor=M.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.+H.+Tanauthor=T.+Y.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.+Yang&title=Afatinib+versus+Placebo+for+Patients+with+Advanced%2C+Metastatic+Non-Small+Cell+Lung+Cancer+After+Failure+of+Erlotinib%2C+Gefitinib%2C+or+both%2C+and+One+or+Two+Lines+of+Chemotherapy+%28LUX-Lung+1%29%3A+A+Phase+2b%2F3+Randomised+Trial&doi=10.1016%2FS1470-2045%2812%2970087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0liy5uxlR5aa5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%2BM.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DChao%26aufirst%3DT.%2BY.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26atitle%3DAfatinib%2520versus%2520Placebo%2520for%2520Patients%2520with%2520Advanced%252C%2520Metastatic%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520After%2520Failure%2520of%2520Erlotinib%252C%2520Gefitinib%252C%2520or%2520both%252C%2520and%2520One%2520or%2520Two%2520Lines%2520of%2520Chemotherapy%2520%2528LUX-Lung%25201%2529%253A%2520A%2520Phase%25202b%252F3%2520Randomised%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D528%26epage%3D538%26doi%3D10.1016%2FS1470-2045%2812%2970087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthakrishnan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Neratinib, an Irreversible pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients with Advanced Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">–</span> <span class="NLM_lpage">3083</span><span class="refDoi"> DOI: 10.1200/JCO.2009.27.9414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1200%2FJCO.2009.27.9414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=20479403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3076-3083&author=L.+V.+Sequistauthor=B.+Besseauthor=T.+J.+Lynchauthor=V.+A.+Millerauthor=K.+K.+Wongauthor=B.+Gitlitzauthor=K.+Eatonauthor=C.+Zacharchukauthor=A.+Freymanauthor=C.+Powellauthor=R.+Ananthakrishnanauthor=S.+Quinnauthor=J.+C.+Soria&title=Neratinib%2C+an+Irreversible+pan-ErbB+Receptor+Tyrosine+Kinase+Inhibitor%3A+Results+of+a+Phase+II+Trial+in+Patients+with+Advanced+Non-Small-Cell+Lung+Cancer&doi=10.1200%2FJCO.2009.27.9414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib, an irreversible Pan-ErbB, receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Besse, Benjamin; Lynch, Thomas J.; Miller, Vincent A.; Wong, Kwok K.; Gitlitz, Barbara; Eaton, Keith; Zacharchuk, Charles; Freyman, Amy; Powell, Christine; Ananthakrishnan, Revathi; Quinn, Susan; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3076-3083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations.  Resistance emerges after 9 to 12 mo, primarily mediated by the T790M resistance mutation.  We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.  Patients with advanced NSCLC underwent EGFR sequencing of available tumor tissue at enrollment.  Those with ≥ 12 wk of prior TKI therapy were placed in arm A if they were EGFR mutation pos. or arm B if they were wild-type.  Arm C included TKI-naive patients with adenocarcinoma and light smoking histories (≤ 20 pack-years).  All patients received daily oral neratinib, initially at 320 mg but subsequently reduced to 240 mg because of excessive diarrhea.  The primary end point was objective response rate (RR).  167 Patients were treated: 91 in arm A, 48 in arm B, and 28 in arm C.  Diarrhea was the most common toxicity; grade 3 incidence was 50% at 320 mg but improved to 25% after dose redn.  The RR was 3% in arm A and zero in arms B and C.  No patients with known T790M responded.  Notably, three of four patients with an exon 18 G719X EGFR mutation had a partial response and the fourth had stable disease lasting 40 wk.  Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naive patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation.  Responses were seen in patients with the rare G719X EGFR mutation, highlighting the importance of obtaining comprehensive genetic information on trials of targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Z3gsvbWbOrVg90H21EOLACvtfcHk0liy5uxlR5aa5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D&md5=460e088e58919bbfcf8c153772f157b0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.27.9414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.27.9414%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGitlitz%26aufirst%3DB.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DFreyman%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DNeratinib%252C%2520an%2520Irreversible%2520pan-ErbB%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%253A%2520Results%2520of%2520a%2520Phase%2520II%2520Trial%2520in%2520Patients%2520with%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D3076%26epage%3D3083%26doi%3D10.1200%2FJCO.2009.27.9414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+Mutant-Selective+Covalent+Inhibitor+of+EGFR+that+Overcomes+T790M-Mediated+Resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lgY2BrWuyRnsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520Mutant-Selective%2520Covalent%2520Inhibitor%2520of%2520EGFR%2520that%2520Overcomes%2520T790M-Mediated%2520Resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lgY2BrWuyRnsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Bartlett, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachtel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roses, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelz, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karakousis, G. C.</span><span> </span><span class="NLM_article-title">The Rise in Metastasectomy Across Cancer Types Over the Past Decade</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">747</span><span class="NLM_x">–</span> <span class="NLM_lpage">757</span><span class="refDoi"> DOI: 10.1002/cncr.29134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1002%2Fcncr.29134" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=747-757&author=E.+K.+Bartlettauthor=K.+D.+Simmonsauthor=H.+Wachtelauthor=R.+E.+Rosesauthor=D.+L.+Frakerauthor=R.+R.+Kelzauthor=G.+C.+Karakousis&title=The+Rise+in+Metastasectomy+Across+Cancer+Types+Over+the+Past+Decade&doi=10.1002%2Fcncr.29134"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29134%26sid%3Dliteratum%253Aachs%26aulast%3DBartlett%26aufirst%3DE.%2BK.%26aulast%3DSimmons%26aufirst%3DK.%2BD.%26aulast%3DWachtel%26aufirst%3DH.%26aulast%3DRoses%26aufirst%3DR.%2BE.%26aulast%3DFraker%26aufirst%3DD.%2BL.%26aulast%3DKelz%26aufirst%3DR.%2BR.%26aulast%3DKarakousis%26aufirst%3DG.%2BC.%26atitle%3DThe%2520Rise%2520in%2520Metastasectomy%2520Across%2520Cancer%2520Types%2520Over%2520the%2520Past%2520Decade%26jtitle%3DCancer%26date%3D2015%26volume%3D121%26spage%3D747%26epage%3D757%26doi%3D10.1002%2Fcncr.29134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Dhingra, K.</span><span> </span><span class="NLM_article-title">Rociletinib: has the TIGER lost a few of its stripes?</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1161</span><span class="NLM_x">–</span> <span class="NLM_lpage">1164</span><span class="refDoi"> DOI: 10.1093/annonc/mdw140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1093%2Fannonc%2Fmdw140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=27045101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A280%3ADC%252BC28fmvVSisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1161-1164&author=K.+Dhingra&title=Rociletinib%3A+has+the+TIGER+lost+a+few+of+its+stripes%3F&doi=10.1093%2Fannonc%2Fmdw140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rociletinib: has the TIGER lost a few of its stripes?</span></div><div class="casAuthors">Dhingra K</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1161-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQv9WkZkIzByiO2kE7krGOBfW6udTcc2eZOOvmYroyZMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fmvVSisA%253D%253D&md5=ce412910e17e83641dc6a5e372201c53</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw140%26sid%3Dliteratum%253Aachs%26aulast%3DDhingra%26aufirst%3DK.%26atitle%3DRociletinib%253A%2520has%2520the%2520TIGER%2520lost%2520a%2520few%2520of%2520its%2520stripes%253F%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26spage%3D1161%26epage%3D1164%26doi%3D10.1093%2Fannonc%2Fmdw140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Update to Rociletinib Data with the RECIST Confirmed Response Rate</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">2296</span><span class="NLM_x">–</span> <span class="NLM_lpage">2297</span><span class="refDoi"> DOI: 10.1056/NEJMc1602688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMc1602688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=27195670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FgvVarug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=2296-2297&author=L.+V.+Sequistauthor=J.+C.+Soriaauthor=D.+R.+Camidge&title=Update+to+Rociletinib+Data+with+the+RECIST+Confirmed+Response+Rate&doi=10.1056%2FNEJMc1602688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Update to Rociletinib Data with the RECIST Confirmed Response Rate</span></div><div class="casAuthors">Sequist Lecia V; Soria Jean-Charles; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2296-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6Df3dbiWDlINpW7w2tapOfW6udTcc2eZOOvmYroyZMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FgvVarug%253D%253D&md5=42e8a350746d423a7a07b556f09105a8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1602688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1602688%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DUpdate%2520to%2520Rociletinib%2520Data%2520with%2520the%2520RECIST%2520Confirmed%2520Response%2520Rate%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D2296%26epage%3D2297%26doi%3D10.1056%2FNEJMc1602688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitrakopoulou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dziadziuszko, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galasso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garon, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heist, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendenhall, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piotrowska, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlovich, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Despain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheny, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">1700</span><span class="NLM_x">–</span> <span class="NLM_lpage">1709</span><span class="refDoi"> DOI: 10.1056/NEJMoa1413654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa1413654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=25923550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1700-1709&author=L.+V.+Sequistauthor=J.+C.+Soriaauthor=J.+W.+Goldmanauthor=H.+A.+Wakeleeauthor=S.+M.+Gadgeelauthor=A.+Vargaauthor=V.+Papadimitrakopoulouauthor=B.+J.+Solomonauthor=G.+R.+Oxnardauthor=R.+Dziadziuszkoauthor=D.+L.+Aisnerauthor=R.+C.+Doebeleauthor=C.+Galassoauthor=E.+B.+Garonauthor=R.+S.+Heistauthor=J.+Loganauthor=J.+W.+Nealauthor=M.+A.+Mendenhallauthor=S.+Nicholsauthor=Z.+Piotrowskaauthor=A.+J.+Wozniakauthor=M.+Raponiauthor=C.+A.+Karlovichauthor=S.+Jaw-Tsaiauthor=J.+Isaacsonauthor=D.+Despainauthor=S.+L.+Mathenyauthor=L.+Rolfeauthor=A.+R.+Allenauthor=D.+R.+Camidge&title=Rociletinib+in+EGFR-Mutated+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1413654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Rociletinib in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Sequist Lecia V; Soria Jean-Charles; Goldman Jonathan W; Wakelee Heather A; Gadgeel Shirish M; Varga Andrea; Papadimitrakopoulou Vassiliki; Solomon Benjamin J; Oxnard Geoffrey R; Dziadziuszko Rafal; Aisner Dara L; Doebele Robert C; Galasso Cathy; Garon Edward B; Heist Rebecca S; Logan Jennifer; Neal Joel W; Mendenhall Melody A; Nichols Suzanne; Piotrowska Zofia; Wozniak Antoinette J; Raponi Mitch; Karlovich Chris A; Jaw-Tsai Sarah; Isaacson Jeffrey; Despain Darrin; Matheny Shannon L; Rolfe Lindsey; Allen Andrew R; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1700-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by the T790M EGFR mutation in most cases.  Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.  METHODS:  In this phase 1-2 study, we administered rociletinib to patients with EGFR-mutated NSCLC who had disease progression during previous treatment with an existing EGFR inhibitor.  In the expansion (phase 2) part of the study, patients with T790M-positive disease received rociletinib at a dose of 500 mg twice daily, 625 mg twice daily, or 750 mg twice daily.  Key objectives were assessment of safety, side-effect profile, pharmacokinetics, and preliminary antitumor activity of rociletinib.  Tumor biopsies to identify T790M were performed during screening.  Treatment was administered in continuous 21-day cycles.  RESULTS:  A total of 130 patients were enrolled.  The first 57 patients to be enrolled received the free-base form of rociletinib (150 mg once daily to 900 mg twice daily).  The remaining patients received the hydrogen bromide salt (HBr) form (500 mg twice daily to 1000 mg twice daily).  A maximum tolerated dose (the highest dose associated with a rate of dose-limiting toxic effects of less than 33%) was not identified.  The only common dose-limiting adverse event was hyperglycemia.  In an efficacy analysis that included patients who received free-base rociletinib at a dose of 900 mg twice daily or the HBr form at any dose, the objective response rate among the 46 patients with T790M-positive disease who could be evaluated was 59% (95% confidence interval [CI], 45 to 73), and the rate among the 17 patients with T790M-negative disease who could be evaluated was 29% (95% CI, 8 to 51).  CONCLUSIONS:  Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3ZPq5LRczm8ffW6udTcc2eZOOvmYroyZMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D&md5=5a5d21d36c081a5ef0f9e650d5cc84b9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413654%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DGalasso%26aufirst%3DC.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMendenhall%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DS.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DDespain%26aufirst%3DD.%26aulast%3DMatheny%26aufirst%3DS.%2BL.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DRociletinib%2520in%2520EGFR-Mutated%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1700%26epage%3D1709%26doi%3D10.1056%2FNEJMoa1413654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Van Der Steen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caparello, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannetti, E.</span><span> </span><span class="NLM_article-title">New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">6065</span><span class="NLM_x">–</span> <span class="NLM_lpage">6074</span><span class="refDoi"> DOI: 10.2147/OTT.S97644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.2147%2FOTT.S97644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=27785053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A280%3ADC%252BC2sngtVGquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=6065-6074&author=N.+Van+Der+Steenauthor=C.+Caparelloauthor=C.+Rolfoauthor=P.+Pauwelsauthor=G.+J.+Petersauthor=E.+Giovannetti&title=New+developments+in+the+management+of+non-small-cell+lung+cancer%2C+focus+on+rociletinib%3A+what+went+wrong%3F&doi=10.2147%2FOTT.S97644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?</span></div><div class="casAuthors">Van Der Steen Nele; Peters Godefridus J; Caparello Chiara; Rolfo Christian; Pauwels Patrick; Giovannetti Elisa</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6065-6074</span>
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    </div><div class="casAbstract">Recently, the development of the third-generation epidermal growth factor receptor-small molecule inhibitor (EGFR-TKI) rociletinib had failed.  In this review, the wide-ranging aspects of the evolution of EGFR-TKIs were collected, with a special focus on rociletinib.  The influence of different oncogenic mutations on EGFR activity was also discussed.  Resistance to the first (erlotinib, gefitinib)- and second (afatinib)-generation EGFR-TKIs provided the rationale behind the development of the third-generation inhibitors (rociletinib, osimertinib).  On the basis of these data, a comparison of their efficacy on the different mutated EGFRs and the respective resistance mechanisms is further reported.  Moreover, the evolution and results of the clinical trials of rociletinib (TIGER trials) are compared with the trials on osimertinib, another third-generation EGFR-TKI that now has been granted US Food and Drug Administration approval.  The reasons behind the arrest in the further development of rociletinib are put in the perspective of future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_s7WmFAisW36HPRus0rAafW6udTcc2eaB-n-P1m33MLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sngtVGquw%253D%253D&md5=b3415f44652e09b0b7a7d8069d47aa1f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2147%2FOTT.S97644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S97644%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDer%2BSteen%26aufirst%3DN.%26aulast%3DCaparello%26aufirst%3DC.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DPauwels%26aufirst%3DP.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DGiovannetti%26aufirst%3DE.%26atitle%3DNew%2520developments%2520in%2520the%2520management%2520of%2520non-small-cell%2520lung%2520cancer%252C%2520focus%2520on%2520rociletinib%253A%2520what%2520went%2520wrong%253F%26jtitle%3DOncoTargets%2520Ther.%26date%3D2016%26volume%3D9%26spage%3D6065%26epage%3D6074%26doi%3D10.2147%2FOTT.S97644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Greig, S. L.</span><span> </span><span class="NLM_article-title">Osimertinib: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1007/s40265-015-0533-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1007%2Fs40265-015-0533-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=26729184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=263-273&author=S.+L.+Greig&title=Osimertinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0533-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: First Global Approval</span></div><div class="casAuthors">Greig, Sarah L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-273</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Osimertinib (Tagrisso, AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC).  Osimertinib has been designed to target the EGFR T790M mutation that is often present in NSCLC patients with acquired EGFR TKI resistance, while sparing wild-type EGFR.  In Nov. 2015, the tablet formulation of osimertinib was granted accelerated approval in the USA for the treatment of patients with metastatic EGFR T790M mutation-pos. NSCLC (as detected by an FDA-approved test) who have progressed on or after EGFR TKI therapy.  Osimertinib has also been granted accelerated assessment status for this indication in the EU, and is in phase III development for first- and second-line and adjuvant treatment of advanced EGFR mutation-pos. NSCLC in several countries.  Phase I trials in patients with advanced solid tumors are also being conducted.  This article summarizes the milestones in the development of osimertinib leading to this first approval for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD-OV6l6JC5rVg90H21EOLACvtfcHk0lgvmAjRjsKNkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D&md5=fb46898918bdfe76320c26177710fb11</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0533-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0533-4%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DS.%2BL.%26atitle%3DOsimertinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D263%26epage%3D273%26doi%3D10.1007%2Fs40265-015-0533-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggstrom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frewer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">1689</span><span class="NLM_x">–</span> <span class="NLM_lpage">1699</span><span class="refDoi"> DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&author=P.+A.+J%C3%A4nneauthor=J.+C.+H.+Yangauthor=D.+W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.+J.+Ahnauthor=S.+W.+Kimauthor=W.+C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.+H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+Inhibitor-Resistant+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2eaB-n-P1m33MLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520Inhibitor-Resistant%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mühlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollipara, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahedi, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10909</span><span class="NLM_x">–</span> <span class="NLM_lpage">10912</span><span class="refDoi"> DOI: 10.1002/anie.201605011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1002%2Fanie.201605011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=27496389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10909-10912&author=J.+Engelauthor=C.+Beckerauthor=J.+Lategahnauthor=M.+Keulauthor=J.+Ketzerauthor=T.+M%C3%BChlenbergauthor=L.+Kolliparaauthor=C.+Schultz-Fademrechtauthor=R.+P.+Zahediauthor=S.+Bauerauthor=D.+Rauh&title=Insight+into+the+Inhibition+of+Drug-Resistant+Mutants+of+the+Receptor+Tyrosine+Kinase+EGFR&doi=10.1002%2Fanie.201605011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR</span></div><div class="casAuthors">Engel, Julian; Becker, Christian; Lategahn, Jonas; Keul, Marina; Ketzer, Julia; Muehlenberg, Thomas; Kollipara, Laxmikanth; Schultz-Fademrecht, Carsten; Zahedi, Rene P.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10909-10912</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance represents the major challenge in the treatment of EGFR-driven nonsmall-cell lung cancer (NSCLC).  Herein, the authors describe the structure-based design, synthesis, and biol. evaluation of a novel class of covalent EGFR inhibitors that exhibit excellent inhibition of EGFR-mutant drug-resistant cells.  Protein x-ray crystallog. combined with detailed kinetic studies led to a deeper understanding of the mode of inhibition of EGFR-T790M and provided insight into the key principles for effective inhibition of the recently discovered tertiary mutation at EGFR-C797S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBqcuaKxIuCbVg90H21EOLACvtfcHk0litug45kmw2Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ&md5=d16c5339a6f2b9ca018c56f6b3f0b8e8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fanie.201605011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201605011%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DKollipara%26aufirst%3DL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInsight%2520into%2520the%2520Inhibition%2520of%2520Drug-Resistant%2520Mutants%2520of%2520the%2520Receptor%2520Tyrosine%2520Kinase%2520EGFR%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10909%26epage%3D10912%26doi%3D10.1002%2Fanie.201605011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00475</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00475" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2-5&author=J.+Engelauthor=J.+Lategahnauthor=D.+Rauh&title=Hope+and+Disappointment%3A+Covalent+Inhibitors+to+Overcome+Drug+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1021%2Facsmedchemlett.5b00475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Engel, Julian; Lategahn, Jonas; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clin. outcomes.  However, the emergence of a newly discovered acquired drug resistance challenges the concept of small mol. targeted cancer therapy in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcxNkfyBm4vrVg90H21EOLACvtfcHk0litug45kmw2Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D&md5=738e3286dd1b1d4110249e33cceec9ac</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00475%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHope%2520and%2520Disappointment%253A%2520Covalent%2520Inhibitors%2520to%2520Overcome%2520Drug%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Facsmedchemlett.5b00475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Termathe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Wrangowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlenbrock, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krüll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaumann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eppmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kibies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffgaard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menninger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Cuaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinnefeld, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahedi, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kast, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6844</span><span class="NLM_x">–</span> <span class="NLM_lpage">6863</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6844-6863&author=J.+Engelauthor=A.+Richtersauthor=M.+Getlikauthor=S.+Tomassiauthor=M.+Keulauthor=M.+Termatheauthor=J.+Lategahnauthor=C.+Beckerauthor=S.+Mayer-Wrangowskiauthor=C.+Gr%C3%BCtterauthor=N.+Uhlenbrockauthor=J.+Kr%C3%BCllauthor=N.+Schaumannauthor=S.+Eppmannauthor=P.+Kibiesauthor=F.+Hoffgaardauthor=J.+Heilauthor=S.+Menningerauthor=S.+Ortiz-Cuaranauthor=J.+M.+Heuckmannauthor=V.+Tinnefeldauthor=R.+P.+Zahediauthor=M.+L.+Sosauthor=C.+Schultz-Fademrechtauthor=R.+K.+Thomasauthor=S.+M.+Kastauthor=D.+Rauh&title=Targeting+Drug+Resistance+in+EGFR+with+Covalent+Inhibitors%3A+A+Structure-Based+Design+Approach&doi=10.1021%2Facs.jmedchem.5b01082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach</span></div><div class="casAuthors">Engel, Julian; Richters, Andre; Getlik, Matthaeus; Tomassi, Stefano; Keul, Marina; Termathe, Martin; Lategahn, Jonas; Becker, Christian; Mayer-Wrangowski, Svenja; Gruetter, Christian; Uhlenbrock, Niklas; Kruell, Jasmin; Schaumann, Niklas; Eppmann, Simone; Kibies, Patrick; Hoffgaard, Franziska; Heil, Jochen; Menninger, Sascha; Ortiz-Cuaran, Sandra; Heuckmann, Johannes M.; Tinnefeld, Verena; Zahedi, Rene P.; Sos, Martin L.; Schultz-Fademrecht, Carsten; Thomas, Roman K.; Kast, Stefan M.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6844-6863</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases represent one of the prime targets in cancer therapy, as the dysregulation of these elementary transducers of extracellular signals, like the epidermal growth factor receptor (EGFR), contributes to the onset of cancer, such as non-small cell lung cancer (NSCLC).  Strong efforts were directed to the development of irreversible inhibitors and led to compd. CO-1686, which takes advantage of increased residence time at EGFR by alkylating Cys797 and thereby preventing toxic effects.  Here, the authors present a structure-based approach, rationalized by subsequent computational anal. of conformational ligand ensembles in soln., to design novel and irreversible EGFR inhibitors based on a screening hit that was identified in a phenotype screen of 80 NSCLC cell lines against approx. 1500 compds.  Using protein x-ray crystallog., the authors deciphered the binding mode in engineered cSrc (T338M/S345C), a validated model system for EGFR-T790M, which constituted the basis for further rational design approaches.  Chem. synthesis led to further compd. collections that revealed increased biochem. potency and, in part, selectivity toward mutated (L858R and L858R/T790M) vs. nonmutated EGFR.  Further cell-based and kinetic studies were performed to substantiate the authors initial findings.  Utilizing proteolytic digestion and nano-LC-MS/MS anal., the authors confirmed the alkylation of Cys797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNGJPIuqoVObVg90H21EOLACvtfcHk0lgLzVTC7_O1-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsrvM&md5=d5264a2a99d7752af0e587f23aeb7723</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01082%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTermathe%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DUhlenbrock%26aufirst%3DN.%26aulast%3DKr%25C3%25BCll%26aufirst%3DJ.%26aulast%3DSchaumann%26aufirst%3DN.%26aulast%3DEppmann%26aufirst%3DS.%26aulast%3DKibies%26aufirst%3DP.%26aulast%3DHoffgaard%26aufirst%3DF.%26aulast%3DHeil%26aufirst%3DJ.%26aulast%3DMenninger%26aufirst%3DS.%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DTinnefeld%26aufirst%3DV.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DKast%26aufirst%3DS.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DTargeting%2520Drug%2520Resistance%2520in%2520EGFR%2520with%2520Covalent%2520Inhibitors%253A%2520A%2520Structure-Based%2520Design%2520Approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6844%26epage%3D6863%26doi%3D10.1021%2Facs.jmedchem.5b01082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span> </span><span class="NLM_article-title">Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span><span class="refDoi"> DOI: 10.1038/nchembio.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+Polypharmacology%3A+Discovery+of+Dual+Inhibitors+of+Tyrosine+and+Phosphoinositide+Kinases&doi=10.1038%2Fnchembio.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0lgLzVTC7_O1-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520Polypharmacology%253A%2520Discovery%2520of%2520Dual%2520Inhibitors%2520of%2520Tyrosine%2520and%2520Phosphoinositide%2520Kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D691%26epage%3D699%26doi%3D10.1038%2Fnchembio.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrill, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothaus, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalrymple, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+Selective+Irreversible+Inhibitors+for+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0lgLzVTC7_O1-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Zapf, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstenberger, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limburg, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulabaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spaulding, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerwinski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medley, Q. G.</span><span> </span><span class="NLM_article-title">Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (ITK) with Nanomolar Potency in a Whole-Blood Assay</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10047</span><span class="NLM_x">–</span> <span class="NLM_lpage">10063</span><span class="refDoi"> DOI: 10.1021/jm301190s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301190s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10047-10063&author=C.+W.+Zapfauthor=B.+S.+Gerstenbergerauthor=L.+Xingauthor=D.+C.+Limburgauthor=D.+R.+Andersonauthor=N.+Caspersauthor=S.+Hanauthor=A.+Aulabaughauthor=R.+Kurumbailauthor=S.+Shakyaauthor=X.+Liauthor=V.+Spauldingauthor=R.+M.+Czerwinskiauthor=N.+Sethauthor=Q.+G.+Medley&title=Covalent+Inhibitors+of+Interleukin-2+Inducible+T+Cell+Kinase+%28ITK%29+with+Nanomolar+Potency+in+a+Whole-Blood+Assay&doi=10.1021%2Fjm301190s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay</span></div><div class="casAuthors">Zapf, Christoph W.; Gerstenberger, Brian S.; Xing, Li; Limburg, David C.; Anderson, David R.; Caspers, Nicole; Han, Seungil; Aulabaugh, Ann; Kurumbail, Ravi; Shakya, Subarna; Li, Xin; Spaulding, Vikki; Czerwinski, Robert M.; Seth, Nilufer; Medley, Quintus G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10047-10063</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We wish to report a strategy that targets interleukin-2 inducible T cell kinase (Itk) with covalent inhibitors.  Thus far, covalent inhibition of Itk has not been disclosed in the literature.  Structure-based drug design was utilized to achieve low nanomolar potency of the disclosed series even at high ATP concns.  Kinetic measurements confirmed an irreversible binding mode with off-rate half-lives exceeding 24 h and moderate on-rates.  The analogs are highly potent in a cellular IP1 assay as well as in a human whole-blood (hWB) assay.  Despite a half-life of approx. 2 h in resting primary T cells, the covalent inhibition of Itk resulted in functional silencing of the TCR pathway for more than 24 h.  This prolonged effect indicates that covalent inhibition is a viable strategy to target the inactivation of Itk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnh9j28SM8jbVg90H21EOLACvtfcHk0lia9U-OKWslIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP&md5=7e39a17151dc9493d13439bc48fa83a3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm301190s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301190s%26sid%3Dliteratum%253Aachs%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSpaulding%26aufirst%3DV.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DMedley%26aufirst%3DQ.%2BG.%26atitle%3DCovalent%2520Inhibitors%2520of%2520Interleukin-2%2520Inducible%2520T%2520Cell%2520Kinase%2520%2528ITK%2529%2520with%2520Nanomolar%2520Potency%2520in%2520a%2520Whole-Blood%2520Assay%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10047%26epage%3D10063%26doi%3D10.1021%2Fjm301190s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutre, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flinn, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharman, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierda, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukbuntherng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clow, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedrick, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span><span class="refDoi"> DOI: 10.1056/NEJMoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0lia9U-OKWslIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D32%26epage%3D42%26doi%3D10.1056%2FNEJMoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Wang, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rule, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahl, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurczak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romaguera, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrientos, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielowska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radford, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stilgenbauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreyling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jedrzejczak, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spurgeon, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newberry, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreivy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clow, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaupre, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1056/NEJMoa1306220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa1306220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=23782157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=507-516&author=M.+L.+Wangauthor=S.+Ruleauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedrzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Liauthor=L.+Zhangauthor=K.+Newberryauthor=Z.+Ouauthor=N.+Chengauthor=B.+Fangauthor=J.+McGreivyauthor=F.+Clowauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=D.+M.+Beaupreauthor=L.+A.+Kunkelauthor=K.+A.+Blum&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+or+Refractory+Mantle-Cell+Lymphoma&doi=10.1056%2FNEJMoa1306220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span></div><div class="casAuthors">Wang, Michael L.; Rule, Simon; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Li, Lei; Zhang, Liang; Newberry, Kate; Ou, Zhishuo; Cheng, Nancy; Fang, Bingliang; McGreivy, Jesse; Clow, Fong; Buggy, Joseph J.; Chang, Betty Y.; Beaupre, Darrin M.; Kunkel, Lori A.; Blum, Kristie A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers.  In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.  METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma.  Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy.  The primary end point was the overall response rate.  Secondary end points were duration of response, progression-free survival, overall survival, and safety.  RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clin. prognostic factors.  Patients had received a median of three prior therapies.  The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea.  Grade 3 or higher hematol. events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%).  A response rate of 68% (75 patients) was obsd., with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate.  With an estd. median follow-up of 15.3 mo, the estd. median response duration was 17.5 mo (95% confidence interval [CI], 15.8 to not reached), the estd. median progression-free survival was 13.9 mo (95% CI, 7.0 to not reached), and the median overall survival was not reached.  The estd. rate of overall survival was 58% at 18 mo.  CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovUuOKvHS0NrVg90H21EOLACvtfcHk0lia9U-OKWslIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF&md5=7a92bbd5acf86e614cea96f44503e12b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNewberry%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DB.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DKunkel%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520or%2520Refractory%2520Mantle-Cell%2520Lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D507%26epage%3D516%26doi%3D10.1056%2FNEJMoa1306220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Hanke, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dow, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weringer, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollok, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connelly, P. A.</span><span> </span><span class="NLM_article-title">Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span><span class="refDoi"> DOI: 10.1074/jbc.271.2.695</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1074%2Fjbc.271.2.695" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=695-701&author=J.+H.+Hankeauthor=J.+P.+Gardnerauthor=R.+L.+Dowauthor=P.+S.+Changelianauthor=W.+H.+Brissetteauthor=E.+J.+Weringerauthor=B.+A.+Pollokauthor=P.+A.+Connelly&title=Discovery+of+a+novel%2C+potent%2C+and+Src+family-selective+tyrosine+kinase+inhibitor.+Study+of+Lck-+and+FynT-dependent+T+cell+activation&doi=10.1074%2Fjbc.271.2.695"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.2.695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.2.695%26sid%3Dliteratum%253Aachs%26aulast%3DHanke%26aufirst%3DJ.%2BH.%26aulast%3DGardner%26aufirst%3DJ.%2BP.%26aulast%3DDow%26aufirst%3DR.%2BL.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DWeringer%26aufirst%3DE.%2BJ.%26aulast%3DPollok%26aufirst%3DB.%2BA.%26aulast%3DConnelly%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520novel%252C%2520potent%252C%2520and%2520Src%2520family-selective%2520tyrosine%2520kinase%2520inhibitor.%2520Study%2520of%2520Lck-%2520and%2520FynT-dependent%2520T%2520cell%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D695%26epage%3D701%26doi%3D10.1074%2Fjbc.271.2.695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0li3Fk_pKos3OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0li3Fk_pKos3OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Schultes, S. d. G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Graaf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haaksma, E. E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Esch, I. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krämer, O.</span><span> </span><span class="NLM_article-title">Ligand efficiency as a guide in fragment hit selection and optimization</span> <span class="citation_source-journal">Drug Discovery Today: Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e157</span><span class="NLM_x">–</span> <span class="NLM_lpage">e162</span><span class="refDoi"> DOI: 10.1016/j.ddtec.2010.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1016%2Fj.ddtec.2010.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVegsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=e157-e162&author=S.+d.+G.+C.+Schultesauthor=C.+de+Graafauthor=E.+E.+J.+Haaksmaauthor=I.+J.+P.+de+Eschauthor=R.+Leursauthor=O.+Kr%C3%A4mer&title=Ligand+efficiency+as+a+guide+in+fragment+hit+selection+and+optimization&doi=10.1016%2Fj.ddtec.2010.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency as a guide in fragment hit selection and optimization</span></div><div class="casAuthors">Schultes, Sabine; de Graaf, Chris; Haaksma, Eric E. J.; de Esch, Iwan J. P.; Leurs, Rob; Kraemer, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">E157-E162</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Fragment-based screening (FBS) has become an established approach for hit identification.  Starting points identified by FBS, are small fragments that require substantial modification to become leads.  As fragments are different from classical hits a process tailored for fragment evolution is required.  Scores for ligand efficiency have been proposed as guides for this process.  Here we review how these have been applied to guide the selection and optimization of fragment hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbfhwn68rv4bVg90H21EOLACvtfcHk0lhvKpRrmgQ3Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVegsL0%253D&md5=a57c85869d5c829159be31449fd04796</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2010.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2010.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DSchultes%26aufirst%3DS.%2Bd.%2BG.%2BC.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DHaaksma%26aufirst%3DE.%2BE.%2BJ.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DO.%26atitle%3DLigand%2520efficiency%2520as%2520a%2520guide%2520in%2520fragment%2520hit%2520selection%2520and%2520optimization%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2010%26volume%3D7%26spage%3De157%26epage%3De162%26doi%3D10.1016%2Fj.ddtec.2010.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gubernator, K.</span><span> </span><span class="NLM_article-title">Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1007</span><span class="NLM_x">–</span> <span class="NLM_lpage">1010</span><span class="refDoi"> DOI: 10.1021/jm970530e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970530e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADyaK1cXhs12kt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=1007-1010&author=M.+Kansyauthor=F.+Sennerauthor=K.+Gubernator&title=Physicochemical+high+throughput+screening%3A+parallel+artificial+membrane+permeation+assay+in+the+description+of+passive+absorption+processes&doi=10.1021%2Fjm970530e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes</span></div><div class="casAuthors">Kansy, Manfred; Senner, Frank; Gubernator, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1007-1010</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The majority of pharmaceutical discovery projects aim for an orally available form of a new therapeutic principle.  One obstacle for per oral treatment is intestinal absorption.  A simple predictive exptl. method to assess the potential of intestinal absorption is therefore highly welcome.  The authors describe here the PAMPA (Parallel Artificial Membrane Permeation Assay) method, a simple, robust, high throughput screen (HTS) which has been shown to be predictive for passive diffusion through membranes and thus for oral absorption.  In addn. PAMPA can deliver information in parallel on the lipophilicity, the ionization state and the soly. of a compd.  Therefore PAMPA complements HTS, combinatorial chem. and parallel synthesis efforts in preclin. pharmaceutical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcwCGodCr1rVg90H21EOLACvtfcHk0lhvKpRrmgQ3Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhs12kt70%253D&md5=85d8ab409313b583de52348eb4d895da</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm970530e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970530e%26sid%3Dliteratum%253Aachs%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DSenner%26aufirst%3DF.%26aulast%3DGubernator%26aufirst%3DK.%26atitle%3DPhysicochemical%2520high%2520throughput%2520screening%253A%2520parallel%2520artificial%2520membrane%2520permeation%2520assay%2520in%2520the%2520description%2520of%2520passive%2520absorption%2520processes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D1007%26epage%3D1010%26doi%3D10.1021%2Fjm970530e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Tomassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumbrink, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mühlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2361</span><span class="NLM_x">–</span> <span class="NLM_lpage">2372</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01626</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01626" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1WltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2361-2372&author=S.+Tomassiauthor=J.+Lategahnauthor=J.+Engelauthor=M.+Keulauthor=H.+L.+Tumbrinkauthor=J.+Ketzerauthor=T.+M%C3%BChlenbergauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=S.+Bauerauthor=D.+Rauh&title=Indazole-Based+Covalent+Inhibitors+To+Target+Drug-Resistant+Epidermal+Growth+Factor+Receptor&doi=10.1021%2Facs.jmedchem.6b01626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor</span></div><div class="casAuthors">Tomassi, Stefano; Lategahn, Jonas; Engel, Julian; Keul, Marina; Tumbrink, Hannah L.; Ketzer, Julia; Muehlenberg, Thomas; Baumann, Matthias; Schultz-Fademrecht, Carsten; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2361-2372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The specific targeting of oncogenic mutant epidermal growth factor receptor (EGFR) is a breakthrough in targeted cancer therapy and marks a drastic change in the treatment of non-small cell lung cancer (NSCLC).  The recurrent emergence of resistance to these targeted drugs requires the development of novel chem. entities that efficiently inhibit drug-resistant EGFR.  Herein, the authors report the optimization process for a hit compd. that has emerged from a phenotypic screen resulting in indazole-based compds.  These inhibitors are conformationally less flexible, target gatekeeper mutated drug resistant EGFR-L858R/T790M and covalently alkylate Cys 797.  Western blot anal., as well as characterization of the binding kinetics and kinase selectivity profiling, substantiates the authors' approach of targeting drug-resistant EGFR-L858R/T790M with inhibitors incorporating the indazole as hinge binder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwwmG17YkaV7Vg90H21EOLACvtfcHk0lhvKpRrmgQ3Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1WltL0%253D&md5=25e24252dc5a03ec5349359289ebd808</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01626%26sid%3Dliteratum%253Aachs%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DIndazole-Based%2520Covalent%2520Inhibitors%2520To%2520Target%2520Drug-Resistant%2520Epidermal%2520Growth%2520Factor%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2361%26epage%3D2372%26doi%3D10.1021%2Facs.jmedchem.6b01626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span> </span><span class="NLM_article-title">Targeted Covalent Enzyme Inhibitors</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/B978-0-12-396492-2.00027-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1016%2FB978-0-12-396492-2.00027-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eju7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=413-439&author=M.+C.+Noeauthor=A.+M.+Gilbert&title=Targeted+Covalent+Enzyme+Inhibitors&doi=10.1016%2FB978-0-12-396492-2.00027-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent enzyme inhibitors</span></div><div class="casAuthors">Noe, Mark C.; Gilbert, Adam M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">413-439</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Selective covalent modification of a biomol. target can offer several important advantages in drug discovery.  The purpose of this report is to broadly detail targeted covalent inhibitor approaches across a variety of enzyme families which were published over the past 5 years.  Covalent modification of essential enzyme cofactors as a design strategy and the development of covalent probes to enable chem. biol. studies are beyond the scope of this review.  Tis review will be divided into several sections based on reactivity of the electrophilic species (producing functionally irreversible or reversible covalent assocn. with the target protein), and type of nucleophile with which the electrophile is known to assoc. in its biol. context (sulfur, oxygen, or nitrogen).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp04K2rcDR5rVg90H21EOLACvtfcHk0lhvKpRrmgQ3Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eju7jK&md5=4957a32f394ad591702a4316ffe9c8df</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396492-2.00027-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396492-2.00027-8%26sid%3Dliteratum%253Aachs%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26atitle%3DTargeted%2520Covalent%2520Enzyme%2520Inhibitors%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2012%26volume%3D47%26spage%3D413%26epage%3D439%26doi%3D10.1016%2FB978-0-12-396492-2.00027-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yonggang Meng, Bin Yu, He Huang, Youmei Peng, Ertong Li, Yongfang Yao, Chuanjun Song, Wenquan Yu, Kaikai Zhu, Kai Wang, Dongxu Yi, Jinfa Du, <span class="NLM_string-name hlFld-ContribAuthor">Junbiao Chang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 925-937. <a href="https://doi.org/10.1021/acs.jmedchem.0c02005" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BDosimertinib%25252C%252Ba%252BHighly%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BEfficacious%252BDeuterated%252BEGFR%252BTargeting%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DMeng%26aufirst%3DYonggang%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D19112020%26date%3D18012021%26volume%3D64%26issue%3D2%26spage%3D925%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Patrik Wolle, Julian Engel, Steven Smith, Lisa Goebel, Elisabeth Hennes, Jonas Lategahn, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of Covalent Pyrazolopyrimidine–MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (11)
                                     , 5541-5546. <a href="https://doi.org/10.1021/acs.jmedchem.9b00472" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00472%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCharacterization%252Bof%252BCovalent%252BPyrazolopyrimidine%2525E2%252580%252593MKK7%252BComplexes%252Band%252Ba%252BReport%252Bon%252Ba%252BUnique%252BDFG-in%25252FLeu-in%252BConformation%252Bof%252BMitogen-Activated%252BProtein%252BKinase%252BKinase%252B7%252B%252528MKK7%252529%26aulast%3DWolle%26aufirst%3DPatrik%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D18032019%26date%3D31052019%26date%3D14052019%26volume%3D62%26issue%3D11%26spage%3D5541%26epage%3D5546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Patrik Wolle, Julia Hardick, Shane J. F. Cronin, Julian Engel, Matthias Baumann, Jonas Lategahn, Josef M. Penninger, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the MKK7–JNK (Mitogen-Activated Protein Kinase Kinase 7–c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (5)
                                     , 2843-2848. <a href="https://doi.org/10.1021/acs.jmedchem.9b00102" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00102%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252Bthe%252BMKK7%2525E2%252580%252593JNK%252B%252528Mitogen-Activated%252BProtein%252BKinase%252BKinase%252B7%2525E2%252580%252593c-Jun%252BN-Terminal%252BKinase%252529%252BPathway%252Bwith%252BCovalent%252BInhibitors%26aulast%3DWolle%26aufirst%3DPatrik%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D16012019%26date%3D21022019%26date%3D15022019%26volume%3D62%26issue%3D5%26spage%3D2843%26epage%3D2848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Asrin  Bahmani</span>, <span class="hlFld-ContribAuthor ">Hamid  Tanzadehpanah</span>, <span class="hlFld-ContribAuthor ">Neda  Hosseinpour Moghadam</span>, <span class="hlFld-ContribAuthor ">Massoud  Saidijam</span>. </span><span class="cited-content_cbyCitation_article-title">Introducing a pyrazolopyrimidine as a multi-tyrosine kinase inhibitor, using multi-QSAR and docking methods. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2021,</strong> <em>25 </em>
                                    (2)
                                     , 949-965. <a href="https://doi.org/10.1007/s11030-020-10080-8" title="DOI URL">https://doi.org/10.1007/s11030-020-10080-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-020-10080-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-020-10080-8%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DIntroducing%252Ba%252Bpyrazolopyrimidine%252Bas%252Ba%252Bmulti-tyrosine%252Bkinase%252Binhibitor%25252C%252Busing%252Bmulti-QSAR%252Band%252Bdocking%252Bmethods%26aulast%3DBahmani%26aufirst%3DAsrin%26date%3D2021%26date%3D2020%26volume%3D25%26issue%3D2%26spage%3D949%26epage%3D965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Phoebe F.  Lamie</span>, <span class="hlFld-ContribAuthor ">Asmaa M.  El-Kalaawy</span>, <span class="hlFld-ContribAuthor ">Noha S.  Abdel Latif</span>, <span class="hlFld-ContribAuthor ">Laila A.  Rashed</span>, <span class="hlFld-ContribAuthor ">John N.  Philoppes</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure–activity relationship and biological activity as potential antitumor and anticonvulsant agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113222. <a href="https://doi.org/10.1016/j.ejmech.2021.113222" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113222</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113222%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrazolo%25255B3%25252C4-d%25255Dpyrimidine-based%252Bdual%252BEGFR%252BT790M%25252FHER2%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Band%252Bbiological%252Bactivity%252Bas%252Bpotential%252Bantitumor%252Band%252Banticonvulsant%252Bagents%26aulast%3DLamie%26aufirst%3DPhoebe%2BF.%26date%3D2021%26volume%3D214%26spage%3D113222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Guo</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 600-620. <a href="https://doi.org/10.1002/cmdc.202000658" title="DOI URL">https://doi.org/10.1002/cmdc.202000658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000658%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BMultitargeted%252BTyrosine%252BKinase%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DGuo%26aufirst%3DTing%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D600%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel J.  Baillache</span>, <span class="hlFld-ContribAuthor ">Asier  Unciti-Broceta</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-
              d
              ]pyrimidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1112-1135. <a href="https://doi.org/10.1039/D0MD00227E" title="DOI URL">https://doi.org/10.1039/D0MD00227E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00227E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00227E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopments%252Bin%252Banticancer%252Bkinase%252Binhibitors%252Bbased%252Bon%252Bthe%252Bpyrazolo%25255B3%25252C4-%252Bd%252B%25255Dpyrimidine%252Bscaffold%26aulast%3DBaillache%26aufirst%3DDaniel%2BJ.%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D10%26spage%3D1112%26epage%3D1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Salarinejad</span>, <span class="hlFld-ContribAuthor ">Maliheh  Safavi</span>, <span class="hlFld-ContribAuthor ">Behjat  Pouramiri</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103811. <a href="https://doi.org/10.1016/j.bioorg.2020.103811" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103811%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Bprogression%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibitors%252Bas%252Ban%252Befficient%252Bapproach%252Bin%252Bcancer%252Btargeted%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2020%26volume%3D99%26spage%3D103811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Lei</span>, <span class="hlFld-ContribAuthor ">Shu  Fan</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan-Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Jun-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">A-Qun  Zheng</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>186 </em>, 111888. <a href="https://doi.org/10.1016/j.ejmech.2019.111888" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111888</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111888%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B9-heterocyclyl%252Bsubstituted%252B9H-purines%252Bas%252BL858R%25252FT790M%25252FC797S%252Bmutant%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DLei%26aufirst%3DHao%26date%3D2020%26volume%3D186%26spage%3D111888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EGFR
              L858R/T790M
              and EGFR
              L858R/T790M/C797S
              resistance mutations in NSCLC: Current developments in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5)
                                     , 1550-1581. <a href="https://doi.org/10.1002/med.21488" title="DOI URL">https://doi.org/10.1002/med.21488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21488%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252BEGFR%252BL858R%25252FT790M%252Band%252BEGFR%252BL858R%25252FT790M%25252FC797S%252Bresistance%252Bmutations%252Bin%252BNSCLC%25253A%252BCurrent%252Bdevelopments%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1550%26epage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Xue-Yan  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Lei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (12)
                                     , 3619-3633. <a href="https://doi.org/10.1016/j.bmc.2018.05.039" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.05.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.05.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.05.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Birreversible%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%252Bcontaining%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bscaffold%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D26%26issue%3D12%26spage%3D3619%26epage%3D3633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Shen</span>, <span class="hlFld-ContribAuthor ">Hui-Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Wei-Ming  Duan</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 221-237. <a href="https://doi.org/10.1016/j.ejmech.2018.02.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4%25252C6-trisubstitued%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bnew%252BEGFR-TKIs%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D148%26spage%3D221%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00515&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative examples of the three generations of EGFR inhibitors. The electrophiles are highlighted in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00515&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic representation of a structure-based design approach to develop a new series of EGFR inhibitors to target the T790M gatekeeper mutant of EGFR. The design strategy is based on a 4-amino pyrazolopyrimidine scaffold and is focused on the particular derivatization of the 3-position of the pyrazolopyrimidine and the <i>N</i>3-position of the piperidine moiety (each highlighted in pink). The 4-amino pyrazolopyrimidine binding mode is adopted (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4hct">4hct</a>) and was modeled into the active site of EGFR-T790M (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ika">3ika</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00515&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Rational design of the pyrazolopyrimidines to covalently address the methionine gatekeeper mutant of EGFR. Schematic illustration of the pyrazolopyrimidine core structure derived from the nonselective kinase inhibitor PP1 and proposed substitutions to investigate the interplay with Met790 (R<sup>1</sup>) and to gain valuable insights into the covalent bond formation with Cys797 (R<sup>2</sup>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00515&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of a Subset of Pyrazolopyripimidine Derivatives (<b>1d</b>–<b>z</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00515&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NIS, DMF, 80 °C; (ii) <i>N</i>-Boc-(<i>S</i>)-3-hydroxypiperidine, DIAD, PPh<sub>3</sub>, THF, rt; (iii) boronic acid/ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, satd Na<sub>2</sub>CO<sub>3</sub>, DME/EtOH (3:1, v/v), 90 °C; (iv) CuI, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, TEA, rt; (v) TFA in DCM, rt; (vi) acryloyl or propionyl chloride, DIPEA, THF, 0 °C; (vii) (<i>E</i>)-4-(dimethylamino)but-2-enoic acid, EDC, HOBt, DIPEA, DCM, rt.</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/medium/jm-2017-005158_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Model of <b>1d</b> (A), <b>1q</b> (B), <b>1r</b> (C), and <b>1y</b> (D) in EGFR-T790M (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5j9y">5j9y</a>). The models provide a reasonable explanation for the observed SAR. <b>1y</b> with its potential of steric repulsion between Met766 and Glu762 are in line with the rather moderate activity in the biochemical assay. In contrast, <b>1d</b> with a comparable activity lacks sufficient hydrophobic interactions in the back pocket of EGFR-L858R/T790M. With its intrinsic flexibility, the benzyl moiety of <b>1r</b> is capable of adapting a position stacked in between Met790 and Lys745, comparable to the more potent bicyclic derivatives. The phenol derivate (<b>1q</b>) seems to be able to form an additional hydrogen bond with Glu762 and therefore gain selectivity compared to the other monocyclic derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00515/20170922/images/large/jm-2017-005158_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00515&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54656" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54656" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 49 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small Cell Lung Cancer to Gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">–</span> <span class="NLM_lpage">2139</span><span class="refDoi"> DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+Mutations+in+the+Epidermal+Growth+Factor+Receptor+Underlying+Responsiveness+of+Non-Small+Cell+Lung+Cancer+to+Gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0liY5OHRQGGdOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520Mutations%2520in%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Underlying%2520Responsiveness%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkaria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupfer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">EGF Receptor Gene Mutations are Common in Lung Cancers from ″Never Smokers″ and are Associated with Sensitivity of Tumors to Gefitinib and Erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">–</span> <span class="NLM_lpage">13311</span><span class="refDoi"> DOI: 10.1073/pnas.0405220101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1073%2Fpnas.0405220101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=15329413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+Receptor+Gene+Mutations+are+Common+in+Lung+Cancers+from+%E2%80%B3Never+Smokers%E2%80%B3+and+are+Associated+with+Sensitivity+of+Tumors+to+Gefitinib+and+Erlotinib&doi=10.1073%2Fpnas.0405220101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib</span></div><div class="casAuthors">Pao, William; Miller, Vincent; Zakowski, Maureen; Doherty, Jennifer; Politi, Katerina; Sarkaria, Inderpal; Singh, Bhuvanesh; Heelan, Robert; Rusch, Valerie; Fulton, Lucinda; Mardis, Elaine; Kupfer, Doris; Wilson, Richard; Kris, Mark; Varmus, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">13306-13311</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly assocd. with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor.  In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21).  We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004).  Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clin. relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003).  Because most mutation-pos. tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime ("never smokers"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers.  Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001).  Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concns. of drug.  Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently contg. mutations within the TK domain of EGFR that are assocd. with gefitinib and erlotinib sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovevWonTGqELVg90H21EOLACvtfcHk0lioLpvrgStUtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D&md5=38f491968552501b7463a688fa0e62ff</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405220101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405220101%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520Receptor%2520Gene%2520Mutations%2520are%2520Common%2520in%2520Lung%2520Cancers%2520from%2520%25E2%2580%25B3Never%2520Smokers%25E2%2580%25B3%2520and%2520are%2520Associated%2520with%2520Sensitivity%2520of%2520Tumors%2520to%2520Gefitinib%2520and%2520Erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311%26doi%3D10.1073%2Fpnas.0405220101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Maemondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugawara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oizumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiwara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nukiwa, T.</span><span> </span><span class="NLM_article-title">North-East Japan Study Group. Gefitinib or Chemotherapy for Non-Small Cell Lung Cancer with Mutated EGFR</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">2380</span><span class="NLM_x">–</span> <span class="NLM_lpage">2388</span><span class="refDoi"> DOI: 10.1056/NEJMoa0909530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa0909530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=20573926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=2380-2388&author=M.+Maemondoauthor=A.+Inoueauthor=K.+Kobayashiauthor=S.+Sugawaraauthor=S.+Oizumiauthor=H.+Isobeauthor=A.+Gemmaauthor=M.+Haradaauthor=H.+Yoshizawaauthor=I.+Kinoshitaauthor=Y.+Fujitaauthor=S.+Okinagaauthor=H.+Hiranoauthor=K.+Yoshimoriauthor=T.+Haradaauthor=T.+Oguraauthor=M.+Andoauthor=H.+Miyazawaauthor=T.+Tanakaauthor=Y.+Saijoauthor=K.+Hagiwaraauthor=S.+Moritaauthor=T.+Nukiwa&title=North-East+Japan+Study+Group.+Gefitinib+or+Chemotherapy+for+Non-Small+Cell+Lung+Cancer+with+Mutated+EGFR&doi=10.1056%2FNEJMoa0909530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span></div><div class="casAuthors">Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, Satoshi; Isobe, Hiroshi; Gemma, Akihiko; Harada, Masao; Yoshizawa, Hirohisa; Kinoshita, Ichiro; Fujita, Yuka; Okinaga, Shoji; Hirano, Haruto; Yoshimori, Kozo; Harada, Toshiyuki; Ogura, Takashi; Ando, Masahiro; Miyazawa, Hitoshi; Tanaka, Tomoaki; Saijo, Yasuo; Hagiwara, Koichi; Morita, Satoshi; Nukiwa, Toshihiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2380-2388</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of std. chemotherapy.  We randomly assigned 230 patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy to receive gefitinib or carboplatin-paclitaxel.  The primary end point was progression-free survival; secondary end points included overall survival, response rate, and toxic effects.  In the planned interim anal. of data for the first 200 patients, progression-free survival was significantly longer in the gefitinib group than in the std.-chemotherapy group (hazard ratio for death or disease progression with gefitinib, 0.36; P<0.001), resulting in early termination of the study.  The gefitinib group had a significantly longer median progression-free survival (10.8 mo, vs. 5.4 mo in the chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; P<0.001), as well as a higher response rate (73.7% vs. 30.7%, P<0.001).  The median overall survival was 30.5 mo in the gefitinib group and 23.6 mo in the chemotherapy group (P = 0.31).  The most common adverse events in the gefitinib group were rash (71.1%) and elevated aminotransferase levels (55.3%), and in the chemotherapy group, neutropenia (77.0%), anemia (64.6%), appetite loss (56.6%), and sensory neuropathy (54.9%).  One patient receiving gefitinib died from interstitial lung disease.  First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with std. chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1G31xQ-ZFWLVg90H21EOLACvtfcHk0lioLpvrgStUtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D&md5=603963e646bf20ecfd936fc98467f5fd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0909530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0909530%26sid%3Dliteratum%253Aachs%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DSugawara%26aufirst%3DS.%26aulast%3DOizumi%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DH.%26aulast%3DGemma%26aufirst%3DA.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DYoshizawa%26aufirst%3DH.%26aulast%3DKinoshita%26aufirst%3DI.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DOkinaga%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DH.%26aulast%3DYoshimori%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DMiyazawa%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSaijo%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DK.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DNukiwa%26aufirst%3DT.%26atitle%3DNorth-East%2520Japan%2520Study%2520Group.%2520Gefitinib%2520or%2520Chemotherapy%2520for%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520with%2520Mutated%2520EGFR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D2380%26epage%3D2388%26doi%3D10.1056%2FNEJMoa0909530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Mok, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunpaweravong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margono, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiwaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chewaskulyong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffield, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuoka, M.</span><span> </span><span class="NLM_article-title">Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">–</span> <span class="NLM_lpage">957</span><span class="refDoi"> DOI: 10.1056/NEJMoa0810699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa0810699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=19692680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=947-957&author=T.+S.+Mokauthor=Y.+L.+Wuauthor=S.+Thongprasertauthor=C.+H.+Yangauthor=D.+T.+Chuauthor=N.+Saijoauthor=P.+Sunpaweravongauthor=B.+Hanauthor=B.+Margonoauthor=Y.+Ichinoseauthor=Y.+Nishiwakiauthor=Y.+Oheauthor=J.+J.+Yangauthor=B.+Chewaskulyongauthor=H.+Jiangauthor=E.+L.+Duffieldauthor=C.+L.+Watkinsauthor=A.+A.+Armourauthor=M.+Fukuoka&title=Gefitinib+or+Carboplatin-Paclitaxel+in+Pulmonary+Adenocarcinoma&doi=10.1056%2FNEJMoa0810699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span></div><div class="casAuthors">Mok, Tony S.; Wu, Yi-Long; Thongprasert, Sumitra; Yang, Chih-Hsin; Chu, Da-Tong; Saijo, Nagahiro; Sunpaweravong, Patrapim; Han, Baohui; Margono, Benjamin; Ichinose, Yukito; Nishiwaki, Yutaka; Ohe, Yuichiro; Yang, Jin-Ji; Chewaskulyong, Busyamas; Jiang, Haiyi; Duffield, Emma L.; Watkins, Claire L.; Armour, Alison A.; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-957</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.  METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calcd. to produce an area under the curve of 5 or 6 mg per mL per min) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients).  The primary end point was progression-free survival.  RESULTS: The 12-mo rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel.  The study met its primary objective of showing the noninferiority of gefitinib and also showed its superiority, as compared with carboplatin-paclitaxel, with respect to progression-free survival in the intention-to-treat population (hazard ratio for progression or death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P < 0.001).  In the subgroup of 261 patients who were pos. for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P < 0.001), whereas in the subgroup of 176 patients who were neg. for the mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel (hazard ratio for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P < 0.001).  The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel group.  CONCLUSIONS: Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia.  The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKhpFOiEQu7Vg90H21EOLACvtfcHk0lh-Sz-g8C_OeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK&md5=31ce0983eedb9f248dcf0726adf18b88</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810699%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%2BS.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DChu%26aufirst%3DD.%2BT.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DSunpaweravong%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DMargono%26aufirst%3DB.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DDuffield%26aufirst%3DE.%2BL.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DArmour%26aufirst%3DA.%2BA.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520or%2520Carboplatin-Paclitaxel%2520in%2520Pulmonary%2520Adenocarcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D947%26epage%3D957%26doi%3D10.1056%2FNEJMoa0810699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span><span class="refDoi"> DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+J%C3%A4nneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+Mutations+in+Lung+Cancer%3A+Correlation+with+Clinical+Response+to+Gefitinib+Therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lh-Sz-g8C_OeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520Mutations%2520in%2520Lung%2520Cancer%253A%2520Correlation%2520with%2520Clinical%2520Response%2520to%2520Gefitinib%2520Therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, M. J.</span><span> </span><span class="NLM_article-title">EGFR Mutations in Circulating Tumour DNA</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">973</span><span class="refDoi"> DOI: 10.1016/S1470-2045(12)70369-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1016%2FS1470-2045%2812%2970369-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=23026821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVCjsbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=971-973&author=R.+Rosellauthor=M.+A.+Molinaauthor=M.+J.+Serrano&title=EGFR+Mutations+in+Circulating+Tumour+DNA&doi=10.1016%2FS1470-2045%2812%2970369-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutations in circulating tumour DNA</span></div><div class="casAuthors">Rosell, Rafael; Molina, Miguel Angel; Serrano, Maria Jose</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">971-973</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  This article discusses the data on EGFR mutations in circulating tumor DNA (ctDNA).  It shows that an abundance of EGFR mutations in plasma or serum could offer further information for gauging of response and monitoring of disease progression and could be utilized to det. the presence of new acquired mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6T_Flo7pD7rVg90H21EOLACvtfcHk0lh-Sz-g8C_OeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVCjsbjN&md5=9887e936b4460d94902a48958c210a84</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970369-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970369-8%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DSerrano%26aufirst%3DM.%2BJ.%26atitle%3DEGFR%2520Mutations%2520in%2520Circulating%2520Tumour%2520DNA%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D971%26epage%3D973%26doi%3D10.1016%2FS1470-2045%2812%2970369-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">–</span> <span class="NLM_lpage">1167</span><span class="refDoi"> DOI: 10.1126/science.1101637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1126%2Fscience.1101637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=15284455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163-1167&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-Sensitizing+EGFR+Mutations+in+Lung+Cancer+Activate+Anti-Apoptotic+Pathways&doi=10.1126%2Fscience.1101637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways</span></div><div class="casAuthors">Sordella, Raffaella; Bell, Daphne W.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5687</span>),
    <span class="NLM_cas:pages">1163-1167</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gefitinib (Iressa, AstraZeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) and induces dramatic clin. responses in nonsmall cell lung cancers (NSCLCs) with activating mutations within the EGFR kinase domain.  The authors report that these mutant EGFRs selectively activate Akt and signal transduction and activator of transcription (STAT) signaling pathways, which promote cell survival, but have no effect on extracellular signal-regulated kinase signaling, which induces proliferation.  NSCLC cells expressing mutant EGFRs underwent extensive apoptosis after small interfering RNA-mediated knockdown of the mutant EGFR or treatment with pharmacol. inhibitors of Akt and STAT signaling and were relatively resistant to apoptosis induced by conventional chemotherapeutic drugs.  Thus, mutant EGFRs selectively transduce survival signals on which NSCLCs become dependent; inhibition of those signals by gefitinib may contribute to the drug's efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrKHDqaSobm7Vg90H21EOLACvtfcHk0lgcw2r1R8IcBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D&md5=e9742920d5e320357b774495746e6581</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.1101637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1101637%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-Sensitizing%2520EGFR%2520Mutations%2520in%2520Lung%2520Cancer%2520Activate%2520Anti-Apoptotic%2520Pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26epage%3D1167%26doi%3D10.1126%2Fscience.1101637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+Mutation+and+Resistance+of+Non-Small-Cell+Lung+Cancer+to+Gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lgcw2r1R8IcBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520Mutation%2520and%2520Resistance%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is Associated with a Second Mutation in the EGFR Kinase Domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+Resistance+of+Lung+Adenocarcinomas+to+Gefitinib+or+Erlotinib+is+Associated+with+a+Second+Mutation+in+the+EGFR+Kinase+Domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eZ4ZtzU_4hxg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520Resistance%2520of%2520Lung%2520Adenocarcinomas%2520to%2520Gefitinib%2520or%2520Erlotinib%2520is%2520Associated%2520with%2520a%2520Second%2520Mutation%2520in%2520the%2520EGFR%2520Kinase%2520Domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Digumarthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turke, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gettinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosper, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhavanfard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heist, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernovsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanuti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">75ra26</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3002003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1126%2Fscitranslmed.3002003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=21430269" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=75ra26&author=L.+V.+Sequistauthor=B.+A.+Waltmanauthor=D.+Dias-Santagataauthor=S.+Digumarthyauthor=A.+B.+Turkeauthor=P.+Fidiasauthor=K.+Bergethonauthor=A.+T.+Shawauthor=S.+Gettingerauthor=A.+K.+Cosperauthor=S.+Akhavanfardauthor=R.+S.+Heistauthor=J.+Temelauthor=J.+G.+Christensenauthor=J.+C.+Wainauthor=T.+J.+Lynchauthor=K.+Vernovskyauthor=E.+J.+Markauthor=M.+Lanutiauthor=A.+J.+Iafrateauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=Genotypic+and+Histological+Evolution+of+Lung+Cancers+Acquiring+Resistance+to+EGFR+Inhibitors&doi=10.1126%2Fscitranslmed.3002003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3002003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3002003%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DWaltman%26aufirst%3DB.%2BA.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DCosper%26aufirst%3DA.%2BK.%26aulast%3DAkhavanfard%26aufirst%3DS.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DTemel%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DVernovsky%26aufirst%3DK.%26aulast%3DMark%26aufirst%3DE.%2BJ.%26aulast%3DLanuti%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DGenotypic%2520and%2520Histological%2520Evolution%2520of%2520Lung%2520Cancers%2520Acquiring%2520Resistance%2520to%2520EGFR%2520Inhibitors%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D75ra26%26doi%3D10.1126%2Fscitranslmed.3002003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raaijmakers, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Otterlo, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Characterization of Irreversible Kinase Inhibitors by Directly Detecting Covalent Bond Formation: a Tool for Dissecting Kinase Drug Resistance</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2557</span><span class="NLM_x">–</span> <span class="NLM_lpage">2566</span><span class="refDoi"> DOI: 10.1002/cbic.201000352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1002%2Fcbic.201000352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=21080395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFahsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=2557-2566&author=S.+Kl%C3%BCterauthor=J.+R.+Simardauthor=H.+B.+Rodeauthor=C.+Gr%C3%BCtterauthor=V.+Pawarauthor=H.+C.+Raaijmakersauthor=T.+A.+Barfauthor=M.+Rabillerauthor=W.+A.+van+Otterloauthor=D.+Rauh&title=Characterization+of+Irreversible+Kinase+Inhibitors+by+Directly+Detecting+Covalent+Bond+Formation%3A+a+Tool+for+Dissecting+Kinase+Drug+Resistance&doi=10.1002%2Fcbic.201000352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Irreversible Kinase Inhibitors by Directly Detecting Covalent Bond Formation: A Tool for Dissecting Kinase Drug Resistance</span></div><div class="casAuthors">Klueter, Sabine; Simard, Jeffrey R.; Rode, Haridas B.; Gruetter, Christian; Pawar, Vijaykumar; Raaijmakers, Hans C. A.; Barf, Tjeerd A.; Rabiller, Matthias; van Otterlo, Willem A. L.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2557-2566</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting protein kinases in cancer therapy with irreversible small-mol. inhibitors is moving to the forefront of kinase-inhibitor research and is thought to be an effective means of overcoming mutation-assocd. drug resistance in epidermal growth factor receptor kinase (EGFR).  We generated a detection technique that allows direct measurements of covalent bond formation without relying on kinase activity, thereby allowing the straightforward investigation of the influence of steric clashes on covalent inhibitors in different resistant kinase mutants.  The obtained results are discussed together with structural biol. and biochem. studies of catalytic activity in both wild-type and gatekeeper mutated kinase variants to draw conclusions about the impact of steric hindrance and increased catalytic activity in drug-resistant kinase variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXBFAgMOxkBLVg90H21EOLACvtfcHk0lgSQvjm49PCJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFahsLrE&md5=5f48cde54e6bad28b4d4f9d47a4e3e3e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201000352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201000352%26sid%3Dliteratum%253Aachs%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DRaaijmakers%26aufirst%3DH.%2BC.%26aulast%3DBarf%26aufirst%3DT.%2BA.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3Dvan%2BOtterlo%26aufirst%3DW.%2BA.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DCharacterization%2520of%2520Irreversible%2520Kinase%2520Inhibitors%2520by%2520Directly%2520Detecting%2520Covalent%2520Bond%2520Formation%253A%2520a%2520Tool%2520for%2520Dissecting%2520Kinase%2520Drug%2520Resistance%26jtitle%3DChemBioChem%26date%3D2010%26volume%3D11%26spage%3D2557%26epage%3D2566%26doi%3D10.1002%2Fcbic.201000352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Michalczyk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Structural Insights Into How Irreversible Inhibitors Can. Overcome Drug Resistance in EGFR</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3482</span><span class="NLM_x">–</span> <span class="NLM_lpage">3488</span><span class="refDoi"> DOI: 10.1016/j.bmc.2008.02.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1016%2Fj.bmc.2008.02.053" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=3482-3488&author=A.+Michalczykauthor=S.+Kl%C3%BCterauthor=H.+B.+Rodeauthor=J.+R.+Simardauthor=C.+Gr%C3%BCtterauthor=M.+Rabillerauthor=D.+Rauh&title=Structural+Insights+Into+How+Irreversible+Inhibitors+Can.+Overcome+Drug+Resistance+in+EGFR&doi=10.1016%2Fj.bmc.2008.02.053"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.02.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.02.053%26sid%3Dliteratum%253Aachs%26aulast%3DMichalczyk%26aufirst%3DA.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStructural%2520Insights%2520Into%2520How%2520Irreversible%2520Inhibitors%2520Can.%2520Overcome%2520Drug%2520Resistance%2520in%2520EGFR%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D3482%26epage%3D3488%26doi%3D10.1016%2Fj.bmc.2008.02.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.+H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+Profiling+Provides+Insights+into+the+Limited+Activity+of+Irreversible+EGFR+Inhibitors+in+Tumor+Cells+Expressing+the+T790M+EGFR+Resistance+Mutation&doi=10.1158%2F0008-5472.CAN-09-3106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0lhTuC_470oqdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520Profiling%2520Provides%2520Insights%2520into%2520the%2520Limited%2520Activity%2520of%2520Irreversible%2520EGFR%2520Inhibitors%2520in%2520Tumor%2520Cells%2520Expressing%2520the%2520T790M%2520EGFR%2520Resistance%2520Mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874%26doi%3D10.1158%2F0008-5472.CAN-09-3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span><span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lhTuC_470oqdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Carey, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garton, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8163</span><span class="NLM_x">–</span> <span class="NLM_lpage">8171</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-0453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1158%2F0008-5472.CAN-06-0453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=16912195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8163-8171&author=K.+D.+Careyauthor=A.+J.+Gartonauthor=M.+S.+Romeroauthor=J.+Kahlerauthor=S.+Thomsonauthor=S.+Rossauthor=F.+Parkauthor=J.+D.+Haleyauthor=N.+Gibsonauthor=M.+X.+Sliwkowski&title=Kinetic+analysis+of+epidermal+growth+factor+receptor+somatic+mutant+proteins+shows+increased+sensitivity+to+the+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+erlotinib&doi=10.1158%2F0008-5472.CAN-06-0453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib</span></div><div class="casAuthors">Carey, Kendall D.; Garton, Andrew J.; Romero, Maria S.; Kahler, Jennifer; Thomson, Stuart; Ross, Sarajane; Park, Frances; Haley, John D.; Gibson, Neil; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8163-8171</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We show that two commonly occurring epidermal growth factor receptor (EGFR) somatic mutations, L858R and an in-frame deletion mutant, Del(746-750), exhibit distinct enzymic properties relative to wild-type EGFR and are differentially sensitive to erlotinib.  Kinetic anal. of the purified intracellular domains of EGFR L858R and EGFR Del(746-750) reveals that both mutants are active but exhibit a higher KM for ATP and a lower Ki for erlotinib relative to wild-type receptor.  When expressed in NR6 cells, a cell line that does not express EGFR or other ErbB receptors, both mutations are ligand dependent for receptor activation, can activate downstream EGFR signaling pathways, and promote cell cycle progression.  As expected from the kinetic anal., the EGFR Del(746-752) is more sensitive to erlotinib inhibition than the EGFR L858R mutant.  Further characterization shows that these mutations promote ligand-dependent and anchorage-independent growth, and cells harboring these mutant receptors form tumors in immunocompromised mice.  Anal. of tumor lysates reveals that the tumorigenicity of the mutant EGFR cell lines may be due to a differential pattern of mutant EGFR autophosphorylation as compared with wild-type receptor.  Significant inhibition of tumor growth, in mice harboring wild-type EGFR receptors, is only obsd. at doses of erlotinib approaching the max. tolerated dose for the mouse.  In contrast, the growth of mutant tumors is inhibited by erlotinib treatment at approx. one third the max. tolerated dose.  These findings suggest that EGFR somatic mutations directly influence both erlotinib sensitivity and cellular transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-kYT9GVzgo7Vg90H21EOLACvtfcHk0lhTuC_470oqdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D&md5=0ea102a026666dc0cb9cf60a3de0e944</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0453%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DK.%2BD.%26aulast%3DGarton%26aufirst%3DA.%2BJ.%26aulast%3DRomero%26aufirst%3DM.%2BS.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DF.%26aulast%3DHaley%26aufirst%3DJ.%2BD.%26aulast%3DGibson%26aufirst%3DN.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DKinetic%2520analysis%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520somatic%2520mutant%2520proteins%2520shows%2520increased%2520sensitivity%2520to%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520erlotinib%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8163%26epage%3D8171%26doi%3D10.1158%2F0008-5472.CAN-06-0453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Mulloy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrand, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">2325</span><span class="NLM_x">–</span> <span class="NLM_lpage">2330</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1158%2F0008-5472.CAN-06-4293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=17332364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=2325-2330&author=R.+Mulloyauthor=A.+Ferrandauthor=Y.+Kimauthor=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=K.+S.+Andersonauthor=J.+Settleman&title=Epidermal+growth+factor+receptor+mutants+from+human+lung+cancers+exhibit+enhanced+catalytic+activity+and+increased+sensitivity+to+gefitinib&doi=10.1158%2F0008-5472.CAN-06-4293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to Gefitinib</span></div><div class="casAuthors">Mulloy, Roseann; Ferrand, Audrey; Kim, Youngjoo; Sordella, Raffaella; Bell, Daphne W.; Haber, Daniel A.; Anderson, Karen S.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2325-2330</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Somatic mutations within the epidermal growth factor receptor (EGFR) kinase domain are detected in 10% to 30% of human non-small cell lung cancers and are correlated with striking clin. responses in a subset of patients treated with EGFR kinase inhibitors, such as gefitinib and erlotinib.  Cell-based studies suggest that these mutant EGFRs promote increased autophosphorylating activity on a subset of EGFR COOH-terminal tyrosines and the consequent engagement of a subset of downstream effectors.  Because EGFR function is regulated at multiple levels in vivo, and it is therefore difficult to assess the direct consequences of these mutations on EGFR enzyme function, we measured EGFR catalytic activity in in vitro kinase assays using purified recombinant proteins corresponding to the cytoplasmic domain of wild-type and two frequently detected EGFR mutants (DelL747-P753insS and L858R).  Both mutants exhibit substantially increased autophosphorylating activity relative to wild-type EGFR, and they exhibit distinct reaction kinetics.  In addn., the mutant kinases are more sensitive to kinase inhibition by gefitinib, which seems to reflect their increased drug affinity.  These findings suggest that the altered signaling properties and drug sensitivity of these EGFR mutants that have been obsd. in vivo largely result from differences in the catalytic properties of the kinase.  In addn., we find that the T790M secondary "drug resistance mutation" of EGFR, which frequently arises in relapsed patients that initially responded to treatment, confers enhanced kinase activity to primary activating EGFR alleles and may, therefore, be oncogenic in some contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ3000le0prLVg90H21EOLACvtfcHk0lg5B0MjXcp8xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjsLk%253D&md5=6bd63e27b220c89e22f0ba6e8682db17</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4293%26sid%3Dliteratum%253Aachs%26aulast%3DMulloy%26aufirst%3DR.%26aulast%3DFerrand%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DAnderson%26aufirst%3DK.%2BS.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutants%2520from%2520human%2520lung%2520cancers%2520exhibit%2520enhanced%2520catalytic%2520activity%2520and%2520increased%2520sensitivity%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D2325%26epage%3D2330%26doi%3D10.1158%2F0008-5472.CAN-06-4293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lg5B0MjXcp8xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4702</span><span class="NLM_x">–</span> <span class="NLM_lpage">4711</span><span class="refDoi"> DOI: 10.1038/onc.2008.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fonc.2008.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=18408761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models&doi=10.1038%2Fonc.2008.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span></div><div class="casAuthors">Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K-K.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4702-4711</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to treatment with small mol. tyrosine kinase inhibitors.  Although first-generation reversible, ATP-competitive inhibitors showed encouraging clin. responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time.  Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3.  Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen.  Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms.  Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib.  These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.  Oncogene (2008) 27, 4702-4711; doi:10.1038/onc.2008.109; published online 14 Apr. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5PQdKep-Sp7Vg90H21EOLACvtfcHk0lg5B0MjXcp8xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D&md5=24945893e83b4e3d01c267100fdaf57c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711%26doi%3D10.1038%2Fonc.2008.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amato, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhoury, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lettiere, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span> </span><span class="NLM_article-title">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1880</span><span class="NLM_x">–</span> <span class="NLM_lpage">1889</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1158%2F1535-7163.MCT-07-2232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=18606718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1880-1889&author=A.+J.+Gonzalesauthor=K.+E.+Hookauthor=I.+W.+Althausauthor=P.+A.+Ellisauthor=E.+Trachetauthor=A.+M.+Delaneyauthor=P.+J.+Harveyauthor=T.+A.+Ellisauthor=D.+M.+Amatoauthor=J.+M.+Nelsonauthor=D.+W.+Fryauthor=T.+Zhuauthor=C.+M.+Loiauthor=S.+A.+Fakhouryauthor=K.+M.+Schlosserauthor=K.+E.+Sextonauthor=R.+T.+Wintersauthor=J.+E.+Reedauthor=A.+J.+Bridgesauthor=D.+J.+Lettiereauthor=D.+A.+Bakerauthor=J.+Yangauthor=H.+T.+Leeauthor=H.+Tecleauthor=P.+W.+Vincent&title=Antitumor+activity+and+pharmacokinetic+properties+of+PF-00299804%2C+a+second-generation+irreversible+pan-erbB+receptor+tyrosine+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-07-2232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Gonzales, Andrea J.; Hook, Kenneth E.; Althaus, Irene W.; Ellis, Paul A.; Trachet, Erin; Delaney, Amy M.; Harvey, Patricia J.; Ellis, Teresa A.; Amato, Danielle M.; Nelson, James M.; Fry, David W.; Zhu, Tong; Loi, Cho-Ming; Fakhoury, Stephen A.; Schlosser, Kevin M.; Sexton, Karen E.; Winters, R. Thomas; Reed, Jessica E.; Bridges, Alex J.; Lettiere, Daniel J.; Baker, Deborah A.; Yang, Jianxin; Lee, Helen T.; Tecle, Haile; Vincent, Patrick W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1880-1889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types.  Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments.  PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor currently in phase I clin. trials.  PF-00299804 is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members.  Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) assocd. with resistance to gefitinib and erlotinib.  Furthermore, PF-00299804 shows exceptional distribution to human tumor xenografts and excellent pharmacokinetic properties across species. [Mol Cancer Ther 2008;7(7):1880-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbL0hP8K2G37Vg90H21EOLACvtfcHk0lgih0rcq7qJ2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D&md5=3392275d1e4f4d5d70e3b22d4893e3c8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2232%26sid%3Dliteratum%253Aachs%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DEllis%26aufirst%3DT.%2BA.%26aulast%3DAmato%26aufirst%3DD.%2BM.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DLoi%26aufirst%3DC.%2BM.%26aulast%3DFakhoury%26aufirst%3DS.%2BA.%26aulast%3DSchlosser%26aufirst%3DK.%2BM.%26aulast%3DSexton%26aufirst%3DK.%2BE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DLettiere%26aufirst%3DD.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacokinetic%2520properties%2520of%2520PF-00299804%252C%2520a%2520second-generation%2520irreversible%2520pan-erbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1880%26epage%3D1889%26doi%3D10.1158%2F1535-7163.MCT-07-2232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-Target Residence Time and its Implications for Lead Optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span><span class="refDoi"> DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-Target+Residence+Time+and+its+Implications+for+Lead+Optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lgih0rcq7qJ2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-Target%2520Residence%2520Time%2520and%2520its%2520Implications%2520for%2520Lead%2520Optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span> </span><span class="NLM_article-title">Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3417</span><span class="NLM_x">–</span> <span class="NLM_lpage">3420</span><span class="refDoi"> DOI: 10.1200/JCO.2012.43.1825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1200%2FJCO.2012.43.1825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=22915655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3417-3420&author=J.+M.+Heuckmannauthor=D.+Rauhauthor=R.+K.+Thomas&title=Epidermal+Growth+Factor+Receptor+%28EGFR%29+Signaling+and+Covalent+EGFR+Inhibition+in+Lung+Cancer&doi=10.1200%2FJCO.2012.43.1825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor (EGFR) signaling and covalent EGF inhibition in lung cancer</span></div><div class="casAuthors">Heuckmann, Johannes M.; Rauh, Daniel; Thomas, Roman K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3417-3420</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The research of Ramalingam et al. (2012) entitled, 'Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, vs. erlotinib in patients with advanced non-small-cell lung cancer' is reviewed with commentary and refs.  In their paper, a novel irreversible ERBB family inhibitor, dacomitinib, improved progression-free survival compared with erlotinib in unselected patients with non-small-cell lung cancer without prior epidermal growth factor receptor-directed therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8PW4hGdL2k7Vg90H21EOLACvtfcHk0lgih0rcq7qJ2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt73O&md5=45192d5ee846d2c25302286226cff733</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.1825%26sid%3Dliteratum%253Aachs%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DEpidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%2520Signaling%2520and%2520Covalent%2520EGFR%2520Inhibition%2520in%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3417%26epage%3D3420%26doi%3D10.1200%2FJCO.2012.43.1825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The Resurgence of Covalent Drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+Resurgence+of+Covalent+Drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0ljVyxgBR-dYGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520Resurgence%2520of%2520Covalent%2520Drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Katakami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atagi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koboyashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebisawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span> </span><span class="NLM_article-title">LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3335</span><span class="NLM_x">–</span> <span class="NLM_lpage">3341</span><span class="refDoi"> DOI: 10.1200/JCO.2012.45.0981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1200%2FJCO.2012.45.0981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=23816963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KrsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3335-3341&author=N.+Katakamiauthor=S.+Atagiauthor=K.+Gotoauthor=T.+Hidaauthor=T.+Horaiauthor=A.+Inoueauthor=Y.+Ichinoseauthor=K.+Koboyashiauthor=K.+Takedaauthor=K.+Kiuraauthor=K.+Nishioauthor=Y.+Sekiauthor=R.+Ebisawaauthor=M.+Shahidiauthor=N.+Yamamoto&title=LUX-Lung+4%3A+A+Phase+II+Trial+of+Afatinib+in+Patients+With+Advanced+Non-Small-Cell+Lung+Cancer+Who+Progressed+During+Prior+Treatment+With+Erlotinib%2C+Gefitinib%2C+or+Both&doi=10.1200%2FJCO.2012.45.0981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">LUX-lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both</span></div><div class="casAuthors">Katakami, Noboyuki; Atagi, Shinji; Goto, Koichi; Hida, Toyoaki; Horai, Takeshi; Inoue, Akira; Ichinose, Yukito; Koboyashi, Kunihiko; Takeda, Koji; Kiura, Katsuyuki; Nishio, Kazuto; Seki, Yoko; Ebisawa, Ryuichi; Shahidi, Mehdi; Yamamoto, Nobuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3335-3341</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose New mol. targeted agents are needed for patients with non-small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both.  Afatinib, an oral irreversible ErbB family blocker, has preclin. activity in epidermal growth factor receptor (EGFR [ErbB1]) mutant models with EGFR-activating mutations, including T790M.  Patients and Methods This was a Japanese single-arm phase II trial conducted in patients with stage IIIB to IV pulmonary adenocarcinoma who progressed after ≥ 12 wk of prior erlotinib and/or gefitinib.  Patients received afatinib 50 mg per day.  The primary end point was objective response rate (complete response or partial response) by independent review.  Secondary end points included progression-free survival (PFS), overall survival (OS), and safety.  Results Of 62 treated patients, 45 (72.6%) were EGFR mutation pos. in their primary tumor according to local and/or central lab. analyses.  Fifty-one patients (82.3%) fulfilled the criteria of acquired resistance to erlotinib and/or gefitinib.  Of 61 evaluable patients, five (8.2%; 95% CI, 2.7% to 18.1 %) had a confirmed objective response rate (partial response).  Median PFS was 4.4 mo (95% CI, 2.8 to 4.6 mo), and median OS was 19.0 mo (95% CI, 14.9 mo to not achieved).  Two patients had acquired T790M mutations: L858R + T790M, and deletion in exon 19 + T790M; they had stable disease for 9 mo and 1 mo, resp.  The most common afatinib-related adverse events (AEs) were diarrhea (100%) and rash/acne (91.9%).  Treatment-related AEs leading to afatinib discontinuation were experienced by 18 patients (29%), of whom four also had progressive disease.  Conclusion Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM0F6fZnWKTbVg90H21EOLACvtfcHk0ljVyxgBR-dYGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KrsrzK&md5=1666aeb642dbc953dd9bcc818bab9098</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.45.0981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.45.0981%26sid%3Dliteratum%253Aachs%26aulast%3DKatakami%26aufirst%3DN.%26aulast%3DAtagi%26aufirst%3DS.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DHorai%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DKoboyashi%26aufirst%3DK.%26aulast%3DTakeda%26aufirst%3DK.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DY.%26aulast%3DEbisawa%26aufirst%3DR.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DN.%26atitle%3DLUX-Lung%25204%253A%2520A%2520Phase%2520II%2520Trial%2520of%2520Afatinib%2520in%2520Patients%2520With%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%2520Who%2520Progressed%2520During%2520Prior%2520Treatment%2520With%2520Erlotinib%252C%2520Gefitinib%252C%2520or%2520Both%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3335%26epage%3D3341%26doi%3D10.1200%2FJCO.2012.45.0981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadranel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span> </span><span class="NLM_article-title">Afatinib versus Placebo for Patients with Advanced, Metastatic Non-Small Cell Lung Cancer After Failure of Erlotinib, Gefitinib, or both, and One or Two Lines of Chemotherapy (LUX-Lung 1): A Phase 2b/3 Randomised Trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">528</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span><span class="refDoi"> DOI: 10.1016/S1470-2045(12)70087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.+M.+Chenauthor=K.+Parkauthor=S.+W.+Kimauthor=C.+Zhouauthor=W.+C.+Suauthor=M.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.+H.+Tanauthor=T.+Y.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.+Yang&title=Afatinib+versus+Placebo+for+Patients+with+Advanced%2C+Metastatic+Non-Small+Cell+Lung+Cancer+After+Failure+of+Erlotinib%2C+Gefitinib%2C+or+both%2C+and+One+or+Two+Lines+of+Chemotherapy+%28LUX-Lung+1%29%3A+A+Phase+2b%2F3+Randomised+Trial&doi=10.1016%2FS1470-2045%2812%2970087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0ljd1ZS99N_mww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%2BM.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DChao%26aufirst%3DT.%2BY.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26atitle%3DAfatinib%2520versus%2520Placebo%2520for%2520Patients%2520with%2520Advanced%252C%2520Metastatic%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520After%2520Failure%2520of%2520Erlotinib%252C%2520Gefitinib%252C%2520or%2520both%252C%2520and%2520One%2520or%2520Two%2520Lines%2520of%2520Chemotherapy%2520%2528LUX-Lung%25201%2529%253A%2520A%2520Phase%25202b%252F3%2520Randomised%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D528%26epage%3D538%26doi%3D10.1016%2FS1470-2045%2812%2970087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthakrishnan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Neratinib, an Irreversible pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients with Advanced Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">–</span> <span class="NLM_lpage">3083</span><span class="refDoi"> DOI: 10.1200/JCO.2009.27.9414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1200%2FJCO.2009.27.9414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=20479403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3076-3083&author=L.+V.+Sequistauthor=B.+Besseauthor=T.+J.+Lynchauthor=V.+A.+Millerauthor=K.+K.+Wongauthor=B.+Gitlitzauthor=K.+Eatonauthor=C.+Zacharchukauthor=A.+Freymanauthor=C.+Powellauthor=R.+Ananthakrishnanauthor=S.+Quinnauthor=J.+C.+Soria&title=Neratinib%2C+an+Irreversible+pan-ErbB+Receptor+Tyrosine+Kinase+Inhibitor%3A+Results+of+a+Phase+II+Trial+in+Patients+with+Advanced+Non-Small-Cell+Lung+Cancer&doi=10.1200%2FJCO.2009.27.9414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib, an irreversible Pan-ErbB, receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Besse, Benjamin; Lynch, Thomas J.; Miller, Vincent A.; Wong, Kwok K.; Gitlitz, Barbara; Eaton, Keith; Zacharchuk, Charles; Freyman, Amy; Powell, Christine; Ananthakrishnan, Revathi; Quinn, Susan; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3076-3083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations.  Resistance emerges after 9 to 12 mo, primarily mediated by the T790M resistance mutation.  We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.  Patients with advanced NSCLC underwent EGFR sequencing of available tumor tissue at enrollment.  Those with ≥ 12 wk of prior TKI therapy were placed in arm A if they were EGFR mutation pos. or arm B if they were wild-type.  Arm C included TKI-naive patients with adenocarcinoma and light smoking histories (≤ 20 pack-years).  All patients received daily oral neratinib, initially at 320 mg but subsequently reduced to 240 mg because of excessive diarrhea.  The primary end point was objective response rate (RR).  167 Patients were treated: 91 in arm A, 48 in arm B, and 28 in arm C.  Diarrhea was the most common toxicity; grade 3 incidence was 50% at 320 mg but improved to 25% after dose redn.  The RR was 3% in arm A and zero in arms B and C.  No patients with known T790M responded.  Notably, three of four patients with an exon 18 G719X EGFR mutation had a partial response and the fourth had stable disease lasting 40 wk.  Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naive patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation.  Responses were seen in patients with the rare G719X EGFR mutation, highlighting the importance of obtaining comprehensive genetic information on trials of targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Z3gsvbWbOrVg90H21EOLACvtfcHk0ljd1ZS99N_mww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D&md5=460e088e58919bbfcf8c153772f157b0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.27.9414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.27.9414%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGitlitz%26aufirst%3DB.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DFreyman%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DNeratinib%252C%2520an%2520Irreversible%2520pan-ErbB%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%253A%2520Results%2520of%2520a%2520Phase%2520II%2520Trial%2520in%2520Patients%2520with%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D3076%26epage%3D3083%26doi%3D10.1200%2FJCO.2009.27.9414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+Mutant-Selective+Covalent+Inhibitor+of+EGFR+that+Overcomes+T790M-Mediated+Resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lgSWKJP5E0y3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520Mutant-Selective%2520Covalent%2520Inhibitor%2520of%2520EGFR%2520that%2520Overcomes%2520T790M-Mediated%2520Resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lgSWKJP5E0y3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Bartlett, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachtel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roses, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelz, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karakousis, G. C.</span><span> </span><span class="NLM_article-title">The Rise in Metastasectomy Across Cancer Types Over the Past Decade</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">747</span><span class="NLM_x">–</span> <span class="NLM_lpage">757</span><span class="refDoi"> DOI: 10.1002/cncr.29134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1002%2Fcncr.29134" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=747-757&author=E.+K.+Bartlettauthor=K.+D.+Simmonsauthor=H.+Wachtelauthor=R.+E.+Rosesauthor=D.+L.+Frakerauthor=R.+R.+Kelzauthor=G.+C.+Karakousis&title=The+Rise+in+Metastasectomy+Across+Cancer+Types+Over+the+Past+Decade&doi=10.1002%2Fcncr.29134"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29134%26sid%3Dliteratum%253Aachs%26aulast%3DBartlett%26aufirst%3DE.%2BK.%26aulast%3DSimmons%26aufirst%3DK.%2BD.%26aulast%3DWachtel%26aufirst%3DH.%26aulast%3DRoses%26aufirst%3DR.%2BE.%26aulast%3DFraker%26aufirst%3DD.%2BL.%26aulast%3DKelz%26aufirst%3DR.%2BR.%26aulast%3DKarakousis%26aufirst%3DG.%2BC.%26atitle%3DThe%2520Rise%2520in%2520Metastasectomy%2520Across%2520Cancer%2520Types%2520Over%2520the%2520Past%2520Decade%26jtitle%3DCancer%26date%3D2015%26volume%3D121%26spage%3D747%26epage%3D757%26doi%3D10.1002%2Fcncr.29134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Dhingra, K.</span><span> </span><span class="NLM_article-title">Rociletinib: has the TIGER lost a few of its stripes?</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1161</span><span class="NLM_x">–</span> <span class="NLM_lpage">1164</span><span class="refDoi"> DOI: 10.1093/annonc/mdw140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1093%2Fannonc%2Fmdw140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=27045101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A280%3ADC%252BC28fmvVSisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1161-1164&author=K.+Dhingra&title=Rociletinib%3A+has+the+TIGER+lost+a+few+of+its+stripes%3F&doi=10.1093%2Fannonc%2Fmdw140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rociletinib: has the TIGER lost a few of its stripes?</span></div><div class="casAuthors">Dhingra K</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1161-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQv9WkZkIzByiO2kE7krGOBfW6udTcc2eagoTnxWqkCN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fmvVSisA%253D%253D&md5=ce412910e17e83641dc6a5e372201c53</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw140%26sid%3Dliteratum%253Aachs%26aulast%3DDhingra%26aufirst%3DK.%26atitle%3DRociletinib%253A%2520has%2520the%2520TIGER%2520lost%2520a%2520few%2520of%2520its%2520stripes%253F%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26spage%3D1161%26epage%3D1164%26doi%3D10.1093%2Fannonc%2Fmdw140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Update to Rociletinib Data with the RECIST Confirmed Response Rate</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">2296</span><span class="NLM_x">–</span> <span class="NLM_lpage">2297</span><span class="refDoi"> DOI: 10.1056/NEJMc1602688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMc1602688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=27195670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FgvVarug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=2296-2297&author=L.+V.+Sequistauthor=J.+C.+Soriaauthor=D.+R.+Camidge&title=Update+to+Rociletinib+Data+with+the+RECIST+Confirmed+Response+Rate&doi=10.1056%2FNEJMc1602688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Update to Rociletinib Data with the RECIST Confirmed Response Rate</span></div><div class="casAuthors">Sequist Lecia V; Soria Jean-Charles; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2296-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6Df3dbiWDlINpW7w2tapOfW6udTcc2ea6e2Mg5Iebibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FgvVarug%253D%253D&md5=42e8a350746d423a7a07b556f09105a8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1602688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1602688%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DUpdate%2520to%2520Rociletinib%2520Data%2520with%2520the%2520RECIST%2520Confirmed%2520Response%2520Rate%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D2296%26epage%3D2297%26doi%3D10.1056%2FNEJMc1602688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitrakopoulou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dziadziuszko, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galasso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garon, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heist, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendenhall, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piotrowska, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlovich, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Despain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheny, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">1700</span><span class="NLM_x">–</span> <span class="NLM_lpage">1709</span><span class="refDoi"> DOI: 10.1056/NEJMoa1413654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa1413654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=25923550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1700-1709&author=L.+V.+Sequistauthor=J.+C.+Soriaauthor=J.+W.+Goldmanauthor=H.+A.+Wakeleeauthor=S.+M.+Gadgeelauthor=A.+Vargaauthor=V.+Papadimitrakopoulouauthor=B.+J.+Solomonauthor=G.+R.+Oxnardauthor=R.+Dziadziuszkoauthor=D.+L.+Aisnerauthor=R.+C.+Doebeleauthor=C.+Galassoauthor=E.+B.+Garonauthor=R.+S.+Heistauthor=J.+Loganauthor=J.+W.+Nealauthor=M.+A.+Mendenhallauthor=S.+Nicholsauthor=Z.+Piotrowskaauthor=A.+J.+Wozniakauthor=M.+Raponiauthor=C.+A.+Karlovichauthor=S.+Jaw-Tsaiauthor=J.+Isaacsonauthor=D.+Despainauthor=S.+L.+Mathenyauthor=L.+Rolfeauthor=A.+R.+Allenauthor=D.+R.+Camidge&title=Rociletinib+in+EGFR-Mutated+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1413654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Rociletinib in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Sequist Lecia V; Soria Jean-Charles; Goldman Jonathan W; Wakelee Heather A; Gadgeel Shirish M; Varga Andrea; Papadimitrakopoulou Vassiliki; Solomon Benjamin J; Oxnard Geoffrey R; Dziadziuszko Rafal; Aisner Dara L; Doebele Robert C; Galasso Cathy; Garon Edward B; Heist Rebecca S; Logan Jennifer; Neal Joel W; Mendenhall Melody A; Nichols Suzanne; Piotrowska Zofia; Wozniak Antoinette J; Raponi Mitch; Karlovich Chris A; Jaw-Tsai Sarah; Isaacson Jeffrey; Despain Darrin; Matheny Shannon L; Rolfe Lindsey; Allen Andrew R; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1700-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by the T790M EGFR mutation in most cases.  Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.  METHODS:  In this phase 1-2 study, we administered rociletinib to patients with EGFR-mutated NSCLC who had disease progression during previous treatment with an existing EGFR inhibitor.  In the expansion (phase 2) part of the study, patients with T790M-positive disease received rociletinib at a dose of 500 mg twice daily, 625 mg twice daily, or 750 mg twice daily.  Key objectives were assessment of safety, side-effect profile, pharmacokinetics, and preliminary antitumor activity of rociletinib.  Tumor biopsies to identify T790M were performed during screening.  Treatment was administered in continuous 21-day cycles.  RESULTS:  A total of 130 patients were enrolled.  The first 57 patients to be enrolled received the free-base form of rociletinib (150 mg once daily to 900 mg twice daily).  The remaining patients received the hydrogen bromide salt (HBr) form (500 mg twice daily to 1000 mg twice daily).  A maximum tolerated dose (the highest dose associated with a rate of dose-limiting toxic effects of less than 33%) was not identified.  The only common dose-limiting adverse event was hyperglycemia.  In an efficacy analysis that included patients who received free-base rociletinib at a dose of 900 mg twice daily or the HBr form at any dose, the objective response rate among the 46 patients with T790M-positive disease who could be evaluated was 59% (95% confidence interval [CI], 45 to 73), and the rate among the 17 patients with T790M-negative disease who could be evaluated was 29% (95% CI, 8 to 51).  CONCLUSIONS:  Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3ZPq5LRczm8ffW6udTcc2ea6e2Mg5Iebibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D&md5=5a5d21d36c081a5ef0f9e650d5cc84b9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413654%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DGalasso%26aufirst%3DC.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMendenhall%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DS.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DDespain%26aufirst%3DD.%26aulast%3DMatheny%26aufirst%3DS.%2BL.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DRociletinib%2520in%2520EGFR-Mutated%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1700%26epage%3D1709%26doi%3D10.1056%2FNEJMoa1413654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Van Der Steen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caparello, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannetti, E.</span><span> </span><span class="NLM_article-title">New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">6065</span><span class="NLM_x">–</span> <span class="NLM_lpage">6074</span><span class="refDoi"> DOI: 10.2147/OTT.S97644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.2147%2FOTT.S97644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=27785053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A280%3ADC%252BC2sngtVGquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=6065-6074&author=N.+Van+Der+Steenauthor=C.+Caparelloauthor=C.+Rolfoauthor=P.+Pauwelsauthor=G.+J.+Petersauthor=E.+Giovannetti&title=New+developments+in+the+management+of+non-small-cell+lung+cancer%2C+focus+on+rociletinib%3A+what+went+wrong%3F&doi=10.2147%2FOTT.S97644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?</span></div><div class="casAuthors">Van Der Steen Nele; Peters Godefridus J; Caparello Chiara; Rolfo Christian; Pauwels Patrick; Giovannetti Elisa</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6065-6074</span>
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    </div><div class="casAbstract">Recently, the development of the third-generation epidermal growth factor receptor-small molecule inhibitor (EGFR-TKI) rociletinib had failed.  In this review, the wide-ranging aspects of the evolution of EGFR-TKIs were collected, with a special focus on rociletinib.  The influence of different oncogenic mutations on EGFR activity was also discussed.  Resistance to the first (erlotinib, gefitinib)- and second (afatinib)-generation EGFR-TKIs provided the rationale behind the development of the third-generation inhibitors (rociletinib, osimertinib).  On the basis of these data, a comparison of their efficacy on the different mutated EGFRs and the respective resistance mechanisms is further reported.  Moreover, the evolution and results of the clinical trials of rociletinib (TIGER trials) are compared with the trials on osimertinib, another third-generation EGFR-TKI that now has been granted US Food and Drug Administration approval.  The reasons behind the arrest in the further development of rociletinib are put in the perspective of future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_s7WmFAisW36HPRus0rAafW6udTcc2ebvN8YZQs-yzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sngtVGquw%253D%253D&md5=b3415f44652e09b0b7a7d8069d47aa1f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2147%2FOTT.S97644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S97644%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDer%2BSteen%26aufirst%3DN.%26aulast%3DCaparello%26aufirst%3DC.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DPauwels%26aufirst%3DP.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DGiovannetti%26aufirst%3DE.%26atitle%3DNew%2520developments%2520in%2520the%2520management%2520of%2520non-small-cell%2520lung%2520cancer%252C%2520focus%2520on%2520rociletinib%253A%2520what%2520went%2520wrong%253F%26jtitle%3DOncoTargets%2520Ther.%26date%3D2016%26volume%3D9%26spage%3D6065%26epage%3D6074%26doi%3D10.2147%2FOTT.S97644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Greig, S. L.</span><span> </span><span class="NLM_article-title">Osimertinib: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1007/s40265-015-0533-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1007%2Fs40265-015-0533-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=26729184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=263-273&author=S.+L.+Greig&title=Osimertinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0533-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: First Global Approval</span></div><div class="casAuthors">Greig, Sarah L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-273</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Osimertinib (Tagrisso, AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC).  Osimertinib has been designed to target the EGFR T790M mutation that is often present in NSCLC patients with acquired EGFR TKI resistance, while sparing wild-type EGFR.  In Nov. 2015, the tablet formulation of osimertinib was granted accelerated approval in the USA for the treatment of patients with metastatic EGFR T790M mutation-pos. NSCLC (as detected by an FDA-approved test) who have progressed on or after EGFR TKI therapy.  Osimertinib has also been granted accelerated assessment status for this indication in the EU, and is in phase III development for first- and second-line and adjuvant treatment of advanced EGFR mutation-pos. NSCLC in several countries.  Phase I trials in patients with advanced solid tumors are also being conducted.  This article summarizes the milestones in the development of osimertinib leading to this first approval for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD-OV6l6JC5rVg90H21EOLACvtfcHk0lixl7gWtTv-Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D&md5=fb46898918bdfe76320c26177710fb11</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0533-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0533-4%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DS.%2BL.%26atitle%3DOsimertinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D263%26epage%3D273%26doi%3D10.1007%2Fs40265-015-0533-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggstrom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frewer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">1689</span><span class="NLM_x">–</span> <span class="NLM_lpage">1699</span><span class="refDoi"> DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&author=P.+A.+J%C3%A4nneauthor=J.+C.+H.+Yangauthor=D.+W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.+J.+Ahnauthor=S.+W.+Kimauthor=W.+C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.+H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+Inhibitor-Resistant+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2ebvN8YZQs-yzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520Inhibitor-Resistant%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mühlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollipara, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahedi, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10909</span><span class="NLM_x">–</span> <span class="NLM_lpage">10912</span><span class="refDoi"> DOI: 10.1002/anie.201605011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1002%2Fanie.201605011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=27496389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10909-10912&author=J.+Engelauthor=C.+Beckerauthor=J.+Lategahnauthor=M.+Keulauthor=J.+Ketzerauthor=T.+M%C3%BChlenbergauthor=L.+Kolliparaauthor=C.+Schultz-Fademrechtauthor=R.+P.+Zahediauthor=S.+Bauerauthor=D.+Rauh&title=Insight+into+the+Inhibition+of+Drug-Resistant+Mutants+of+the+Receptor+Tyrosine+Kinase+EGFR&doi=10.1002%2Fanie.201605011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR</span></div><div class="casAuthors">Engel, Julian; Becker, Christian; Lategahn, Jonas; Keul, Marina; Ketzer, Julia; Muehlenberg, Thomas; Kollipara, Laxmikanth; Schultz-Fademrecht, Carsten; Zahedi, Rene P.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10909-10912</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance represents the major challenge in the treatment of EGFR-driven nonsmall-cell lung cancer (NSCLC).  Herein, the authors describe the structure-based design, synthesis, and biol. evaluation of a novel class of covalent EGFR inhibitors that exhibit excellent inhibition of EGFR-mutant drug-resistant cells.  Protein x-ray crystallog. combined with detailed kinetic studies led to a deeper understanding of the mode of inhibition of EGFR-T790M and provided insight into the key principles for effective inhibition of the recently discovered tertiary mutation at EGFR-C797S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBqcuaKxIuCbVg90H21EOLACvtfcHk0li59yeIuKvxkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ&md5=d16c5339a6f2b9ca018c56f6b3f0b8e8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fanie.201605011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201605011%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DKollipara%26aufirst%3DL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInsight%2520into%2520the%2520Inhibition%2520of%2520Drug-Resistant%2520Mutants%2520of%2520the%2520Receptor%2520Tyrosine%2520Kinase%2520EGFR%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10909%26epage%3D10912%26doi%3D10.1002%2Fanie.201605011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00475</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00475" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2-5&author=J.+Engelauthor=J.+Lategahnauthor=D.+Rauh&title=Hope+and+Disappointment%3A+Covalent+Inhibitors+to+Overcome+Drug+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1021%2Facsmedchemlett.5b00475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Engel, Julian; Lategahn, Jonas; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clin. outcomes.  However, the emergence of a newly discovered acquired drug resistance challenges the concept of small mol. targeted cancer therapy in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcxNkfyBm4vrVg90H21EOLACvtfcHk0li59yeIuKvxkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D&md5=738e3286dd1b1d4110249e33cceec9ac</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00475%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHope%2520and%2520Disappointment%253A%2520Covalent%2520Inhibitors%2520to%2520Overcome%2520Drug%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Facsmedchemlett.5b00475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Termathe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Wrangowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlenbrock, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krüll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaumann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eppmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kibies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffgaard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menninger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Cuaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinnefeld, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahedi, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kast, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6844</span><span class="NLM_x">–</span> <span class="NLM_lpage">6863</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6844-6863&author=J.+Engelauthor=A.+Richtersauthor=M.+Getlikauthor=S.+Tomassiauthor=M.+Keulauthor=M.+Termatheauthor=J.+Lategahnauthor=C.+Beckerauthor=S.+Mayer-Wrangowskiauthor=C.+Gr%C3%BCtterauthor=N.+Uhlenbrockauthor=J.+Kr%C3%BCllauthor=N.+Schaumannauthor=S.+Eppmannauthor=P.+Kibiesauthor=F.+Hoffgaardauthor=J.+Heilauthor=S.+Menningerauthor=S.+Ortiz-Cuaranauthor=J.+M.+Heuckmannauthor=V.+Tinnefeldauthor=R.+P.+Zahediauthor=M.+L.+Sosauthor=C.+Schultz-Fademrechtauthor=R.+K.+Thomasauthor=S.+M.+Kastauthor=D.+Rauh&title=Targeting+Drug+Resistance+in+EGFR+with+Covalent+Inhibitors%3A+A+Structure-Based+Design+Approach&doi=10.1021%2Facs.jmedchem.5b01082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach</span></div><div class="casAuthors">Engel, Julian; Richters, Andre; Getlik, Matthaeus; Tomassi, Stefano; Keul, Marina; Termathe, Martin; Lategahn, Jonas; Becker, Christian; Mayer-Wrangowski, Svenja; Gruetter, Christian; Uhlenbrock, Niklas; Kruell, Jasmin; Schaumann, Niklas; Eppmann, Simone; Kibies, Patrick; Hoffgaard, Franziska; Heil, Jochen; Menninger, Sascha; Ortiz-Cuaran, Sandra; Heuckmann, Johannes M.; Tinnefeld, Verena; Zahedi, Rene P.; Sos, Martin L.; Schultz-Fademrecht, Carsten; Thomas, Roman K.; Kast, Stefan M.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6844-6863</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases represent one of the prime targets in cancer therapy, as the dysregulation of these elementary transducers of extracellular signals, like the epidermal growth factor receptor (EGFR), contributes to the onset of cancer, such as non-small cell lung cancer (NSCLC).  Strong efforts were directed to the development of irreversible inhibitors and led to compd. CO-1686, which takes advantage of increased residence time at EGFR by alkylating Cys797 and thereby preventing toxic effects.  Here, the authors present a structure-based approach, rationalized by subsequent computational anal. of conformational ligand ensembles in soln., to design novel and irreversible EGFR inhibitors based on a screening hit that was identified in a phenotype screen of 80 NSCLC cell lines against approx. 1500 compds.  Using protein x-ray crystallog., the authors deciphered the binding mode in engineered cSrc (T338M/S345C), a validated model system for EGFR-T790M, which constituted the basis for further rational design approaches.  Chem. synthesis led to further compd. collections that revealed increased biochem. potency and, in part, selectivity toward mutated (L858R and L858R/T790M) vs. nonmutated EGFR.  Further cell-based and kinetic studies were performed to substantiate the authors initial findings.  Utilizing proteolytic digestion and nano-LC-MS/MS anal., the authors confirmed the alkylation of Cys797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNGJPIuqoVObVg90H21EOLACvtfcHk0li59yeIuKvxkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsrvM&md5=d5264a2a99d7752af0e587f23aeb7723</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01082%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTermathe%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DUhlenbrock%26aufirst%3DN.%26aulast%3DKr%25C3%25BCll%26aufirst%3DJ.%26aulast%3DSchaumann%26aufirst%3DN.%26aulast%3DEppmann%26aufirst%3DS.%26aulast%3DKibies%26aufirst%3DP.%26aulast%3DHoffgaard%26aufirst%3DF.%26aulast%3DHeil%26aufirst%3DJ.%26aulast%3DMenninger%26aufirst%3DS.%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DTinnefeld%26aufirst%3DV.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DKast%26aufirst%3DS.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DTargeting%2520Drug%2520Resistance%2520in%2520EGFR%2520with%2520Covalent%2520Inhibitors%253A%2520A%2520Structure-Based%2520Design%2520Approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6844%26epage%3D6863%26doi%3D10.1021%2Facs.jmedchem.5b01082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span> </span><span class="NLM_article-title">Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span><span class="refDoi"> DOI: 10.1038/nchembio.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+Polypharmacology%3A+Discovery+of+Dual+Inhibitors+of+Tyrosine+and+Phosphoinositide+Kinases&doi=10.1038%2Fnchembio.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0lgVdQxs_YOQZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520Polypharmacology%253A%2520Discovery%2520of%2520Dual%2520Inhibitors%2520of%2520Tyrosine%2520and%2520Phosphoinositide%2520Kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D691%26epage%3D699%26doi%3D10.1038%2Fnchembio.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrill, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothaus, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalrymple, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+Selective+Irreversible+Inhibitors+for+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0lgVdQxs_YOQZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Zapf, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstenberger, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limburg, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulabaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spaulding, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerwinski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medley, Q. G.</span><span> </span><span class="NLM_article-title">Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (ITK) with Nanomolar Potency in a Whole-Blood Assay</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10047</span><span class="NLM_x">–</span> <span class="NLM_lpage">10063</span><span class="refDoi"> DOI: 10.1021/jm301190s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301190s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10047-10063&author=C.+W.+Zapfauthor=B.+S.+Gerstenbergerauthor=L.+Xingauthor=D.+C.+Limburgauthor=D.+R.+Andersonauthor=N.+Caspersauthor=S.+Hanauthor=A.+Aulabaughauthor=R.+Kurumbailauthor=S.+Shakyaauthor=X.+Liauthor=V.+Spauldingauthor=R.+M.+Czerwinskiauthor=N.+Sethauthor=Q.+G.+Medley&title=Covalent+Inhibitors+of+Interleukin-2+Inducible+T+Cell+Kinase+%28ITK%29+with+Nanomolar+Potency+in+a+Whole-Blood+Assay&doi=10.1021%2Fjm301190s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay</span></div><div class="casAuthors">Zapf, Christoph W.; Gerstenberger, Brian S.; Xing, Li; Limburg, David C.; Anderson, David R.; Caspers, Nicole; Han, Seungil; Aulabaugh, Ann; Kurumbail, Ravi; Shakya, Subarna; Li, Xin; Spaulding, Vikki; Czerwinski, Robert M.; Seth, Nilufer; Medley, Quintus G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10047-10063</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We wish to report a strategy that targets interleukin-2 inducible T cell kinase (Itk) with covalent inhibitors.  Thus far, covalent inhibition of Itk has not been disclosed in the literature.  Structure-based drug design was utilized to achieve low nanomolar potency of the disclosed series even at high ATP concns.  Kinetic measurements confirmed an irreversible binding mode with off-rate half-lives exceeding 24 h and moderate on-rates.  The analogs are highly potent in a cellular IP1 assay as well as in a human whole-blood (hWB) assay.  Despite a half-life of approx. 2 h in resting primary T cells, the covalent inhibition of Itk resulted in functional silencing of the TCR pathway for more than 24 h.  This prolonged effect indicates that covalent inhibition is a viable strategy to target the inactivation of Itk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnh9j28SM8jbVg90H21EOLACvtfcHk0ljeFnJJygi2iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP&md5=7e39a17151dc9493d13439bc48fa83a3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm301190s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301190s%26sid%3Dliteratum%253Aachs%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSpaulding%26aufirst%3DV.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DMedley%26aufirst%3DQ.%2BG.%26atitle%3DCovalent%2520Inhibitors%2520of%2520Interleukin-2%2520Inducible%2520T%2520Cell%2520Kinase%2520%2528ITK%2529%2520with%2520Nanomolar%2520Potency%2520in%2520a%2520Whole-Blood%2520Assay%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10047%26epage%3D10063%26doi%3D10.1021%2Fjm301190s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutre, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flinn, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharman, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierda, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukbuntherng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clow, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedrick, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span><span class="refDoi"> DOI: 10.1056/NEJMoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0ljeFnJJygi2iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D32%26epage%3D42%26doi%3D10.1056%2FNEJMoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Wang, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rule, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahl, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurczak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romaguera, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrientos, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielowska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radford, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stilgenbauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreyling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jedrzejczak, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spurgeon, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newberry, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreivy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clow, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaupre, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1056/NEJMoa1306220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1056%2FNEJMoa1306220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=23782157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=507-516&author=M.+L.+Wangauthor=S.+Ruleauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedrzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Liauthor=L.+Zhangauthor=K.+Newberryauthor=Z.+Ouauthor=N.+Chengauthor=B.+Fangauthor=J.+McGreivyauthor=F.+Clowauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=D.+M.+Beaupreauthor=L.+A.+Kunkelauthor=K.+A.+Blum&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+or+Refractory+Mantle-Cell+Lymphoma&doi=10.1056%2FNEJMoa1306220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span></div><div class="casAuthors">Wang, Michael L.; Rule, Simon; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Li, Lei; Zhang, Liang; Newberry, Kate; Ou, Zhishuo; Cheng, Nancy; Fang, Bingliang; McGreivy, Jesse; Clow, Fong; Buggy, Joseph J.; Chang, Betty Y.; Beaupre, Darrin M.; Kunkel, Lori A.; Blum, Kristie A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers.  In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.  METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma.  Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy.  The primary end point was the overall response rate.  Secondary end points were duration of response, progression-free survival, overall survival, and safety.  RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clin. prognostic factors.  Patients had received a median of three prior therapies.  The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea.  Grade 3 or higher hematol. events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%).  A response rate of 68% (75 patients) was obsd., with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate.  With an estd. median follow-up of 15.3 mo, the estd. median response duration was 17.5 mo (95% confidence interval [CI], 15.8 to not reached), the estd. median progression-free survival was 13.9 mo (95% CI, 7.0 to not reached), and the median overall survival was not reached.  The estd. rate of overall survival was 58% at 18 mo.  CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovUuOKvHS0NrVg90H21EOLACvtfcHk0lhW775_aHlLaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF&md5=7a92bbd5acf86e614cea96f44503e12b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNewberry%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DB.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DKunkel%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520or%2520Refractory%2520Mantle-Cell%2520Lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D507%26epage%3D516%26doi%3D10.1056%2FNEJMoa1306220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Hanke, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dow, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weringer, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollok, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connelly, P. A.</span><span> </span><span class="NLM_article-title">Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span><span class="refDoi"> DOI: 10.1074/jbc.271.2.695</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1074%2Fjbc.271.2.695" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=695-701&author=J.+H.+Hankeauthor=J.+P.+Gardnerauthor=R.+L.+Dowauthor=P.+S.+Changelianauthor=W.+H.+Brissetteauthor=E.+J.+Weringerauthor=B.+A.+Pollokauthor=P.+A.+Connelly&title=Discovery+of+a+novel%2C+potent%2C+and+Src+family-selective+tyrosine+kinase+inhibitor.+Study+of+Lck-+and+FynT-dependent+T+cell+activation&doi=10.1074%2Fjbc.271.2.695"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.2.695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.2.695%26sid%3Dliteratum%253Aachs%26aulast%3DHanke%26aufirst%3DJ.%2BH.%26aulast%3DGardner%26aufirst%3DJ.%2BP.%26aulast%3DDow%26aufirst%3DR.%2BL.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DWeringer%26aufirst%3DE.%2BJ.%26aulast%3DPollok%26aufirst%3DB.%2BA.%26aulast%3DConnelly%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520novel%252C%2520potent%252C%2520and%2520Src%2520family-selective%2520tyrosine%2520kinase%2520inhibitor.%2520Study%2520of%2520Lck-%2520and%2520FynT-dependent%2520T%2520cell%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D695%26epage%3D701%26doi%3D10.1074%2Fjbc.271.2.695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lhW775_aHlLaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lhfdh3rznzxWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Schultes, S. d. G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Graaf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haaksma, E. E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Esch, I. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krämer, O.</span><span> </span><span class="NLM_article-title">Ligand efficiency as a guide in fragment hit selection and optimization</span> <span class="citation_source-journal">Drug Discovery Today: Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e157</span><span class="NLM_x">–</span> <span class="NLM_lpage">e162</span><span class="refDoi"> DOI: 10.1016/j.ddtec.2010.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1016%2Fj.ddtec.2010.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVegsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=e157-e162&author=S.+d.+G.+C.+Schultesauthor=C.+de+Graafauthor=E.+E.+J.+Haaksmaauthor=I.+J.+P.+de+Eschauthor=R.+Leursauthor=O.+Kr%C3%A4mer&title=Ligand+efficiency+as+a+guide+in+fragment+hit+selection+and+optimization&doi=10.1016%2Fj.ddtec.2010.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency as a guide in fragment hit selection and optimization</span></div><div class="casAuthors">Schultes, Sabine; de Graaf, Chris; Haaksma, Eric E. J.; de Esch, Iwan J. P.; Leurs, Rob; Kraemer, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">E157-E162</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Fragment-based screening (FBS) has become an established approach for hit identification.  Starting points identified by FBS, are small fragments that require substantial modification to become leads.  As fragments are different from classical hits a process tailored for fragment evolution is required.  Scores for ligand efficiency have been proposed as guides for this process.  Here we review how these have been applied to guide the selection and optimization of fragment hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbfhwn68rv4bVg90H21EOLACvtfcHk0lhfdh3rznzxWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVegsL0%253D&md5=a57c85869d5c829159be31449fd04796</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2010.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2010.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DSchultes%26aufirst%3DS.%2Bd.%2BG.%2BC.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DHaaksma%26aufirst%3DE.%2BE.%2BJ.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DO.%26atitle%3DLigand%2520efficiency%2520as%2520a%2520guide%2520in%2520fragment%2520hit%2520selection%2520and%2520optimization%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2010%26volume%3D7%26spage%3De157%26epage%3De162%26doi%3D10.1016%2Fj.ddtec.2010.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gubernator, K.</span><span> </span><span class="NLM_article-title">Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1007</span><span class="NLM_x">–</span> <span class="NLM_lpage">1010</span><span class="refDoi"> DOI: 10.1021/jm970530e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970530e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADyaK1cXhs12kt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=1007-1010&author=M.+Kansyauthor=F.+Sennerauthor=K.+Gubernator&title=Physicochemical+high+throughput+screening%3A+parallel+artificial+membrane+permeation+assay+in+the+description+of+passive+absorption+processes&doi=10.1021%2Fjm970530e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes</span></div><div class="casAuthors">Kansy, Manfred; Senner, Frank; Gubernator, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1007-1010</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The majority of pharmaceutical discovery projects aim for an orally available form of a new therapeutic principle.  One obstacle for per oral treatment is intestinal absorption.  A simple predictive exptl. method to assess the potential of intestinal absorption is therefore highly welcome.  The authors describe here the PAMPA (Parallel Artificial Membrane Permeation Assay) method, a simple, robust, high throughput screen (HTS) which has been shown to be predictive for passive diffusion through membranes and thus for oral absorption.  In addn. PAMPA can deliver information in parallel on the lipophilicity, the ionization state and the soly. of a compd.  Therefore PAMPA complements HTS, combinatorial chem. and parallel synthesis efforts in preclin. pharmaceutical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcwCGodCr1rVg90H21EOLACvtfcHk0lhfdh3rznzxWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhs12kt70%253D&md5=85d8ab409313b583de52348eb4d895da</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm970530e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970530e%26sid%3Dliteratum%253Aachs%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DSenner%26aufirst%3DF.%26aulast%3DGubernator%26aufirst%3DK.%26atitle%3DPhysicochemical%2520high%2520throughput%2520screening%253A%2520parallel%2520artificial%2520membrane%2520permeation%2520assay%2520in%2520the%2520description%2520of%2520passive%2520absorption%2520processes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D1007%26epage%3D1010%26doi%3D10.1021%2Fjm970530e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Tomassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumbrink, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mühlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2361</span><span class="NLM_x">–</span> <span class="NLM_lpage">2372</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01626</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01626" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1WltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2361-2372&author=S.+Tomassiauthor=J.+Lategahnauthor=J.+Engelauthor=M.+Keulauthor=H.+L.+Tumbrinkauthor=J.+Ketzerauthor=T.+M%C3%BChlenbergauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=S.+Bauerauthor=D.+Rauh&title=Indazole-Based+Covalent+Inhibitors+To+Target+Drug-Resistant+Epidermal+Growth+Factor+Receptor&doi=10.1021%2Facs.jmedchem.6b01626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor</span></div><div class="casAuthors">Tomassi, Stefano; Lategahn, Jonas; Engel, Julian; Keul, Marina; Tumbrink, Hannah L.; Ketzer, Julia; Muehlenberg, Thomas; Baumann, Matthias; Schultz-Fademrecht, Carsten; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2361-2372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The specific targeting of oncogenic mutant epidermal growth factor receptor (EGFR) is a breakthrough in targeted cancer therapy and marks a drastic change in the treatment of non-small cell lung cancer (NSCLC).  The recurrent emergence of resistance to these targeted drugs requires the development of novel chem. entities that efficiently inhibit drug-resistant EGFR.  Herein, the authors report the optimization process for a hit compd. that has emerged from a phenotypic screen resulting in indazole-based compds.  These inhibitors are conformationally less flexible, target gatekeeper mutated drug resistant EGFR-L858R/T790M and covalently alkylate Cys 797.  Western blot anal., as well as characterization of the binding kinetics and kinase selectivity profiling, substantiates the authors' approach of targeting drug-resistant EGFR-L858R/T790M with inhibitors incorporating the indazole as hinge binder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwwmG17YkaV7Vg90H21EOLACvtfcHk0lhfdh3rznzxWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1WltL0%253D&md5=25e24252dc5a03ec5349359289ebd808</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01626%26sid%3Dliteratum%253Aachs%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DIndazole-Based%2520Covalent%2520Inhibitors%2520To%2520Target%2520Drug-Resistant%2520Epidermal%2520Growth%2520Factor%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2361%26epage%3D2372%26doi%3D10.1021%2Facs.jmedchem.6b01626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span> </span><span class="NLM_article-title">Targeted Covalent Enzyme Inhibitors</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/B978-0-12-396492-2.00027-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=10.1016%2FB978-0-12-396492-2.00027-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eju7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=413-439&author=M.+C.+Noeauthor=A.+M.+Gilbert&title=Targeted+Covalent+Enzyme+Inhibitors&doi=10.1016%2FB978-0-12-396492-2.00027-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent enzyme inhibitors</span></div><div class="casAuthors">Noe, Mark C.; Gilbert, Adam M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">413-439</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Selective covalent modification of a biomol. target can offer several important advantages in drug discovery.  The purpose of this report is to broadly detail targeted covalent inhibitor approaches across a variety of enzyme families which were published over the past 5 years.  Covalent modification of essential enzyme cofactors as a design strategy and the development of covalent probes to enable chem. biol. studies are beyond the scope of this review.  Tis review will be divided into several sections based on reactivity of the electrophilic species (producing functionally irreversible or reversible covalent assocn. with the target protein), and type of nucleophile with which the electrophile is known to assoc. in its biol. context (sulfur, oxygen, or nitrogen).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp04K2rcDR5rVg90H21EOLACvtfcHk0lhzLC7QCgRFWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eju7jK&md5=4957a32f394ad591702a4316ffe9c8df</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396492-2.00027-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396492-2.00027-8%26sid%3Dliteratum%253Aachs%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26atitle%3DTargeted%2520Covalent%2520Enzyme%2520Inhibitors%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2012%26volume%3D47%26spage%3D413%26epage%3D439%26doi%3D10.1016%2FB978-0-12-396492-2.00027-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4hct" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4hct','PDB','4hct'); return false;">PDB: 4hct</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ika" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ika','PDB','3ika'); return false;">PDB: 3ika</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5j9y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5j9y','PDB','5j9y'); return false;">PDB: 5j9y</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-5"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i71"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00515">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_01783"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00515">10.1021/acs.jmedchem.7b00515</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic routes used to generate presented compounds; crystal structure and interaction map of <b>1w</b> and <b>1x</b> in EGFR<sup>L858R/T790M</sup>; plot of pEC50 against clogD for entire series of pyrazolopyrimidines; plasma concentration/time profile of <b>1w</b>; cellular growth inhibition (EC<sub>50</sub>) of <b>1a</b>–<b>z</b> against H358; collection of pyrazolopyrimidine-based derivatives calcd LLE and clogD values (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_001.pdf">jm7b00515_si_001.pdf (911.68 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00515/suppl_file/jm7b00515_si_002.csv">jm7b00515_si_002.csv (7.5 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-18%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00515%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00515" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a99617e032254","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
